AGREEMENT AND PLAN OF MERGER by and among: INVERNESS MEDICAL INNOVATIONS, INC., a Delaware corporation; INCA ACQUISITION, INC., a Delaware corporation; and BIOSITE INCORPORATED, a Delaware corporation Dated as of May 17, 2007

Exhibit 2.1

AGREEMENT AND PLAN OF MERGER

by and among:

INVERNESS MEDICAL INNOVATIONS, INC.,

a Delaware corporation;

INCA ACQUISITION, INC.,

a Delaware corporation; and

BIOSITE INCORPORATED,

a Delaware corporation

Dated as of May 17, 2007

TABLE OF CONTENTS


		Page
SECTION 1.	THE OFFER	2
1.1.	The Offer	2
1.2.	Actions of Parent and Purchaser	3
1.3.	Actions of the Company	4
1.4.	Board of Directors	5
1.5.	Actions by Directors	6
1.6.	Top-Up Option	7

SECTION 2.	THE MERGER; EFFECTIVE TIME	8
2.1.	Merger of the Purchaser into Company	8
2.2.	Effect of the Merger	8
2.3.	Effective Time	8
2.4.	Certificate of Incorporation and Bylaws; Officers and Directors	8
2.5.	Conversion of Company Shares	9
2.6.	Closing of the Company’s Transfer Books	9
2.7.	Payment for Company Shares	10
2.8.	Appraisal Rights	11
2.9.	Further Action	12

SECTION 3.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY	12
3.1.	Due Organization and Good Standing; Subsidiaries	12
3.2.	Authority; Binding Nature of Agreement	13
3.3.	Non-Contravention; Consents	13
3.4.	Certificate of Incorporation; Bylaws	14
3.5.	Capitalization	14
3.6.	SEC Filings; Financial Statements	15
3.7.	Information Supplied	17
3.8.	Schedule 14D-9	17
3.9.	Internal Controls; ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act	18
3.10.	Absence of Certain Changes	19
3.11.	Title to Assets; Real Property	19
3.12.	Intellectual Property Rights	21
3.13.	Contracts	24
3.14.	Compliance with Legal Requirements	27
3.15.	Foreign Corrupt Practices and International Trade Sanctions	27
3.16.	Governmental Authorizations	27
3.17.	Legal Proceedings; Orders	28
3.18.	Regulatory Matters	28
3.19.	Product Recalls	30
3.20.	Tax Matters	31
3.21.	Employee Benefit Plans	33
3.22.	Labor Matters	36


3.23.	Environmental Matters	38
3.24.	Insurance	39
3.25.	Transactions with Affiliates	39
3.26.	Vote Required	39
3.27.	Section 203 of the DGCL; Company Rights Agreement	39
3.28.	Opinion of Financial Advisor	40
3.29.	Brokers	40
3.30.	▇▇▇▇▇▇▇ Merger Agreement	40

SECTION 4.	REPRESENTATIONS AND WARRANTIES OF PARENT AND PURCHASER	40
4.1.	Due Organization	40
4.2.	Authority; Binding Nature of Agreement	40
4.3.	Non-Contravention; Consents; Certain Contract Matters	41
4.4.	Not an Interested Stockholder	42
4.5.	Financing	42
4.6.	Ownership of Company Shares	42
4.7.	Offer Documents	42
4.8.	Information in Schedule 14D-9 and Proxy Statement	42

SECTION 5.	COVENANTS	43
5.1.	Interim Operations of the Company	43
5.2.	No Solicitation	48
5.3.	Board Recommendation	50
5.4.	Meeting of the Company’s Stockholders	52
5.5.	Filings; Other Action	53
5.6.	Access	55
5.7.	Interim Operations of Purchaser	55
5.8.	Publicity	55
5.9.	Stock Options/ESPP	56
5.10.	Other Employee Benefits	57
5.11.	Indemnification; Directors’ and Officers’ Insurance	59
5.12.	Section 16 Matters	60
5.13.	Rule 14d-10(d)	60
5.14.	Cooperation Regarding Transition of Business	61
5.15.	Termination of Certain Company Plans	61
5.16.	Financing	61
5.17.	Tax Matters	62
5.18.	Inverness Payment	63

SECTION 6.	CONDITIONS TO EACH PARTY’S OBLIGATION TO EFFECT THE MERGER	63
6.1.	Stockholder Approval	63
6.2.	No Injunctions; Laws	63


6.3.	Government Consents	63
6.4.	Offers Purchased	64

SECTION 7.	TERMINATION	64
7.1.	Termination	64
7.2.	Effect of Termination	66
7.3.	Termination Fee	66

SECTION 8.	MISCELLANEOUS PROVISIONS	67
8.1.	Amendment	67
8.2.	Waiver	67
8.3.	No Survival of Representations and Warranties	68
8.4.	Entire Agreement; Counterparts	68
8.5.	Applicable Law; Jurisdiction; Waiver of Jury Trial	68
8.6.	Payment of Expenses	69
8.7.	Assignability; No Third Party Rights	69
8.8.	Notices	70
8.9.	Severability	71
8.10.	Obligation of Parent	71
8.11.	Specific Performance	71
8.12.	Cumulative Remedies	71
8.13.	Representation by Counsel	71
8.14.	Construction	72


Schedule A		Products Under Development
Annex I		Offer Conditions
Exhibit A		Certain Definitions
Exhibit B		Certificate of Incorporation of Surviving Corporation

iii

AGREEMENT AND PLAN OF MERGER

THIS AGREEMENT AND PLAN OF MERGER (“Agreement”) is made and entered into as of May 17, 2007, by and among INVERNESS MEDICAL INNOVATIONS, INC., a Delaware corporation (“Parent”); INCA ACQUISITION, INC., a Delaware corporation and a wholly-owned Subsidiary of Parent (“Purchaser”); and BIOSITE INCORPORATED, a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

RECITALS

WHEREAS, the board of directors of each of Parent, Purchaser and the Company has approved the acquisition of the Company by Parent on the terms and conditions set forth in this Agreement;

WHEREAS, on the terms and subject to the conditions set forth herein, Purchaser has agreed to commence a tender offer (the “Offer”) to purchase all outstanding Company Shares, at a price of $92.50 per Company Share, in cash without interest, plus if the Acceptance Time shall not have occurred on or prior to the date that is forty-five days from the date hereof (or the next succeeding business day) (the “Target Date”), an amount of cash equal to $0.015205 per Company Share per day for each day during the period commencing on the day following the Target Date through the Acceptance Time (such price, or any higher price as may be paid in the Offer in accordance with this Agreement, the “Offer Price”);

WHEREAS, contemporaneously with the execution and delivery of this Agreement, Parent and Purchaser have entered into Non-competition, Non-disclosure and Intellectual Property Assignment Agreements, dated as of the date hereof, with certain employees of the Company;

WHEREAS, following consummation of the Offer, on the terms and subject to the conditions set forth herein Purchaser shall merge with and into the Company (the “Merger”) and each Company Share that is issued and outstanding immediately prior to the Effective Time (other than Company Shares held in the treasury of the Company or owned by Parent, Purchaser or any direct or indirect wholly-owned Subsidiary of Parent or the Company immediately prior to the Effective Time, which will be canceled with no consideration issued in exchange therefor, and other than Appraisal Shares) will be canceled and converted into the right to receive cash in an amount equal to the Offer Price (the “Merger Consideration”), all upon the terms and conditions set forth herein;

WHEREAS, the Company Board has, on the terms and subject to the conditions set forth herein, unanimously and duly adopted resolutions (i) determining that the transactions contemplated by this Agreement are advisable and fair to, and in the best interests of, the Company and its stockholders, (ii) adopting and approving this Agreement and the transactions contemplated hereby, including the Offer, the Merger and the “agreement of merger” (as such term is used in Section 251 of the Delaware General Corporation Law (the “DGCL”)), in accordance with the DGCL, (iii) directing that the “agreement of merger” (as such term is used in Section 251 of the DGCL) contained in this Agreement be submitted to the stockholders of the Company for adoption (unless the Merger is consummated in accordance with Section 253 of the DGCL as contemplated herein), and (iv) recommending that the Company’s stockholders

accept the Offer, tender their Company Shares to Purchaser pursuant to the Offer, and adopt the “agreement of merger” (as such term is used in Section 251 of the DGCL) set forth in this Agreement;

WHEREAS, the board of directors of Parent and Purchaser have, on the terms and subject to the conditions set forth herein, unanimously approved and declared advisable this Agreement and the transactions contemplated hereby, including the Offer and the Merger, and Parent, in its capacity as the sole stockholder of Purchaser, has adopted the “agreement of merger” set forth in this Agreement, in each case, in accordance with the DGCL; and

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, Parent, Purchaser and the Company hereby agree as follows:

SECTION 1. THE OFFER

1.1. The Offer

(a) Provided that this Agreement shall not have previously been validly terminated in accordance with Section 7, as promptly as practicable after the date hereof, but in any event within nine calendar days (or the next succeeding business day) after the date of this Agreement, Purchaser shall commence (within the meaning of Rule 14d-2 under the Exchange Act) the Offer for all of the outstanding Company Shares (including any Company Shares subject to repurchase rights in favor of the Company) for consideration per Company Share consisting of the Offer Price. (The date on which Purchaser commences the Offer, within the meaning of Rule 14d-2 under the Exchange Act, is referred to in this Agreement as the “Offer Commencement Date”).

(b) As promptly as practicable on the later of: (i) the earliest date as of which Purchaser is permitted under applicable Legal Requirements to accept for payment Company Shares tendered pursuant to the Offer; and (ii) the earliest date as of which each of the conditions set forth in Annex I (the “Offer Conditions”) shall have been satisfied or waived, Purchaser shall (and Parent shall cause Purchaser to) accept for payment all Company Shares tendered pursuant to the Offer (and not validly withdrawn). The obligation of Purchaser to accept for payment Company Shares tendered pursuant to the Offer shall be subject only to the satisfaction or waiver of each of the Offer Conditions (and shall not be subject to any other conditions). As promptly as practicable after the acceptance for payment of any Company Shares tendered pursuant to the Offer, Purchaser shall pay for such Company Shares.

(c) Notwithstanding anything to the contrary contained in this Agreement, neither Parent nor Purchaser shall (without the prior written consent of the Company):

(i) change or waive the Minimum Condition (as defined in Annex I);

(ii) decrease the number of Company Shares sought to be purchased by Purchaser in the Offer;

(iii) reduce the Offer Price;

(iv) extend or otherwise change the expiration date of the Offer (except to the extent required pursuant to Section 1.1(d));

(v) change the form of consideration payable in the Offer; or amend, modify or supplement any of the Offer Conditions or terms of the Offer in a manner that adversely affects, or would reasonably be expected to adversely affect, the holders of Company Shares.

(d) Unless extended as provided in this Agreement, the Offer shall expire on the date (the “Initial Expiration Date”) that is 20 business days (calculated as set forth in Rule 14d-1(g)(3) under the Exchange Act) after the Offer Commencement Date. Notwithstanding the foregoing, if, on the Initial Expiration Date or any subsequent date as of which the Offer is scheduled to expire, any Offer Condition is not satisfied and has not been waived, then Purchaser, without the consent of the Company, may (and, to the extent requested by the Company, from time to time, shall) extend (and re-extend) the Offer and its expiration date for one or more periods ending no later than the Outside Date, to permit such Offer Condition to be satisfied; provided, however, that no individual extension shall be for a period of more than 10 business days without the prior written consent of the Company. The Offer may be terminated prior to its expiration date (as such expiration date may be extended and re-extended in accordance with this Agreement), but only if this Agreement is validly terminated in accordance with Section 7.

(e) Purchaser may, in its discretion, elect to provide for a subsequent offering period (and one or more extensions thereof) (and, if immediately following the Acceptance Time (as defined in Section 1.4(a)), Parent, Purchaser and their respective Subsidiaries and Affiliates own more than 80% of the Company Shares outstanding at that time (which shares beneficially owned shall include shares tendered in the Offer and not withdrawn), to the extent requested by the Company, Purchaser shall provide for a subsequent offering period of at least 10 business days) in accordance with Rule 14d-1 1 under the Exchange Act following the Acceptance Time.

(f) The Offer Price shall be adjusted to the extent appropriate to reflect the effect of any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to Company Shares occurring or having a record date on or after the date of this Agreement and prior to the payment by Purchaser for the Company Shares.

1.2. Actions of Parent and Purchaser.

(a) On the Offer Commencement Date Parent shall: (i) cause to be filed with the SEC a Tender Offer Statement on Schedule TO with respect to the Offer, which will contain Purchaser’s offer to purchase and related letter of transmittal (the

forms of which shall be reasonably acceptable to the Company) and the related form of summary advertisement (such Tender Offer Statement on Schedule TO, all exhibits, amendments and supplements thereto being referred to collectively in this Agreement as the “Offer Documents”) and (ii) cause the Offer Documents to be disseminated to holders of Company Shares to the extent required by applicable Legal Requirements. Parent and Purchaser shall cause the Offer Documents to comply in all material respects with the applicable requirements of the Exchange Act and the rules and regulations thereunder. The Company and its counsel shall be given a reasonable opportunity to review and comment on the Offer Documents (including any amendment or supplement thereto) prior to the filing thereof with the SEC. Parent and Purchaser shall promptly provide the Company and its counsel with a copy or a description of any comments received by Parent or Purchaser (or by counsel to Parent or Purchaser) from the SEC or its staff with respect to the Offer Documents. Each of Parent and Purchaser shall respond as promptly as practicable to any comments of the SEC or its staff with respect to the Offer Documents or the Offer.

(b) To the extent required by the applicable requirements of the Exchange Act and the rules and regulations thereunder: (i) each of Parent, Purchaser and the Company shall correct promptly any information provided by it for use in the Offer Documents if such information shall have become false or misleading in any material respect; and (ii) each of Parent and Purchaser shall take all steps necessary to promptly cause the Offer Documents, as supplemented or amended to correct such information, to be filed with the SEC and to be disseminated to holders of Company Shares. The Company shall promptly furnish to Parent all information concerning the Company that may be reasonably requested by Parent in connection with any action contemplated by Section 1.2(a) or (b). No representation is made by Parent or Purchaser with respect to information supplied by the Company for inclusion in the Offer Documents.

(c) Without limiting the generality of Section 8.10, Parent shall cause to be provided to Purchaser all of the funds necessary to purchase any Company Shares that Purchaser becomes obligated to purchase pursuant to the Offer, and shall cause Purchaser to perform, on a timely basis, all of Purchaser’s obligations under this Agreement.

1.3. Actions of the Company.

(a) The Company hereby approves of and consents to the Offer.

(b) On the Offer Commencement Date, the Company shall file with the SEC and (following or contemporaneously with the initial dissemination of the Offer Documents to holders of Company Shares to the extent required by applicable federal securities laws) disseminate to holders of Company Shares a Solicitation/Recommendation Statement on Schedule 14D-9 (together with any amendments or supplements thereto, the “Schedule 14D-9”) that, subject to Section 5.3(c), shall contain the Company Recommendation. Except in connection with a Company Change in Recommendation made in accordance with Section 5.3(c), Parent and its counsel shall be given a reasonable opportunity to review and comment on the

Schedule 14D-9 (including any amendment or supplement thereto) prior to the filing thereof with the SEC. The Company shall: (i) promptly provide Parent and its counsel with a copy of any written comments and a description of any oral comments received by the Company (or its counsel) from the SEC or its staff with respect to the Schedule 14D-9; (ii) except with respect to disclosure made relating to a Company Change in Recommendation in accordance with Section 5.3(c), give Parent and its counsel a reasonable opportunity to review and comment on any response formulated in connection with such comments prior to the filing thereof with the SEC; and (iii) respond promptly to any such comments. To the extent required by the applicable requirements of the Exchange Act and the rules and regulations thereunder: (A) each of Parent, Purchaser and the Company shall promptly correct any information provided by it for use in the Schedule 14D-9 if such information shall have become false or misleading in any material respect; and (B) the Company shall take all steps necessary to cause the Schedule 14D-9, as supplemented or amended to correct such information, to be filed with the SEC. Parent and Purchaser shall promptly furnish to the Company all information concerning Parent or Purchaser that may be reasonably requested in connection with any action contemplated by this Section 1.3(b). To the extent requested by the Company, Parent shall cause the Schedule 14D-9 to be mailed or otherwise disseminated to the Company’s stockholders together with the Offer Documents disseminated to the Company’s stockholders.

(c) In connection with the Offer, the Company shall instruct its transfer agent to furnish to Purchaser a list, as of the most recent practicable date, of the record holders of Company Shares and their addresses, as well as mailing labels containing such names and addresses. The Company will furnish Purchaser with such additional information (including any security position listings in the Company’s possession or reasonably obtainable by the Company) and assistance as Purchaser may reasonably request for purposes of communicating the Offer to the record holders and beneficial holders of Company Shares. All information furnished in accordance with this Section 1.3(c) shall be held in confidence by Parent and Purchaser in accordance with the requirements of the letter agreement, dated April 11, 2007, between Parent and the Company, (the “Confidentiality Agreement”), and shall be used by Parent and Purchaser only in connection with the communication of the Offer and the dissemination of any proxy or information statement relating to the Merger to the holders of Company Shares.

1.4. Board of Directors.

(a) After the first time that Purchaser accepts for payment any Company Shares tendered pursuant to the Offer (the “Acceptance Time”), and at all times thereafter, the Company will, upon Parent’s request and subject to compliance with applicable Legal Requirements, take all actions necessary to cause persons designated by Parent to become directors of the Company so that the total number of such persons equals that number of directors, rounded up to the next whole number, determined by multiplying: (i) the total number of directors on the Company Board (after giving effect to the directors elected or designated by Parent in accordance with this Section 1.4(a)); by (ii) the percentage that the number of Company Shares beneficially owned by Parent, Purchaser or any of their respective Affiliates bears to the total number of Company

Shares outstanding at the Acceptance Time (determined on a fully-diluted basis but disregarding any unvested stock options and other unvested rights to acquire Company Shares). The Company will take all actions necessary to permit Parent’s designees to be elected to the Company Board in accordance with this Section 1.4(a), including using reasonable efforts to secure the resignation of directors, promptly filling vacancies or newly created directorships on the Company Board, increasing the size of the Company Board, and/or amending the bylaws of the Company; provided, however, that prior to the Effective Time, the Company Board shall always have at least two Continuing Directors. The Company shall, upon Parent’s request following the Acceptance Time, and at all times thereafter, also cause Persons designated by Parent to constitute the same percentage (rounded up to the next whole number) as is on the Company Board of (i) each committee of the Company Board, (ii) each board of directors (or similar body) of each Subsidiary of the Company and (iii) each committee (or similar body) of each such board, in each case to the extent permitted by applicable Legal Requirements and the Marketplace Rules of the NASDAQ Global Select Market. Upon the election or appointment of all of Parent’s designees to the Company Board in accordance with this Section 1.4(a), the Company shall take all action necessary to elect to be treated as a “controlled company” as defined by NASDAQ Marketplace Rule 4350(c) and make all necessary filings and disclosures associated with such status. The provisions of this Section 1.4(a) are in addition to and shall not limit any rights that any of Purchaser, Parent or any of their respective affiliates may have as a record holder or beneficial owner of Company Shares as a matter of applicable Legal Requirements with respect to the election of directors or otherwise.

(b) The Company’s obligation to cause Parent’s designees to be elected or appointed to the Company Board shall be subject to Section 14(f) of the Exchange Act and Rule 14f-1 thereunder. The Company shall promptly take all actions, and shall include in the Schedule 14D-9 such information with respect to the Company and its officers and directors, as Section 14(f) of the Exchange Act and Rule 14f-1 thereunder require in order to fulfill its obligations under this Section 1.4, so long as Parent shall have provided to the Company all information with respect to Parent and its designees, officers, directors and Affiliates required by Section 14(f) of the Exchange Act and Rule 14f-1 thereunder. Parent shall promptly supply to the Company in writing, and shall be solely responsible for, all such information.

1.5. Actions by Directors. Following the election or appointment of Parent’s designees to the Company Board pursuant to Section 1.4(a), and until the Effective Time, the approval of a majority of the Continuing Directors shall be required to authorize: (i) any amendment to or termination of this Agreement by the Company; (ii) any amendment to the Company’s certificate of incorporation; (iii) any extension of time for the performance of any of the obligations or other acts of Parent or Purchaser; (iv) any waiver of compliance with any covenant of Parent or Purchaser or any condition to any obligation of the Company or any waiver of any right of the Company under this Agreement; (v) any Company Change in Recommendation; and (vi) any other consent or action by the Company Board with respect to this Agreement, the Offer or the Merger. The authorization of any such matter by a majority of the Continuing Directors shall constitute the authorization of such matter by the Company Board, and no other action on the part of the Company or any other director of the Company shall be required to authorize such matter.

1.6. Top-Up Option.

(a) The Company hereby grants to Purchaser an irrevocable option (the “Top-Up Option”), exercisable only upon the terms and subject to the conditions set forth herein, to purchase, at a price per share equal to the Offer Price, that number of Company Shares (the “Top-Up Option Shares”) equal to the lesser of (x) the lowest number of Company Shares that, when added to the number of Company Shares owned by Parent, Purchaser and their respective Subsidiaries and Affiliates at the time of such exercise, shall constitute ten thousand (10,000) shares more than 90% of the Company Shares then outstanding (after giving effect to the issuance of the Top-Up Option Shares) and (y) an aggregate number of Company Shares that is equal to 19.9% of the Company Shares issued and outstanding as of the date hereof; provided, however, that the Top-Up Option shall not be exercisable unless, (i) immediately prior to such exercise, Parent, Purchaser and their respective Subsidiaries and Affiliates own more than 80% of the Company Shares then outstanding and (ii) immediately after such exercise and the issuance of Company Shares pursuant thereto, Parent, Purchaser and their respective Subsidiaries and Affiliates own more than 90% of the Company Shares then outstanding; and provided, further, that in no event shall the Top-Up Option be exercisable for a number of Company Shares in excess of the Company’s total authorized and unissued Company Shares.

(b) Provided that no applicable Legal Requirement shall prohibit the exercise of the Top-Up Option or the issuance of the Top-Up Option Shares pursuant thereto, or otherwise make such exercise or issuance illegal, Purchaser may exercise and re-exercise the Top-Up Option multiple times, in whole but not in part, at any time or times after the Acceptance Time and prior to the earlier to occur of (i) the Effective Time and (ii) the termination of this Agreement pursuant to Section 7.

(c) Each time that Purchaser wishes to exercise the Top-Up Option, Purchaser shall send to the Company a written notice (a “Top-Up Exercise Notice”) specifying the denominations of the certificate or certificates evidencing the Top-Up Option Shares which the Purchaser wishes to receive, and the place, time and date for the closing of the purchase and sale pursuant to the Top-Up Option (a “Top-Up Closing”). The Company shall, promptly after receipt of a Top-Up Exercise Notice, deliver a written notice to the Purchaser confirming the number of Top-Up Option Shares and the aggregate purchase price therefore. At each Top-Up Closing, Purchaser shall pay the Company the aggregate price required to be paid for the Top-Up Option Shares issuable at such Top-Up Closing, by delivery of, at Purchaser’s option, (A) immediately available funds by wire transfer to an account designated by the Company, (B) a promissory note, bearing simple interest at 5% per annum, and due six months after the Top-Up Closing, or (C) any combination thereof. At each Top-Up Closing, the Company shall cause to be issued to Purchaser a certificate or certificates representing the Top-Up Option Shares issuable at such Top-Up Closing. Certificates representing Company Shares in connection with the Top-Up Option may include any legends that are required by federal or state securities laws.

SECTION 2. THE MERGER; EFFECTIVE TIME

2.1. Merger of the Purchaser into Company. Upon the terms and subject to the conditions set forth in this Agreement and in accordance with the DGCL, at the Effective Time (as defined in Section 2.3), Purchaser shall be merged with and into the Company, and the separate existence of Purchaser shall cease. The Company will continue as the surviving corporation in the Merger (the “Surviving Corporation”).

2.2. Effect of the Merger. The Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL. Without limiting the generality of the foregoing and subject thereto, at the Effective Time, all the property rights, privileges, immunities, powers and franchises of the Company and Purchaser shall vest in the Surviving Corporation and all debts, liabilities and duties of the Company and Purchaser shall become the debts, liabilities and duties of the Surviving Corporation.

2.3. Effective Time. As soon as practicable after the satisfaction or waiver of the conditions set forth in Section 6, the parties hereto shall cause a properly executed certificate of merger conforming to the requirements of the DGCL (the “Certificate of Merger”) to be filed with the Secretary of State of the State of Delaware. The Merger shall become effective at the time the Certificate of Merger is filed with the Secretary of State of the State of Delaware, or at such later time as is agreed to by the parties hereto and specified in the Certificate of Merger (the time at which the Merger becomes effective being referred to in this Agreement as the “Effective Time”). At 10:00 a.m. (Pacific time) on the date on which the Certificate of Merger is to be so filed, a closing shall be held at the offices of ▇▇▇▇▇▇▇ Procter LLP, Exchange Place, ▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ (or such other place or time as Parent and the Company may jointly designate).

2.4. Certificate of Incorporation and Bylaws; Officers and Directors. Unless otherwise jointly determined by Parent and the Company prior to the Effective Time:

(a) the certificate of incorporation of the Surviving Corporation shall be amended and restated as of the Effective Time to conform to Exhibit B;

(b) subject to Section 5.11(a), the bylaws of the Surviving Corporation shall be amended and restated as of the Effective Time to conform to the bylaws of Purchaser as in effect immediately prior to the Effective Time;

(c) the directors of the Surviving Corporation immediately after the Effective Time shall be the respective individuals who are directors of Purchaser immediately prior to the Effective Time; and

(d) the officers of the Surviving Corporation immediately after the Effective Time shall be the respective individuals who are officers of Purchaser immediately prior to the Effective Time.

2.5. Conversion of Company Shares.

(a) Subject to Section 2.8, at the Effective Time, by virtue of the Merger and without any further action on the part of Parent, Purchaser, the Company or any stockholder of the Company:

(i) any Company Shares then held by the Company or any wholly owned Subsidiary of the Company (or held in the Company’s treasury) shall cease to exist, and no consideration shall be paid in exchange therefor;

(ii) any Company Shares then held by Parent, Purchaser or any other wholly owned Subsidiary of Parent shall cease to exist, and no consideration shall be paid in exchange therefor;

(iii) except as provided in clauses “(i)” and “(ii)” above, each Company Share then outstanding (including any outstanding Company Shares subject to any repurchase rights in favor of the Company, but excluding any Appraisal Shares), shall be converted into the right to receive the Merger Consideration, without interest; and

(iv) each share of common stock, par value $0.001 per share, of Purchaser then outstanding shall be converted into one share of the common stock of the Surviving Corporation.

(b) The Merger Consideration shall be adjusted to the extent appropriate to reflect the effect of any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to Company Shares occurring or having a record date on or after the date of this Agreement and prior to the Effective Time.

2.6. Closing of the Company’s Transfer Books. At the Effective Time: (a) all Company Shares outstanding immediately prior to the Effective Time shall cease to exist as provided in Section 2.5 and all holders of certificates representing Company Shares that were outstanding immediately prior to the Effective Time shall cease to have any rights as stockholders of the Company; and (b) the stock transfer books of the Company shall be closed with respect to all Company Shares outstanding immediately prior to the Effective Time. No further transfer of any such Company Shares shall be made on such stock transfer books after the Effective Time. If, after the Effective Time, a valid certificate previously representing any of such Company Shares (a “Company Stock Certificate”) is presented to the Payment Agent (as defined in Section 2.7(a)) or to the Surviving Corporation or Parent, such Company Stock Certificate shall be canceled and shall be exchanged as provided in Section 2.7.

2.7. Payment for Company Shares.

(a) Prior to the Acceptance Time (i) Parent shall select a bank or trust company (reasonably acceptable to the Company) to act as payment agent with respect to the payment of the Merger Consideration (the “Payment Agent”) and (ii) Parent shall cause to be made available to the Payment Agent cash amounts sufficient to enable the Payment Agent to make payments pursuant to Section 2.5 to holders of Company Shares outstanding immediately prior to the Effective Time.

(b) Promptly after the Effective Time, Parent shall cause the Payment Agent to mail to each Person who was, immediately prior to the Effective Time, a holder of record of Company Shares described in Section 2.5(a)(iii) a form of letter of transmittal (reasonably acceptable to the Company) and instructions for use in effecting the surrender of Company Stock Certificates representing such Company Shares in exchange for payment therefor. Parent shall ensure that, upon surrender to the Payment Agent of each such Company Stock Certificate, together with a properly executed letter of transmittal, the holder of such Company Stock Certificate (or, under the circumstances described in Section 2.7(e), the transferee of the Company Shares represented by such Company Stock Certificate) shall promptly receive in exchange therefor the consideration to which such holder (or transferee) is entitled pursuant to Section 2.5(a)(iii).

(c) On or after the first anniversary of the Effective Time, Parent or the Surviving Corporation shall be entitled to cause the Payment Agent to deliver to Parent or the Surviving Corporation any funds made available by Parent to the Payment Agent which have not been disbursed to holders of Company Stock Certificates, and thereafter such holders shall be entitled to look only to Parent and the Surviving Corporation with respect to the consideration payable and issuable upon surrender of their Company Stock Certificates. Neither the Payment Agent, Parent nor the Surviving Corporation shall be liable to any holder of a Company Stock Certificate for any amount properly paid to a public official pursuant to any applicable abandoned property or escheat law. If any Company Stock Certificates shall not have been surrendered before the third anniversary of the Effective Time (or immediately prior to such earlier date on which any Merger Consideration payable in respect of such Company Stock Certificates would otherwise escheat to or become the property of any Governmental Entity), any such Merger Consideration in respect thereof shall, to the extent permitted by applicable Legal Requirements, become the property of Parent, free and clear of all claims or interest of any Person previously entitled thereto.

(d) If any Company Stock Certificate shall have been lost, stolen or destroyed, then, upon the making of an affidavit of that fact by the Person claiming such Company Stock Certificate to be lost, stolen or destroyed in a form reasonably satisfactory to Parent (together with an indemnity in form reasonably satisfactory to Parent against any claim that may be made against the Payment Agent or Parent or otherwise with respect to such certificate and, if required by Parent, the posting by such Person of a bond in such reasonable amount as Parent may direct to support such indemnity), Parent shall cause the Payment Agent to pay in exchange for such lost, stolen or destroyed Company Stock Certificate the consideration payable and issuable in respect thereof pursuant to this Agreement.

(e) In the event of a transfer of ownership of Company Shares which is not registered in the transfer records of the Company, the consideration may be paid and issued with respect to such Company Shares to a transferee of such Company Shares if the Company Stock Certificate representing such Company Shares is presented to the Payment Agent, accompanied by all documents reasonably required by the Payment Agent to evidence and effect such transfer and to evidence that any applicable stock transfer taxes relating to such transfer have been paid.

(f) The Surviving Corporation or Parent shall bear and pay all charges and expenses, including those of the Payment Agent, incurred in connection with the exchange of the Company Shares.

(g) Parent, the Surviving Corporation and the Payment Agent shall be entitled to deduct and withhold from the consideration otherwise payable pursuant to the Offer, the Merger or this Agreement to any holder of Company Shares or Company Options that are to be cancelled and terminated in exchange for a cash payment pursuant to Section 5.9(b) hereof, such amounts as Parent, the Surviving Corporation or the Payment Agent are required to deduct and withhold under the Code, or any Legal Requirement, with respect to the making of such payment. To the extent that amounts are so withheld by Parent, the Surviving Corporation or the Payment Agent, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the holder of Company Shares or Company Options in respect of whom such deduction and withholding was made by Parent, the Surviving Corporation or the Payment Agent.

2.8. Appraisal Rights.

(a) Notwithstanding anything to the contrary contained in this Agreement, any Company Shares that constitute Appraisal Shares shall not be converted into or represent the right to receive payment in accordance with Section 2.5, and each holder of Appraisal Shares shall be entitled only to such rights with respect to such Appraisal Shares as may be granted to such holder pursuant to Section 262 of the DGCL. From and after the Effective Time, a holder of Appraisal Shares shall not have and shall not be entitled to exercise any of the voting rights or other rights of a stockholder of the Surviving Corporation.

(b) The Company: (i) shall give Parent prompt written notice of any demand by any stockholder of the Company for appraisal of such stockholder’s Company Shares pursuant to Section 262 of the DGCL; and (ii) shall give Parent the opportunity to participate in all negotiations and proceedings with respect to any such demand. Except with the prior written consent of Purchaser (which consent may be withheld in the sole and absolute discretion of Purchaser) or as may otherwise be required by applicable Legal Requirements, the Company shall not make any payment with respect to, or settle or offer to settle, any such demands.

(c) For purposes of this Agreement, “Appraisal Shares” shall refer to any Company Shares outstanding immediately prior to the Effective Time that are held by stockholders who have preserved their appraisal rights under Section 262 of the DGCL with respect to such Company Shares. If any holder of Appraisal Shares shall fail to perfect or shall otherwise lose such holder’s right of appraisal under Section 262 of the DGCL, then: (i) any right of such holder with respect to such Company Shares as may be granted to such holder pursuant to Section 262 of the DGCL shall be extinguished; and (ii) such Appraisal Shares shall automatically be converted into and shall represent only the right to receive (upon the surrender of the Company Stock Certificate(s) representing such Appraisal Shares) payment for such Appraisal Shares in accordance with Section 2.5.

2.9. Further Action. If, at any time after the Effective Time, any further action is necessary to carry out the purposes of this Agreement, the officers and directors of the Surviving Corporation and Parent shall be authorized (in the name of Purchaser, in the name of the Company or otherwise) to take such action.

SECTION 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY

The Company represents and warrants to Parent and Purchaser that, except as set forth in the disclosure schedule delivered to Parent on the date of this Agreement (the “Company Disclosure Schedule”):

3.1. Due Organization and Good Standing; Subsidiaries.

(a) Each of the Company and the Company Subsidiaries is a corporation duly organized, validly existing and (where such concept is recognized under the laws of the jurisdiction in which it is incorporated) in good standing under the laws of the jurisdiction in which it is incorporated, and has all requisite corporate power and authority necessary to own, lease and operate its properties and to carry on its business as it is now being conducted. The Company and each of the Company Subsidiaries is duly qualified or licensed to do business and is in good standing in each state in which the nature of the business conducted by it makes such qualification or license necessary, except where the failure to be so qualified does not have a Company Material Adverse Effect.

(b) Part 3.1 of the Company Disclosure Schedule lists all Company Subsidiaries in existence as of the date of this Agreement, together with the jurisdiction of organization of each such Subsidiary and, if the Company, together with the Company Subsidiaries, does not own all of the outstanding equity interests of such Company Subsidiary, the percentage of equity interests of such Company Subsidiary owned by the Company and the Company Subsidiaries. All the outstanding shares of capital stock and other equity interests of each Company Subsidiary have been duly authorized and validly issued, are fully paid and nonassessable are not subject to any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right entitling the holders thereof to acquire shares of capital stock or other equity interests from such Company Subsidiary under any provision of the Legal Requirements pursuant

to which such Company Subsidiary is formed, such Company Subsidiary’s organizational documents or any Contract to which such Company Subsidiary is a party or is otherwise bound, and are owned directly or indirectly by the Company free and clear of all liens, pledges or Encumbrances, except for Permitted Encumbrances. Except for the capital stock of, or other equity interests in, the Company Subsidiaries, and except for marketable securities held from time to time by the Company in connection with its normal cash management activities, the Company does not own, directly or indirectly, any capital stock of, or other equity or voting interests in, any Person.

3.2. Authority; Binding Nature of Agreement. The Company has the requisite corporate power and authority to enter into and to perform its obligations under this Agreement. The Company Board, at a meeting duly called and held, has unanimously: (a) determined that this Agreement, the Offer, the Merger, the Top-Up Option and the other transactions contemplated by this Agreement are fair to, and in the best interests of, the Company’s stockholders; (b) duly and validly authorized and approved the execution, delivery and performance of this Agreement by the Company; (c) declared that this Agreement is advisable; and (d) resolved to make the Company Recommendation. The execution and delivery of this Agreement by the Company and the consummation by the Company of the Merger have been duly authorized by all necessary corporate action on the part of the Company, and no other corporate proceedings on the part of the Company are necessary to authorize this Agreement other than, with respect to the Merger, the adoption of this Agreement by the holders of a majority of the then outstanding Company Shares (if required under the DGCL) and the filing of the appropriate merger documents as required by the DGCL. This Agreement has been duly executed and delivered on behalf of the Company and, assuming the due authorization, execution and delivery of this Agreement by Parent and Purchaser, constitutes the valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to (i) laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies.

3.3. Non-Contravention; Consents. Except as set forth on Part 3.3 of the Company Disclosure Schedule, the execution and delivery of this Agreement by the Company, the acquisition of Company Shares by Purchaser pursuant to the Offer and the consummation by the Company of the Merger and the other transactions contemplated by this Agreement will not: (a) cause a violation of any of the provisions of the certificate of incorporation or bylaws of the Company or any of the equivalent organizational documents of the Company Subsidiaries; (b) cause a violation by the Company or any of the Company Subsidiaries of any Legal Requirement applicable to the business of the Company or any of the Company Subsidiaries; or (c) result in a modification, violation or breach of, or constitute (with or without notice or lapse of time or both) a default (or give rise to any right, including any right of termination, amendment, cancellation or acceleration) under, any of the terms, conditions or provisions of any Contract to which the Company or any Company Subsidiary is a party or by which its properties or assets are otherwise bound; except in the case of clauses (b) and (c) does not result in a Company Material Adverse Effect. Except as may be required by the Exchange Act, the DGCL, the HSR Act or the antitrust or competition laws of foreign jurisdictions, the

Company is not required to make any filing with, or to obtain any consent from, any Person in connection with the execution and delivery of this Agreement by the Company or the consummation by the Company of the Merger, except where the failure to make any such filing or obtain any such consent does not result in a Company Material Adverse Effect.

3.4. Certificate of Incorporation; Bylaws. The Company has delivered or made available to Parent complete and correct copies of the certificate of incorporation and bylaws of the Company, including all amendments thereto. The Company is not in violation of its certificate of incorporation or bylaws.

3.5. Capitalization.

(a) The authorized capital stock of the Company consists of 60,000,000 Company Shares and 5,000,000 shares of preferred stock, par value $0.01 per share (“Preferred Shares”), of which 25,000 shares have been designated Series A Participating Preferred Stock and reserved for issuance in connection with the Company Rights. As of May 11, 2007: (i) 17,142,895 Company Shares were issued and outstanding; (ii) no Preferred Shares were outstanding; (iii) no Company Shares or Preferred Shares were issued and held in the treasury of the Company or otherwise owned, directly or indirectly, by the Company, (iv) 3,460,903 Company Shares were reserved for future issuance pursuant to the Company Option Plans, of which 3,157,528 Company Shares were subject to outstanding Company Options; and (v) 404,853 Company Shares were reserved for future issuance pursuant to the Company’s Amended and Restated Employee Stock Purchase Plan (the “Company ESPP”). The Company has delivered or made available to Parent complete and correct copies of: (A) the Company Option Plans, which cover the stock options granted by the Company that are outstanding as of the date of this Agreement; and (B) the Company ESPP. The treatment of Company Options set forth in Section 5.9 does not require the approval or consent of any holder of Company Options and does not conflict with the terms of the Company Option Plans.

(b) All of the outstanding Company Shares are duly authorized, validly issued, fully paid and nonassessable. No class of capital stock of the Company or any Company Subsidiary is entitled to any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right entitling the holders thereof to acquire capital stock or other equity interests from the Company under any provision of the DGCL, the Company’s certificate of incorporation, the Company’s bylaws or any Contract to which the Company is a party or is otherwise bound. All of the Company Shares that may be issued pursuant to the Company Options or under the Company ESPP will be, when issued, duly authorized, validly issued, fully paid and nonassessable and not subject to any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right entitling the holders thereof to acquire capital stock or other equity interests from the Company under any provision of the DGCL, the Company’s certificate of incorporation, the Company’s bylaws or any Contract to which the Company is a party or is otherwise bound.

(c) Part 3.5 of the Company Disclosure Schedule contains a true and complete list, as of May 11, 2007, of all outstanding options to purchase Company Shares, whether or not granted under the Company Option Plans, including the date of grant, the number of Company Shares subject to each such option, the exercise price per share, the maximum term of each such option and, where applicable, the Company Option Plan under which such option was granted. All outstanding Company Options are evidenced by stock option agreements. From May 11, 2007 until the date of this Agreement, the Company has not issued, or reserved for issuance, any capital stock or any options, warrants or other rights to acquire capital stock or other equity interests (or securities convertible into or exercisable or exchangeable for capital stock or other equity interests), other than the issuance of Company Shares pursuant to the exercise of Company Options that were outstanding as of the close of business on May 11, 2007.

(d) Except as set forth above in this Section 3.5 or in Part 3.5 of the Company Disclosure Schedule, as of the date of this Agreement, there are not any options, warrants, rights, convertible or exchangeable securities, “phantom” stock rights, stock appreciation rights, stock-based performance units, commitments, Contracts, arrangements or undertakings of any kind to which the Company or any of the Company Subsidiaries is a party or by which any of them is bound (i) obligating the Company or any of the Company Subsidiaries to issue, deliver or sell, or cause to be issued, delivered or sold, equity interests in the Company or any of the Company Subsidiaries, (ii) obligating the Company or any of the Company Subsidiaries to issue, grant, extend or enter into any such option, warrant, right, security, unit commitment, Contract, arrangement or undertaking or (iii) that give any Person the right to receive any economic benefit or right similar to or derived from the economic benefits and rights occurring to holders of Company Shares. There are no outstanding obligations of the Company or any of the Company Subsidiaries to repurchase, redeem or otherwise acquire any shares of capital stock or other equity interests of the Company or any of the Company Subsidiaries. There are no bonds, debentures, notes or other Indebtedness of the Company or the Company Subsidiaries having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters on which stockholders of the Company may vote.

(e) There are no voting trusts or other agreements or understandings to which the Company or any Company Subsidiary is a party or of which, as of the date of this Agreement, the Company has knowledge, with respect to the voting of Company Shares or any capital stock of, or other equity interest of the Company or any of the Company Subsidiaries.

3.6. SEC Filings; Financial Statements.

(a) The Company has filed or furnished (as required or permitted) all forms, reports, schedules, proxy statements, registration statements and other documents (including exhibits and other information incorporated therein) required to be filed by the Company with the SEC since January 1, 2003 (the “Company SEC Documents”). As of the time it became effective (with respect to filings made under the Securities Act) and as of the time it was filed with or furnished to the SEC (with respect to filings made under

the Exchange Act and, with respect to proxy statements, at the time such proxy statement was mailed to stockholders of the Company) (or, with respect to filings made under the Exchange Act and amended or superseded by a filing prior to the date of this Agreement, then on the date of the filing or furnishing of such amendment or, with respect to an amendment to a proxy statement, on the date such amendment to the proxy statement was mailed to stockholders of the Company, if applicable): (i) each of the Company SEC Documents complied in all material respects with the applicable requirements of the Securities Act or the Exchange Act (as the case may be); and (ii) the Company SEC Documents did not (and with respect to Company SEC Documents filed after the date of this Agreement, will not) contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company has made available to Parent copies of all comment letters received by the Company from the SEC since January 1, 2003, and relating to the Company SEC Documents, together with all written responses of the Company thereto. As of the date of this Agreement, to the Company’s knowledge, there are no outstanding or unresolved comments in such comment letters received by the Company from the SEC. As of the date of this Agreement, to the knowledge of the Company none of the SEC Documents is the subject of any ongoing review by the SEC. No Company Subsidiary is, or has ever been, required to file any reports, schedules, proxy statements, registration statements or other documents with the SEC.

(b) The financial statements (including any related notes) contained in the Company SEC Documents fairly present, in all material respects, the consolidated financial position of the Company and the Company Subsidiaries as of the respective dates thereof and the consolidated results of operations of the Company and the Company Subsidiaries for the periods covered thereby, have been prepared in accordance with GAAP applied on a consistent basis throughout the periods covered (except as may be indicated in the notes to such financial statements or, in the case of unaudited statements, as permitted by Form 10-Q of the SEC, and except that unaudited financial statements are subject to normal year-end audit adjustments) and complied at the time they were filed as to form in all material respects with the applicable accounting requirements and the published rules and regulations of the SEC with respect thereto at the time of filing.

(c) Neither the Company nor any Company Subsidiary is a party to, or has any commitment to become a party to, any joint venture, off-balance sheet partnership or any similar Contract (including any Contract relating to any transaction or relationship between or among the Company and any Company Subsidiary, on the one hand, and any unconsolidated affiliate, including any structured finance, special purpose or limited purpose Entity or Person, on the other hand, or any “off-balance sheet arrangements” (as defined in Item 303(a) of Regulation S-K of the SEC)), where the result, purpose or intended effect of such Contract is to avoid disclosure of any material transaction involving, or material liabilities of, the Company or any Company Subsidiary in the Company’s or any Company Subsidiary’s published financial statements or other Company SEC Documents.

(d) The independent registered public accounting firm engaged to express its opinion with respect to the financial statements included in the Company SEC Documents is, and has been throughout the periods covered thereby “independent” within the meaning of Rule 2-01 of Regulation S-X. Ernst & Young, LLP has not resigned or been dismissed as an independent public accountant of the Company as a result of or in connection with any disagreement with the Company on a matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure.

(e) Neither the Company nor any of the Company Subsidiaries (taken together as a whole) has any material liabilities of any nature (whether accrued, absolute, contingent determined or otherwise) required by GAAP to be recognized or disclosed on a consolidated balance sheet of the Company or any Company Subsidiary or in the notes thereto, except for: (i) liabilities disclosed in the financial statements (including any related notes) contained in the Company SEC Documents filed prior to the date of this Agreement; (ii) for liabilities and obligations incurred under any Material Contract other than liabilities or obligations due to breaches thereunder; and (iii) liabilities incurred in the Ordinary Course of Business since December 31, 2006 that could not reasonably be expected to, individually or in the aggregate, have a Company Material Adverse Effect.

3.7. Information Supplied. None of the information included or incorporated by reference in the Proxy Statement will, at the date it is first mailed to the Company’s stockholders, at the time of the Special Meeting or at the time of any amendment or supplement thereof, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading, except that no representation, warranty or covenant is made by the Company with respect to statements made or incorporated by reference therein based on written information supplied by Parent or Purchaser expressly for inclusion or incorporation by reference in the Proxy Statement. The Proxy Statement will comply as to form in all material respects with the requirements of the Exchange Act. The written information provided by or on behalf of the Company expressly for inclusion or incorporation by reference in the Offer Documents shall not, at the time the Offer Documents are mailed to the stockholders of the Company, or at any other time at or prior to the Acceptance Time, contain an untrue statement of material fact or omit to state a material fact required to be stated therein, or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.

3.8. Schedule 14D-9. The Schedule 14D-9 will comply as to form in all material respects with the requirements of the Exchange Act and, on the date filed with the SEC and on the date first published, sent or given to the Company’s stockholders, the Schedule 1 4D-9 will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that no representation, warranty or covenant is made by the Company with respect to statements made or incorporated by reference therein based on any written information supplied by Parent or Purchaser expressly for inclusion or incorporation by reference in the Schedule 14D-9.

3.9. Internal Controls; ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act.

(a) The Company has designed and maintains a system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) sufficient to provide reasonable assurance regarding the reliability of financial reporting. The Company (i) has designed and maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and 1 5d-15(e) of the Exchange Act) to ensure that material information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to the Company’s management as appropriate to allow timely decisions regarding required disclosure and (ii) has disclosed to the Company’s auditors and the audit committee of the Company Board (and made summaries of such disclosures available to Parent) (A) any significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect in any material respect the Company’s ability to record, process, summarize and report financial information and (B) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal controls over financial reporting. The Company is in compliance in all material respects with all effective provisions of the ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act.

(b) Each of the principal executive officer of the Company and the principal financial officer of the Company (or each former principal executive officer of the Company and each former principal financial officer of the Company, as applicable) has made all certifications required by Rule 13a-14 or 15d-14 under the Exchange Act or Sections 302 and 906 of the Sarbanes Oxley Act and the rules and regulations of the SEC promulgated thereunder with respect to the Company SEC Documents, and the statements contained in such certifications are true and correct. For purposes of this Section 3.9(b), “principal executive officer” and “principal financial officer” shall have the meanings given to such terms in the ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act. Neither the Company nor any Company Subsidiary has outstanding, or has arranged any outstanding, “extensions of credit” to directors or executive officers within the meaning of Section 402 of the Sarbanes Oxley-Act.

(c) Neither the Company nor any of the Company Subsidiaries nor, to the Company’s knowledge, any director, officer, auditor, accountant, consultant or representative of the Company or any of the Company Subsidiaries has received or otherwise had or obtained knowledge of any substantive and material complaint, allegation, assertion or claim, whether written or oral, that the Company or any of the Company Subsidiaries has engaged in questionable accounting or auditing practices. No current or former attorney representing the Company or any of the Company Subsidiaries has reported evidence of a material violation of securities laws, breach of fiduciary duty or similar violation by the Company or any of its officers, directors, employees or agents to the current Company Board or any committee thereof or to any current director or executive officer of the Company.

(d) To the Company’s knowledge, no employee of the Company or any of the Company’s Subsidiaries has provided information to any law enforcement agency regarding the commission or possible commission of any crime or the violation or possible violation of any applicable Legal Requirements described in Section 806 of the ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act by the Company or any of the Company Subsidiaries. Neither the Company nor any of the Company’s Subsidiaries nor, to the knowledge of the Company, any director, officer, employee, contractor, subcontractor or agent of the Company or any such Subsidiary has discharged, demoted, suspended, threatened, harassed or in any other manner discriminated against an employee of the Company or any of the Company’s Subsidiaries in the terms and conditions of employment because of any lawful act of such employee described in Section 806 of the ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act.

3.10. Absence of Certain Changes.

(a) Between December 31, 2006 and the date of this Agreement, neither the Company nor any Company Subsidiary has: (i) suffered any Company Material Adverse Effect; (ii) conducted its respective business other than in the Ordinary Course of Business.

(b) Between December 31, 2006 and the date of this Agreement, neither the Company nor any Company Subsidiary has, except as disclosed in Part 3.10(b) of the Company Disclosure Schedule taken any action that, if taken during the period from the date of this Agreement through the Effective Time, would constitute a breach of Section 5.1.

3.11. Title to Assets; Real Property.

(a) The Company or one of the Company Subsidiaries owns, and has good title to, each of the tangible assets reflected as owned by the Company or the Company Subsidiaries on the Latest Balance Sheet (except for tangible assets sold or disposed of since that date in the Ordinary Course of Business) free of any liens or Encumbrances (other than Permitted Encumbrances). The material properties and tangible assets owned or leased by the Company and the Company Subsidiaries are sufficient (subject to normal wear and tear) to operate their businesses in substantially the same manner as they are currently conducted by the Company and the Company Subsidiaries.

(b) Part 3.11(b) of the Company Disclosure Schedule lists each real property that is owned by the Company or any Company Subsidiary as of the date of this Agreement (such property, together with any real property acquired by the Company after the date of this Agreement (which will have been so acquired in compliance with Section 5.1), the “Owned Real Property”). Except as disclosed in Part 3.11(b) of the Company Disclosure Schedule, each of the Company and or a Company Subsidiary has good title to the Owned Real Property, free and clear of all Encumbrances, other than Permitted Encumbrances. Except as set forth on Part 3.11(b) of the Company Disclosure Schedule, (i) there are no outstanding Contracts for the sale of any of the Owned Real Property, (ii) there are no leases, subleases, licenses, concessions or any other Contracts

granting to any Person other than the Company or any of the Company Subsidiaries any right to the possession, use, occupancy or enjoyment of any of the Owned Real Property or any portion thereof and (iii) there are no easements, covenants, rights-of-way and other similar restrictions of record, if any, that, individually or in the aggregate, materially impair, or would reasonably be expected to impair materially, the continued use and operation of the Owned Real Property to which they relate in the conduct of the business of the Company and the Company Subsidiaries as presently conducted. Any reciprocal easements, operating agreements, option agreements, rights of first refusal or rights of first offer with respect to any Owned Real Property are set forth in Part 3.11(b) of the Company Disclosure Schedule. There are no physical conditions or defects at any of the Owned Real Property which materially impair or would be reasonably expected to materially impair the continued operation of such facility as presently conducted. The present use of the land, buildings, structures and improvements on the Owned Real Property are, in all material respects, in conformity with all Legal Requirements, including all applicable zoning laws, ordinances and regulations and with all registered deeds or other restrictions of record, and neither the Company nor any of the Company Subsidiaries, as the case may be, has received any written notice of violation thereof, except for such nonconformities or violations that do not, and would not, individually or in the aggregate, reasonably be expected to materially interfere with the operations at the Owned Real Property as presently conducted (or as would be conducted at full capacity). Neither the Company nor any of the Company Subsidiaries, as the case may be, has received any written notice of any material conflict or dispute with any Governmental Entity or other Person relating to any Owned Real Property or the activities thereon, other than where there is no current or reasonably likely material interference with the operations at the Owned Real Property as presently conducted (or as would be conducted at full capacity). As of the date hereof, there are no existing, or to the knowledge of the Company, any threatened or pending condemnation or eminent domain proceedings (or proceedings in lieu thereof) affecting the Owned Real Property or any portion thereof.

(c) Part 3.11(c) of the Company Disclosure Schedule lists each real property that is leased by the Company or any Company Subsidiary as of the date of this Agreement, pursuant to which the Company or such Company Subsidiary is required to pay a monthly rental in excess of $50,000 (such property, together with any such lease entered into by the Company or a Company Subsidiary after the date of this Agreement which will have been so acquired in compliance with Section 5.1, the “Leased Real Property”). Except as disclosed in Part 3.11(c) of the Company Disclosure Schedule, the Company or a Company Subsidiary holds a valid leasehold interest in the Leased Real Property free and clear of all Encumbrances, other than Permitted Encumbrances or Encumbrances encumbering a lessor’s interest in the Leased Real Property incurred by the lessor. Each of the leases under which the Leased Real Property is held (A) is in full force and effect, and (B) is enforceable against the Company or the Company Subsidiaries and the other party or parties thereto, in accordance with its terms, except as the same may be limited by (i) laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies. No material default exists under any lease under which the Leased Real Property is held to which the Company or any of the Company Subsidiaries is a party and no circumstance exists which, with the giving of

notice, the passage of time or both, is reasonably likely to result in such a default. Except as set forth on Part 3.11(c) of the Company Disclosure Schedule, there are no material subleases, licenses, concessions or any other Contracts or agreements to which the Company or any of the Company Subsidiaries is a party or by which any of them is otherwise bound granting to any Person or entity other than the Company or any of the Company Subsidiaries any right to the possession, use, occupancy or enjoyment of any of the Leased Real Property or any portion thereof. Any material reciprocal easements, operating agreements, option agreements, rights of first refusal or rights of first offer to which the Company or any of the Company Subsidiaries is a party or by which any of them is otherwise bound with respect to any Leased Real Property are set forth in Part 3.11(c) of the Company Disclosure Schedule. There are no physical conditions or defects at any of the Leased Real Property which materially impair or would be reasonably expected to materially impair the continued operation of such facility as presently conducted. As of the date hereof, there are no existing, or to the knowledge of the Company, any threatened or pending condemnation or eminent domain proceedings (or proceedings in lieu thereof) affecting the Leased Real Property or any portion thereof. The present use of the land, buildings, structures and improvements on the Leased Real Property are, to the knowledge of the Company, in conformity with all Legal Requirements, including all applicable zoning laws, ordinances and regulations and with all registered deeds or other restrictions of record, and neither the Company nor any of the Company Subsidiaries, as the case may be, has received any written notice of violation thereof, except for such nonconformities or violations that would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. Neither the Company nor any of the Company Subsidiaries, as the case may be, has received any written notice of any conflict or dispute with any Governmental Entity or other Person relating to any Leased Real Property or the activities thereon, other than where there is no current or reasonably likely material interference with the operations at the Leased Real Property as presently conducted (or as would be conducted at full capacity).

3.12. Intellectual Property Rights.

(a) Part 3.12(a) of the Company Disclosure Schedule sets forth with respect to the Intellectual Property Rights owned by the Company or the Company Subsidiaries: (i) for each patent and patent application, the patent number or application serial number for each jurisdiction in which the patent or application has been filed, the date filed or issued, and the present status thereof, as maintained in records by the Company, a Company Subsidiary, or its or their outside intellectual property counsel; (ii) for each registered trademark, trade name or service ▇▇▇▇, the application serial number or registration number, for each country, province and state, and the class of goods covered, as maintained in records by the Company, a Company Subsidiary, or its or their outside intellectual property counsel; and (iii) for any URL or domain name, the registration date, any renewal date and name of registry, as maintained in records by the Company, a Company Subsidiary, or its or their outside intellectual property counsel. As of the date of this Agreement, to the knowledge of the Company, all registered trademarks, issued patents and registered copyrights owned by the Company or a Company Subsidiary are valid and subsisting. To the knowledge of the Company,

neither the Company nor any Company Subsidiary is engaging in or has engaged at any time in any patent or copyright misuse or any fraud or inequitable conduct, including with respect to its patent applications, trademark applications or copyright registration applications.

(b) To the knowledge of the Company, the Intellectual Property Rights and Technology owned or licensed by the Company and the Company Subsidiaries, or that the Company or any Company Subsidiary has a right to use pursuant to a covenant not to ▇▇▇, constitute all Intellectual Property Rights and Technology used in or necessary for the conduct of the Company’s or the Company Subsidiaries’ business as presently conducted, including the design, manufacture, license, sale and support of all (i) Products Under Development or (ii) products currently offered for sale by the Company or a Company Subsidiary.

(c) Except pursuant to licenses or with respect to the subject matter listed in Part 3.12(c) of the Company Disclosure Schedule, to the knowledge of the Company neither the Company nor any Company Subsidiary is compensating or has any obligation to compensate or account to any Person for the use of any of the Company’s or any Company Subsidiary’s Intellectual Property Rights or Technology used in the design, manufacture, license, sale and support of all (i) Products Under Development or (ii) products currently offered for sale by the Company and the Company Subsidiaries.

(d) The Company or each Company Subsidiary (i) owns all right, title and interest in and to the Intellectual Property Rights and Technology owned or purported to be owned by the Company, including the Intellectual Property Rights and Technology listed on Part 3.12(a) of the Company Disclosure Schedule, free and clear of any mortgage, easement, lien, pledge (including any negative pledge) or security interest (other than Permitted Encumbrances); and (ii) has a valid and enforceable right or license to use all other Intellectual Property Rights and Technology used in the design, manufacture, license, sale and support of all products currently offered for sale or with respect to Products Under Development by the Company and the Company Subsidiaries, and, except as disclosed in Part 3.12(d) of the Company Disclosure Schedule, all such licensed Intellectual Property Rights and rights to use Technology will not cease to be valid and enforceable rights of the Company or the applicable Company Subsidiary by reason of the execution, delivery and performance of this Agreement, or by any ancillary agreements executed in connection with this Agreement, or the consummation of the transactions contemplated hereby or thereby.

(e) Except as disclosed in Part 3.12(e) of the Company Disclosure Schedule, no Legal Proceedings are pending against the Company or a Company Subsidiary, or, to the knowledge of the Company, are threatened, that challenge the right of Company or the Company Subsidiaries with respect to the use or ownership of the Intellectual Property Rights or Technology owned or licensed by the Company and the Company Subsidiaries. Without limiting the foregoing, and except as disclosed in Part 3.12(e) of the Company Disclosure Schedule, no interference, opposition, reexamination, or other Legal Proceeding initiated by a third party is pending against the Company or a Company Subsidiary, or, to the Company’s knowledge, is threatened, or has during the

past three years been threatened but did not develop into a Legal Proceeding in which the scope, validity, or enforceability of any of Company’s or the Company Subsidiaries’ Intellectual Property Rights is being or has been challenged. Except as disclosed in Part 3.12(e) of the Company Disclosure Schedule, to the knowledge of the Company, neither the Company’s nor any Company Subsidiary’s past or present use of Intellectual Property Rights or Technology owned by the Company or any Company Subsidiary infringes upon or misappropriates, breaches or otherwise conflicts with the Intellectual Property Rights of any third party and neither the Company nor any Company Subsidiary has received any notice alleging any such infringement or misappropriation. Except as disclosed in Part 3.12(e) of the Company Disclosure Schedule, the Intellectual Property Rights and Technology owned by the Company and each Company Subsidiary are not subject to any outstanding judgment, decree, order, writ, award, injunction or determination of an arbitrator or court or other governmental authority (other than office actions and correspondence regarding pending patent applications and trademark applications) restricting the rights of the Company or any Company Subsidiary with respect thereto. To the knowledge of the Company, no Person has interfered with, infringed upon or misappropriated any of the Intellectual Property Rights owned by the Company or any Company Subsidiary, or is currently doing so.

(f) To the knowledge of the Company, all of the registrations and pending applications to Governmental Entities with respect to the Intellectual Property Rights owned by the Company and the Company Subsidiaries are being duly maintained and prosecuted and all maintenance and related fees due as of the date hereof have been paid. The Company and each Company Subsidiary has taken reasonable steps to safeguard and maintain the secrecy and confidentiality of trade secrets that are material to the Company and the Company Subsidiaries. The Company has entered into an employee confidentiality and assignment of inventions agreement in the standard form that has been made available to Parent with each U.S. based employee of the Company or a Company Subsidiary. Without limiting the foregoing, except as disclosed in Part 3.12(f) of the Company Disclosure Schedule, to the knowledge of the Company, (i) there has been no misappropriation of any trade secrets or other confidential Intellectual Property Rights or Technology used in connection with the business of the Company or the Company Subsidiaries by any Person; (ii) no employee, independent contractor or agent of the Company or any Company Subsidiary has misappropriated any trade secrets of any other Person in the course of performance as an employee, independent contractor or agent of the business; and (iii) no employee, independent contractor or agent of the Company or any Company Subsidiary is in default or breach of any term of any employment agreement, nondisclosure agreement, assignment of invention agreement or similar Contract relating in any way to the protection, ownership, development, use or transfer of the Intellectual Property Rights and Technology of the Company or the Company Subsidiaries. No funding, facilities, or personnel of any Governmental Entity or educational institution were used, directly or indirectly, to develop or create, in whole or in part, any Intellectual Property Rights or Technology owned by the Company or any Company Subsidiary. Neither the Company nor any Company Subsidiary has made any written submission to, and is not subject to any Contract with, any standards bodies or other entities that would obligate the Company or any Company Subsidiary to grant licenses to or otherwise impair its control of its Intellectual Property Rights.

(g) To the knowledge of the Company, any software or firmware incorporated in or provided with the products, and any media used to distribute it, contain at delivery no computer instructions, circuitry or other technological means whose purpose or effect is to disrupt, damage or negatively interfere with any use of any customer’s computer and communications facilities or equipment (“Harmful Code”), and the Company and each Company Subsidiary have used commercially reasonable efforts to prevent the introduction of such Harmful Code to all software, firmware and media distributed, licensed or sold by the Company or any Company Subsidiary. “Harmful Code” includes (i) any instrumentality that could cause the software or firmware to fail to be operative upon command of or by design by the Company or any Company Subsidiary, and (ii) any code containing viruses, trojan horses, worms, or like destructive code or code that self-replicates. Except as disclosed in Part 3.12(g) of the Company Disclosure Schedule, to the knowledge of the Company, none of the software incorporated in the Company’s or any Company Subsidiary’s products is, in whole or in part, subject to the provisions of any open source or quasi-open source license agreement, or any other Contract obligating the Company to make source code available to third parties or to publish source code. Except as disclosed in Part 3.12(g) of the Company Disclosure Schedule, neither the Company nor any Company Subsidiary have entered into any Contract requiring the Company or any Company Subsidiary to place the source code or other Technology incorporated in the Company’s or Subsidiaries’ products in escrow so that a licensee might obtain access to it upon the occurrence of any release condition.

(h) The Company and the Subsidiaries have obtained all material approvals necessary for exporting the Company’s and the Subsidiaries’ products outside the United States in accordance with all applicable United States export control regulations, and importing the products into any country in which the products are now sold or licensed for use, and all such export and import Governmental Authorizations or approvals in the United States and throughout the world are valid, current, outstanding and in full force and effect in all material respects.

(i) To the actual knowledge of the individuals specified in Part 3.12(i)(1) of the Company Disclosure Schedule, there is no basis in existence as of the date of this Agreement that would give the Person specified in Part 3.12(i)(2) of the Company Disclosure Schedule the legal right to terminate the Confidential Agreement pursuant to Section 9.2 of the Confidential Agreement. The Confidential Agreement has not been amended or modified in any material respect since December 31, 2006.

3.13. Contracts.

(a) Part 3.13 of the Company Disclosure Schedule contains a list as of the date of this Agreement of each of the following Contracts to which the Company or any of the Company Subsidiaries is a party or by which any of them or their respective assets are otherwise bound:

(i) other than distribution Contracts, each Contract that provides for exclusivity or restricts in any material respect the ability of the Company or any of the Company Subsidiaries or any of the Company’s current or

future Affiliates to compete in any geographic area or line of business, in each case for a period extending beyond three months from the date of this Agreement, or pursuant to which any benefit or right is required to be given or lost as a result of so competing;

(ii) each indemnification or employment contract with any director or officer of the Company or the Company Subsidiaries;

(iii) each Contract evidencing Indebtedness in excess of $500,000 in aggregate principal amount;

(iv) each (A) distributor Contract or (B) supply Contract pursuant to which goods, raw materials, or equipment are supplied to the Company or any Company Subsidiary (excluding purchase orders given or received in the Ordinary Course of Business), in each case under which the Company or any Company Subsidiary paid or received in excess of $500,000 in fiscal 2006 or is expected to pay or receive in excess of $ 500,000 in fiscal 2007;

(v) each customer Contract (excluding purchase orders given or received in the Ordinary Course of Business) under which the Company or any Company Subsidiary received in excess of $1,500,000 in fiscal 2006 or is expected to receive in excess of $1,500,000 in fiscal 2007;

(vi) each material “single source” supply Contract pursuant to which goods, raw materials or equipment are supplied to the Company or any Company Subsidiary from an exclusive source;

(vii) each collective bargaining agreement;

(viii) each lease involving real property pursuant to which the Company or any of the Company Subsidiaries is required to pay a monthly rental in excess of $50,000;

(ix) each lease or rental Contract involving personal property (and not relating primarily to real property) pursuant to which the Company or any of the Company Subsidiaries is required to make rental payments in excess of $50,000 per year;

(x) each Contract that involves “take or pay” provisions under which the Company or any Company Subsidiary paid or received in excess of $500,000 in fiscal 2006 or is expected to pay or receive in excess of $500,000 in fiscal 2007 or, based on the Company’s present operations, any fiscal year thereafter;

(xi) each Contract pursuant to which any of the benefits to any party of which will be materially increased, or the vesting of the benefits to any party of which will be materially accelerated, by the occurrence of any of the transactions contemplated by this Agreement or the value of any of the material benefits to any party of which will be calculated on the basis of any of the transactions contemplated by this Agreement;

(xii) each Contract for any joint venture (whether in partnership, limited liability company or other organizational form), co-promote agreements or co-branding agreements (other than distribution agreements) or agreements pursuant to which the Company or a Company Subsidiary permitted distribution of the Company’s products under another party’s name or trademarks;

(xiii) each Contract providing for future performance by the Company or a Company Subsidiary in consideration of amounts previously paid the balance of which exceeds $250,000 as of the date of this Agreement;

(xiv) each Contract where, in settlement of an actual or threatened Legal Proceeding for patent infringement, trade secret misappropriation or similar intellectual property action, another Person agrees in writing not to contest the validity or ownership of Intellectual Property Rights of the Company; and

(xv) each Contract granting a third party any license to use Intellectual Property Rights of the Company relating to Products Under Development in the field of clinical diagnostics.

In this Agreement, “Material Contract” refers to each Contract (x) identified in this Section 3.13, whether or not listed in Part 3.13 of the Company Disclosure Schedule, (y) entered into after the date of this Agreement that would be required to be listed in Part 3.13 of the Company Disclosure Schedule if such Contract were in effect as of the date of this Agreement, or (z) that would be required to be filed as an exhibit to a Registration Statement on Form S-1 filed by the Company under the Securities Act or as an exhibit to an Annual Report on Form 10-K filed by the Company under the Exchange Act.

(b) Each Material Contract is enforceable against the Company and each Company Subsidiary that is a party thereto and each other party thereto, except as the same may be limited by (i) laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies. There are no material existing breaches or defaults on the part of the Company or any of the Company Subsidiaries under (or any condition to which with the passage of time or the giving of notice would cause such a breach of or default under) any Material Contract and, to the knowledge of the Company, there are no material existing breaches or defaults on the part of any other Person under (or any condition to the knowledge of the Company which with the passage of time or the giving of notice would cause such a breach of or default under) any Material Contract. The Company has made available to Parent copies of each Material Contract in effect as of the date of this Agreement, together with all amendments and supplements thereto in effect as of the date of this Agreement.

3.14. Compliance with Legal Requirements. Except as set forth in Section 3.18 pertaining to compliance with FDA Laws, the Company and the Company Subsidiaries are and at all time have been in material compliance with all material Legal Requirements applicable to their businesses.

3.15. Foreign Corrupt Practices and International Trade Sanctions. Except as disclosed in Part 3.15 of the Company Disclosure Schedule, neither the Company, nor any Company Subsidiary, nor any of their respective directors, officers, agents, employees or any other Persons acting on their behalf has (i) violated the Foreign Corrupt ▇▇▇▇▇▇▇▇▇ ▇▇▇, ▇▇ ▇.▇.▇. § ▇▇▇▇-▇ et seq., or any other similar applicable foreign, federal, or state Legal Requirement, (ii) made or provided, or caused to be made or provided, directly or indirectly, any payment or thing of value to a foreign official, foreign political party, candidate for office or any other person knowing that the person will pay or offer to pay the foreign official, party or candidate, for the purpose of influencing a decision, inducing an official to violate their lawful duty, securing any improper advantage, or inducing a foreign official to use their influence to affect a governmental decision, (iii) paid, accepted or received any unlawful contributions, payments, expenditures or gifts, or (iv) violated or operated in noncompliance with any export restrictions, money laundering law, anti-terrorism law or regulation, anti-boycott regulations or embargo regulations.

3.16. Governmental Authorizations. As of the date of this Agreement, the Company and the Company Subsidiaries hold all Governmental Authorizations necessary to enable them to conduct their businesses in all material respects in the manner in which such businesses are currently being conducted and are proposed to be conducted. The material Governmental Authorizations held by the Company and the Company Subsidiaries are, in all material respects, valid and in full force and effect. The Company and the Company Subsidiaries are in compliance with the terms and requirements of such Governmental Authorizations in all material respects. The execution and delivery of this Agreement by the Company does not, and the consummation of the Offer, the Merger or the other transactions contemplated hereby and compliance with the terms hereof would not reasonably be expected to cause the revocation or cancellation of any material Governmental Authorization. To the knowledge of the Company, there are no facts or circumstances existing which would lead to any suspension, loss of or material modification to any material Governmental Authorization or refusal by a Governmental Entity to renew or accept for filing any material Governmental Authorizations on terms not substantially less advantageous, in the aggregate, to the Company and the Company Subsidiaries than the terms of those Governmental Authorization currently in force. All Governmental Authorizations material to the operation of the Company’s or any Company Subsidiary’s business is transferable to Parent or any of its Subsidiaries at the Effective Time if necessary to be so transferred following the Acceptance Time. Since January 1, 2004, neither the Company nor any of the Company Subsidiaries has been notified by any Governmental Entity: (a) asserting any material violation of any term or requirement of any Governmental Authorization or Legal Requirement; or (b) notifying the Company or one of the Company Subsidiaries of the suspension, revocation of, loss of or material modification to any Governmental Authorization.

3.17. Legal Proceedings; Orders. As of the date of this Agreement:

(a) except as disclosed in Part 3.17 of the Company Disclosure Schedule, (i) there is no Legal Proceeding pending (or, to the knowledge of the Company, threatened) against the Company or any of the Company Subsidiaries or any of their respective properties or rights or any executive officer or director of the Company or any Company Subsidiary (in their capacity as such), in which the claim is for more than $200,000 in damages, or for an injunction or specific performance, and (ii) neither the Company, any Company Subsidiary, nor, to the knowledge of the Company, any of its or their current or former officers, directors, employees, or independent contractors, each in their capacity as such, has been identified by any Governmental Entity as a subject or target of a government investigation, or otherwise been informed or become aware that their conduct is being investigated by a Governmental Entity. Except as set forth in Part 3.17 of the Company Disclosure Schedule, there is no Legal Proceeding brought by the Company against any Person that is pending as of the date of this Agreement; and

(b) there is no material order, injunction, decree or judgment specific to the Company or any of the Company Subsidiaries to which the Company or any of the Company Subsidiaries is subject.

3.18. Regulatory Matters.

(a) The Company and the Company Subsidiaries have established and administer compliance programs (including written compliance policies) applicable to the Company and the Company Subsidiaries (i) to assist the Company, the Company Subsidiaries and their respective directors, officers and employees in complying with all Legal Requirements and guidelines (including those administered by the FDA) applicable to the Company, the Company Subsidiaries or their businesses and (ii) to provide compliance policies governing activities and requirements applicable to medical device companies (including pre-clinical and clinical testing, product design and development, product testing, product manufacturing, product labeling, product storage, pre-market clearance and approval, marketing, advertising and promotion, product sales and distribution, medical device recall and reporting regulations, and record keeping).

(b) Except as set forth in Part 3.18(b) of the Company Disclosure Schedule, the Company and each Company Subsidiary is in compliance in all material respects with all Legal Requirements applicable to the Company’s products and activities, including product design, development, testing, manufacture, marketing, distribution, labeling, storage and transport, in all jurisdictions in which such acts or any of them occur or are reasonably likely to occur or such products or any of them are likely to be sold or used (including any FDA Laws). All applications, submissions, information, claims, reports and statistics and other data and conclusions derived therefrom, utilized as the basis for or submitted in connection with any and all requests for authorizations, approvals, certificates, waivers, certifications, clearances, exemptions, notifications, consents, orders, registrations, licenses or permits of the FDA or comparable Governmental Entities relating to the Company, the Company Subsidiaries,

their businesses and their products were, when submitted to the FDA or other Governmental Entities, true, complete and correct in all material respects and in conformance with Legal Requirements as of the date of submission and any updates, changes, corrections or modification to such applications, submissions, information and data which were or are necessary or required to be filed, maintained, or furnished to the FDA or other Governmental Entities have been timely filed, maintained, or furnished and were true, complete and correct in all material respects and in conformance with Legal Requirements as of the date of submission. The labeling claims made by the Company and the Company Subsidiaries for each of their products are consistent with the scope of regulatory clearance, exemption or approval for each product in each jurisdiction where it is marketed in all material respects, and supported by proper research design, testing, analysis and disclosure that conforms with Legal Requirements.

(c) The activities, products and facilities of the Company and the Company Subsidiaries, as well as, to the Company’s knowledge, its suppliers, distributors, contractors and other intermediaries, are in compliance with all applicable requirements of CLIA, the FDCA and implementing FDA regulations, including the registration, listing, labeling and manufacturing requirements of 21 C.F.R. Parts 807, 809 and 820, all to the extent applicable to the Company’s products and services. The Company and each Company Subsidiary is not subject to any obligation arising under any consent decree, consent agreement, or warning letter issued by or entered into with the FDA or any other Governmental Entity or other notice, response or commitment made to the FDA or any other Governmental Entity. The Company has delivered to Parent true, correct and complete copies of all customer complaints relating to the Company’s and the Company Subsidiaries’ products and all Medical Device Reports, in each case, filed with the FDA within the last five years. The Company has delivered to Parent true, complete and correct copies of all warning letters, untitled letters, notices of inspectional observations (Form FDA 483s), or similar notices, or other correspondence relating to the Company’s and the Company Subsidiaries’ products and its compliance with Legal Requirements from the FDA and any other Governmental Entity and all of the Company’s responses thereto within the last five years.

(d) Except as set forth in Part 3.18(d) of the Company Disclosure Schedule, since January 1, 2003, no exemptions, clearances or approvals for the Company and the Company Subsidiaries’ products have been subjected to reevaluation or suspension of sale by the FDA and no products manufactured, marketed or sold by the Company or any Company Subsidiary have been recalled or subject to a field notification, field correction or safety alert (whether voluntarily or otherwise) and no proceedings have occurred (whether completed or pending) seeking to recall, reclassify, re-label, suspend, or seize any product sold or proposed to be sold by the Company or a Company Subsidiary. To the Company’s knowledge, there are no facts which are reasonably likely to cause: (A) the recall, suspension, field notification, field correction, reclassification, re-labeling or safety alert of any product sold or intended to be sold by the Company or any Company Subsidiary; (B) a change in the marketing classification or a material change in labeling of any such products; or (C) a termination or suspension of marketing of any such products.

(e) All products being manufactured, distributed, or developed by the Company and the Company Subsidiaries that are subject to the jurisdiction of the FDA or comparable Governmental Entity are being manufactured, labeled, stored, tested, distributed, and marketed in material compliance with all applicable requirements and implementing regulations thereunder.

(f) Except as set forth in Part 3.18(f) of the Company Disclosure Schedule, all pre-clinical trials and clinical trials conducted by or on behalf of the Company and the Company Subsidiaries have been, and are being conducted in material compliance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all applicable Legal Requirements relating thereto, including the FDCA and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56 and 812.

(g) Neither the Company, the Company Subsidiaries, nor, to the knowledge of the Company, any of their collective officers, employees or agents has committed any act, made any statement, or failed to make any statement, that would be reasonably expected to provide a basis for the FDA to invoke its policy respecting “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,” set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto.

(h) Neither the Company, the Company Subsidiaries, nor, to the knowledge of the Company, any of their collective officers, employees or agents has been convicted of any crime or engaged in any conduct that could result in a material debarment or exclusion under 21 U.S.C. Section 335a or under any similar Legal Requirement. No claims, actions, proceedings or investigations that could reasonably be expected to result in such a material debarment or exclusion are pending or threatened against the Company, the Company Subsidiaries, or, to the knowledge of the Company, any of their collective officers, employees or agents.

(i) Except as disclosed on Part 3.18(i) of the Company Disclosure Schedule, there are no investigations, audits, actions or other proceedings pending with respect to a violation by the Company or any Company Subsidiary of any Legal Requirement that reasonably would be expected to result in administrative, civil, or criminal liability, and there are no facts or circumstances existing that would reasonably be expected to serve as a basis for such an investigation, audit, action or other proceeding.

(j) The Company and each of the Company Subsidiaries is in material compliance with all applicable FDA import and export requirements, including import-for-export requirements, export notifications or authorizations and record keeping requirements.

3.19. Product Recalls. Part 3.19 of the Company Disclosure Schedule sets forth a list of (i) all recalls, field notifications, field corrections and safety alerts with respect to products manufactured and/or distributed by the Company or any Company Subsidiary, or by any Person on behalf of the Company or any Company Subsidiary, in each case

between January 1, 2004 and the date of this Agreement, and the dates, if any, such recalls, field notifications, field corrections and safety alerts were resolved or closed, and (ii) to the knowledge of the Company, any material complaints with respect to products produced by the Company or any or any Company Subsidiary, or by any Person on behalf of the Company or any or any Company Subsidiary, that are open as of the date of this Agreement. There are no outstanding recalls, field notifications, field corrections, safety alerts or product complaints with respect to the products manufactured and/or distributed by the Company or any or any Company Subsidiary, or by any Person on behalf of the Company or any or any Company Subsidiary, and to the Company’s knowledge, there are no facts that would be reasonably likely to result in a material product recall, field notification, field correction or safety alert with respect to any such products.

3.20. Tax Matters.

(a) Each of the Company and the Company Subsidiaries has timely filed with the appropriate Governmental Entity all Tax Returns required to be filed. All such Tax Returns are complete and accurate in all material respects and have been prepared in compliance with applicable Legal Requirements. All material Taxes due and owing by the Company and the Company Subsidiaries (whether or not shown on any Tax Return) have been paid. Neither the Company nor any Company Subsidiary is the beneficiary of any extension of time within which to file any material Tax Return. No written claim has ever been received by the Company or any Company Subsidiary from a Governmental Entity in a jurisdiction where the Company or any Company Subsidiary does not file Tax Returns that it is or may be subject to taxation by that jurisdiction.

(b) The unpaid Taxes of the Company and the Company Subsidiaries did not, as of the date of the Latest Balance Sheet, exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the face of such balance sheets (rather than in any notes thereto). Since the date of the Latest Balance Sheet, neither the Company nor any Company Subsidiary has incurred any liability for Taxes outside the ordinary course of business or otherwise inconsistent with past custom and practice.

(c) There are no examinations, audits or Legal Proceedings with respect to material Taxes of the Company or any Company Subsidiary currently pending or underway (and to the knowledge of the Company no such examination, audit or proceeding is threatened) nor has the Company or any Company Subsidiary received any notice from a Governmental Entity relating to any issue which could result in a material Tax liability for the Company or any Company Subsidiary. No deficiency for material Taxes against the Company or any Company Subsidiary has been claimed, proposed or assessed by any Governmental Entity that has not been satisfied by payment or withdrawn. No extension or waiver of the limitation period applicable to any material Taxes or material Tax Return is in effect. The Company has delivered or made available to Parent complete and accurate copies of federal, state and local Tax Returns of the Company and each Company Subsidiary and their predecessors for all open Tax years, and complete and accurate copies of all examination reports and statements of deficiencies assessed against or agreed to by the Company, any Company Subsidiary or any predecessors since its last open Tax year.

(d) There are no Encumbrances for material Taxes (other than Permitted Encumbrances) upon any of the assets of the Company or any Company Subsidiary.

(e) Neither the Company nor any Company Subsidiary will be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any period (or any portion thereof) ending after the Acceptance Time as a result of any installment sale or other transaction on or prior to the Acceptance Time, any accounting method change or agreement with any Governmental Entity, any prepaid amount received on or prior to the Acceptance Time or any intercompany transaction or excess loss account described in Code Section 1502 (or any corresponding provision of state, local or foreign Tax law).

(f) None of the outstanding indebtedness of the Company or any Company Subsidiary constitutes indebtedness with respect to which any interest deductions may be disallowed under Sections 163(i), 163(l) or 279 of the Code or under any other provision of applicable Legal Requirements.

(g) The Company and each Company Subsidiary has withheld and paid all Taxes required to have been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, service provider, creditor, stockholder or other third party and is not liable for any arrears of wages or any taxes or any penalty for failure to withhold or pay such amounts.

(h) Neither the Company nor any Company Subsidiary: (i) is a party to or bound by a Tax sharing, allocation, indemnification or similar agreement; (ii) has been a member of an affiliated group of corporations within the meaning of Section 1504 of the Code or any group that has filed a consolidated, combined or unitary Tax Return other than a consolidated, combined or unitary group of which the Company is the common parent; or (iii) has any liability for material Taxes of any Person (other than Taxes of the Company and the Company Subsidiaries) under Treasury regulation Section 1.1502-6 (or any similar provision of a Legal Requirement), as a transferee or successor, by Contract, or otherwise. For the purposes of this Section 3.20(h), commercially reasonable Contracts providing for the allocation or payment of real property Taxes attributable to real property leased or occupied by the Company or any Company Subsidiary shall be disregarded.

(i) Neither the Company nor any Company Subsidiary: (i) has ever been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code; (ii) has been a stockholder of a “controlled foreign corporation” as defined in Section 957 of the Code (or any similar provision of a Legal Requirement); (iii) has been a “personal holding company” as defined in Section 542 of the Code (or any similar provision of a Legal Requirement); (iv) has had a material liability with respect to Taxes as a result of being a stockholder of a “passive foreign investment

company” within the meaning of Section 1297 of the Code; or (v) has engaged in a trade or business, had a permanent establishment (within the meaning of an applicable Tax treaty) or has otherwise become subject to Tax jurisdiction in a country other than the country of its formation.

(j) None of the Company, any Company Subsidiary or predecessor has within the past three (3) years been a party to a transaction intended to qualify under Section 355 of the Code or under so much of Section 356 of the Code as relates to Section 355 of the Code.

(k) None of the Company Subsidiaries organized outside of the United States is a “surrogate foreign corporation” within the meaning of Section 7874(a)(2)(B) of the Code or is treated as a United States corporation under Section 7874(b) of the Code.

(l) Neither the Company nor any Company Subsidiary has entered into any transaction identified as a “reportable transaction” for purposes of Treasury regulations Sections 1.6011 -4(b)(2) or 301.6111 -2(b)(2).

3.21. Employee Benefit Plans.

(a) For purposes of this Section 3.21(a), “Company Plan” means each “employee benefit plan” as defined in Section 3(3) of ERISA (whether or not subject to ERISA) and each other plan, policy, program, practice, agreement, understanding or arrangement (whether written or oral) providing compensation or other benefits to any current or former director, officer, employee or consultant (or to any dependent or beneficiary thereof) of the Company or any ERISA Affiliate (as defined below), which is now, or was within the past six years, maintained, sponsored or contributed to by the Company or any ERISA Affiliate, or under which the Company or any ERISA Affiliate has or may have any obligation or liability, whether actual or contingent, including all incentive, bonus, deferred compensation, vacation, holiday, cafeteria, medical, disability, stock purchase, stock option, stock appreciation, phantom stock, restricted stock or other stock-based compensation plans, policies, programs, practices or arrangements. Part 3.21(a) of the Company Disclosure Schedule sets forth a complete list of each Company Plan under which the Company or any ERISA Affiliate has or may have any material obligation or material liability, whether actual or contingent.

(b) Each Company Plan which is intended to qualify under Section 401(a), Section 401(k), Section 401(m) or Section 4975(e)(7) of the Code has either (i) received a favorable determination letter from the IRS as to its qualified status, or (ii) may rely upon a favorable prototype opinion letter from the IRS, and each trust established in connection with any Company Plan which is intended to be exempt from federal income taxation under Section 501(a) of the Code is so exempt, and to Company’s knowledge, no fact or event has occurred that could adversely affect the qualified status of any such Company Plan or the exempt status of any such trust.

(c) Each Company Plan complies in all material respects in form and operation, and has been administered in all material respects in accordance with, its terms and all applicable Legal Requirements, including ERISA and the Code, and all contributions required to be made under the terms of any of the Company Plans as of the date of this Agreement have been timely made or, if not yet due, have been properly reflected on the most recent consolidated balance sheet filed or incorporated by reference in the Company financial statements prior to the date of this Agreement. With respect to each Company Plan, all Tax, annual reporting and other filings with a Governmental Entity required by ERISA and the Code have been timely filed with the appropriate Governmental Entity and all notices and disclosures have been timely provided to participants. With respect to the Company Plans, no event has occurred and, to the knowledge of Company, there exists no condition or set of circumstances in connection with which the Company or any Company Subsidiary could be subject to any material liability (other than for routine benefit liabilities) under the terms of, or with respect to, such Company Plans, ERISA, the Code or any other applicable Legal Requirement.

(d) To the Company’s knowledge, there has been no prohibited transaction (within the meaning of Section 406 of ERISA or Section 4975 of the Code and other than a transaction that is exempt under a statutory or administrative exemption) with respect to any Company Plan that could result in liability to the Company or any ERISA Affiliate. Each Company Plan can be amended, terminated or otherwise discontinued after the Effective Time in accordance with its terms, without liability (other than (A) liability for ordinary administrative expenses typically incurred in a termination event or (B) if the Company Plan is a pension benefit plan subject to Part 2 of Title I of ERISA, liability for the accrued benefits as of the date of such termination (if and to the extent required by ERISA) to the extent that either there are sufficient assets set aside in a trust or insurance contract to satisfy such liability or such liability is reflected on the most recent balance sheet included in the Company financial statements prior to the date of this Agreement). Neither the Company, nor to the knowledge of the Company, any other Person or Entity has any express or implied commitment, whether legally enforceable or not, to modify, change or terminate any Company Plan, other than with respect to a modification, change or termination required by ERISA or the Code. No Legal Proceeding has been brought, or to the knowledge of Company is threatened, against or with respect to any such Company Plan, including any audit or inquiry by the IRS or United States Department of Labor. Neither the Company nor any ERISA Affiliate has any liability under ERISA Section 502. All contributions and payments to such Company Plan are deductible under Code Sections 162 or 404. No excise Tax could reasonably be expected to be imposed upon the Company under Chapter 43 of the Code.

(e) No Company Plan is a “multiemployer plan” (as defined in Section 3(37) of ERISA) (a “Multiemployer Plan”) or other pension plan subject to Title IV or Part 3 of Title I of ERISA or Section 412 of the Code, and neither the Company nor any ERISA Affiliate has sponsored, maintained, participated in, contributed to, or has been required to participate in or contribute to a Multiemployer Plan or other pension plan subject to Title IV or Part 3 of Title I of ERISA or Section 412 of the Code. None of the assets of Company or any ERISA Affiliate is, or may reasonably be expected to become, the subject of any Encumbrance arising under ERISA or Section 412(n) of the Code.

(f) Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will result in any payment, acceleration or creation of any rights of any Person to benefits under any Company Plan. No amount that could be received (whether in cash, property, the vesting of property or otherwise) as a result of or in connection with the consummation of the transactions contemplated by this Agreement (either alone or in combination with any other event) or by any of the ancillary agreements, by any employee, officer, director or other service provider of the Company or any of the Company Subsidiaries who is a “disqualified individual” (as such term is defined in Treasury Regulation Section 1.280G-1) could be characterized as an “excess parachute payment” (as defined in Section 280G(b)(1) of the Code).

(g) Except as required by applicable Legal Requirements, no Company Plan provides any of the following retiree or post-employment benefits to any Person: medical, disability or life insurance benefits. No Company Plan is a voluntary employee benefit association under Section 501(a)(9) of the Code. The Company and each ERISA Affiliate is in compliance in all material respects with (i) the requirements of the applicable health care continuation and notice provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, and the regulations (including proposed regulations) thereunder and any similar state law and (ii) the applicable requirements of the Health Insurance Portability and Accountability Act of 1996, as amended, and the regulations (including the proposed regulations) thereunder.

(h) Except as set forth in Part 3.21(h) of the Company Disclosure Schedule, no Company Plan or payment or benefit provided pursuant to any Company Plan between the Company or any of the Company Subsidiaries and any “service provider” (within the meaning of Section 409A of the Code), including the grant, vesting or exercise of any stock option or stock appreciation right, will or may provide for the deferral of compensation subject to Section 409A of the Code, whether pursuant to the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby (either alone or upon the occurrence of any additional or subsequent events) or otherwise. Each Company Plan that is a nonqualified deferred compensation plan subject to Section 409A of the Code has been operated and administered in good faith compliance with Section 409A of the Code from the period beginning January 1, 2005 and continuing through the date hereof. All stock options granted under the Company Option Plans have been granted in compliance with the terms of applicable Legal Requirements and the applicable Company Option Plans and have (or with respect to such options which have been exercised as of the date of this Agreement, had) a per share exercise price that is (or with respect to such options which have been exercised as of the date of this Agreement, was) at least equal to the fair market value of a share of the underlying stock as of the date the option was granted (determined in accordance with applicable Legal Requirements, including, to the extent applicable, Section 409A of the Code).

(i) The Company and each of the Company Subsidiaries have properly classified all individuals providing services to the Company or any of the Company Subsidiaries as employees or non-employees for all relevant purposes.

(j) With respect to each employee benefit plan, program, or other arrangement providing compensation or benefits to any employee or former employee of the Company or any of the Company Subsidiaries (or any dependent thereof) which is subject to the Legal Requirements of any jurisdiction outside of the United States (the “Foreign Plans”): (i) such Foreign Plan has been maintained in all material respects in accordance with all applicable Legal Requirements, (ii) if intended to qualify for special Tax treatment, such Foreign Plan meets all Legal Requirements for such treatment, (iii) if intended or required to be funded and/or book-reserved, such Foreign Plan is fully funded and/or book reserved, as appropriate, based upon reasonable actuarial assumptions, and (iv) no material liability exists or reasonably could be imposed upon the assets of the Company or any of the Company Subsidiaries by reason of such Foreign Plan.

(k) The execution and delivery of this Agreement and the consummation of the Offer and the Merger: (i) will not materially increase the benefits payable by the Company or any of the Company Subsidiaries under any Company Plan; and (ii) will not result in any acceleration of the time of payment or vesting of any material benefits payable by the Company or any of the Company Subsidiaries under any Company Plan.

(l) The Company Board, at a meeting duly called and held or by a duly executed action by unanimous written consent, has determined that each of the members of the Compensation Committee of the Company Board (the “Compensation Committee”) are, and the Company represents and warrants that each of the members of the Compensation Committee are and at the Acceptance Time will be, “independent directors” as defined in Rule 4200(a)(15) of the Nasdaq Marketplace Rules and eligible to serve on the Compensation Committee under the Exchange Act and all applicable Marketplace Rules of the NASDAQ Global Select Market. On or prior to the date hereof, the Compensation Committee, at a meeting duly called and held or by a duly executed action by unanimous written consent, approved each Company Compensation Arrangement as an “employment compensation, severance or other employee benefit arrangement” within the meaning of Rule 14d- 10(d)( 1) under the Exchange Act (an “Employment Compensation Arrangement”), and has taken all other action necessary to satisfy the requirements of the non-exclusive safe harbor with respect to such Company Compensation Arrangements in accordance with Rule 14d-10(d)(2) under the Exchange Act. All amounts payable under each Company Compensation Arrangement (i) are being paid or granted as compensation for past services performed, future services to be performed, or future services to be refrained from performing (and matters incidental thereto) and (ii) are not calculated based on the number of shares tendered or to be tendered into the Offer by the applicable holder or holders of Company Shares.

3.22. Labor Matters.

(a) There are no Legal Proceedings pending against the Company or any of the Company Subsidiaries asserting that the Company or any of the Company Subsidiaries has committed an unfair labor practice, nor have any such Legal Proceedings been threatened to the knowledge of the Company. There are no collective bargaining agreements or other labor union agreements to which the Company or any of the

Company Subsidiaries is a party, and, to the knowledge of the Company, as of the date of this Agreement, neither the Company nor any of the Company Subsidiaries is the subject of any Legal Proceeding seeking to compel any of them to bargain with any labor organization as to wages or conditions. To the Company’s knowledge, since January 1, 2004, neither the Company nor any of the Company Subsidiaries was the subject of any labor union organizing activity or had any actual or threatened employee strikes, work stoppages, slowdowns or lockouts.

(b) The Company and each Company Subsidiary has materially complied and is in material compliance with all applicable Legal Requirements with respect to employment, immigration, occupational health and safety, and wages and hours. There are no Legal Proceedings pending, or, to the knowledge of the Company, threatened, against the Company or any of the Company Subsidiaries with respect to employment, immigration, occupational health and safety, or wages and hours and that would reasonably be expected to have a Company Material Adverse Effect. Except as set forth in Part 3.22(b) of the Company Disclosure Schedule, neither the Company nor any of the Company Subsidiaries is a party to or bound by any Contract limiting the right of the Company to terminate the employment of any of its Executives at will or requiring the payment of severance upon termination.

(c) To the Company’s knowledge, there has not been a representation question respecting any of the employees of the Company or any of the Company Subsidiaries, there are no campaigns being conducted to solicit cards from or otherwise organize employees of the Company or any of the Company Subsidiaries to authorize representation by any labor organization, there has been no labor strike, slow-down or other concerted work stoppage with respect to the business activities of the Company or any of the Company Subsidiaries during the last three years, and no such labor strike, slow-down, or other concerted work stoppage is currently threatened.

(d) To the Company’s knowledge, no employee of the Company or any of the Company Subsidiaries are in any material respect in violation of any term of any employment agreement, non-disclosure agreement, noncompetition agreement, or any restrictive covenant to a former employer relating to the right of any such employee to be employed by the Company or any of the Company Subsidiaries because of (i) the nature of the business conducted or presently proposed to be conducted by the Company or any of the Company Subsidiaries or (ii) the use of trade secrets or proprietary information of others. No Executive of the Company or any of the Company Subsidiaries has given notice to the Company or any of the Company Subsidiaries that any such Executive intends to terminate his or her employment with the Company or any of the Company Subsidiaries. Except as set forth in Part 3.22(d) of the Company Disclosure Schedule, there are no Legal Proceedings pending or, to the knowledge of the Company, threatened, between the Company or any of the Company Subsidiaries and any of their respective current or former employees, which Legal Proceedings would reasonably be expected to have a Company Material Adverse Effect, individually or collectively.

3.23. Environmental Matters. The Company and the Company Subsidiaries are in material compliance with all applicable Environmental Laws. Since January 1, 2003, neither the Company nor any of the Company Subsidiaries received any written notice from a Governmental Entity or third party that alleged that the Company or any of the Company Subsidiaries was materially violating any Environmental Law. To the knowledge of the Company, no current or prior owner of any property leased or controlled by the Company or any of the Company Subsidiaries received any written notice from a Governmental Entity or third party since January 1, 2003 that alleged that such current or prior owner or the Company or any of the Company Subsidiaries was materially violating any Environmental Law. The Company has all the Environmental Permits necessary for the conduct and operation of the business as now being conducted, and all such permits are in good standing. Neither the Company nor any of the Company Subsidiaries has entered into or agreed to any material consent decree, order or agreement under any Environmental Law, and neither the Company nor any of the Company Subsidiaries is subject to any material judgment, decree or order relating to compliance with any Environmental Law or to investigation, cleanup, remediation or removal of Hazardous Substances under any Environmental Law. There are no underground storage tanks or known or suspected asbestos-containing materials on, under or about real property owned or leased by the Company or a Company Subsidiary. To the knowledge of the Company, there are no above-ground storage tanks on, under or about any property currently or previously owned or leased by the Company, the presence of which would reasonably be expected to have a Company Material Adverse Effect. True and correct summaries of all environmental audits or assessments which have been conducted by or on behalf of the Company at any Owned Real Property or Leased Real Property, have been delivered to Parent or Purchaser.

(For purposes of this Section 3.23, “Environmental Laws” shall mean any and all applicable international, federal, state, or local laws, statutes, ordinances, regulations, policies, guidance, rules, judgments, orders, court decisions or rule of common law, permits, restrictions and licenses, which (i) regulate or relate to the protection or clean up of the environment; the use, treatment, storage, transportation, handling, disposal or release of Hazardous Substances, the preservation or protection of waterways, groundwater, drinking water, air, wildlife, plants or other natural resources; or the health and safety of persons or property, including protection of the health and safety of employees; or (ii) impose liability or responsibility with respect to any of the foregoing, including the Comprehensive Environmental Response, Compensation and Liability Act (42 U.S.C. § 9601 et seq.), or any other Legal Requirement of similar effect. “Environmental Permits” shall mean any material permit, license, authorization or approval required under applicable Environmental Laws. “Hazardous Substances” shall mean any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject to regulation, control or remediation under any Environmental Laws, including any quantity of asbestos in any form, urea formaldehyde, PCBs, radon gas, crude oil or any fraction thereof, all forms of natural gas, petroleum products or by-products or derivatives.)

3.24. Insurance. The Company maintains insurance coverage with reputable and financially sound insurers, or maintains self-insurance practices, in such amounts and covering such risks of the Company and the Company Subsidiaries as are in accordance with normal industry practice for publicly traded companies that are engaged in businesses similar to that of the Company and the Company Subsidiaries (taking into account the cost and availability of such insurance). All such policies are in full force and effect, all premiums due and payable have been paid, and since January 1, 2005, the Company has not received any written communication notifying the Company of any: (a) cancellation or invalidation of any material insurance policy held by the Company (except with respect to policies that have been replaced with similar policies); (b) refusal of any coverage or rejection of any material claim under any material insurance policy held by the Company; or (c) material adjustment in the amount of the premiums payable with respect to any insurance policy held by the Company. There is no pending material claim by the Company under any insurance policy held by the Company. Neither the Company nor any Company Subsidiary is in material breach or default, and neither the Company nor any Company Subsidiary has taken any action or failed to take any action which, with notice or the lapse of time, would constitute such a breach or default, or permit termination or material modification of any of the insurance policies. The consummation of the transactions contemplated by this Agreement will not, in and of itself, cause the revocation, cancellation or termination of any such insurance policies.

3.25. Transactions with Affiliates. To the knowledge of the Company, between the date of the Company’s last proxy statement filed with the SEC and the date of this Agreement, no event has occurred that would be required to be reported by the Company pursuant to Item 404 of Regulation S-K promulgated by the SEC.

3.26. Vote Required. If required under applicable Legal Requirements in order to permit the consummation of the Merger, the affirmative vote of the holders of a majority of the Company Shares outstanding on the record date for the Special Meeting is the only vote of the holders of any class or series of the Company’s capital stock necessary to adopt this Agreement or consummate the transaction contemplated by this Agreement, including the Offer and the Merger.

3.27. Section 203 of the DGCL; Company Rights Agreement. Assuming the accuracy of the representations and warranties contained in Sections 4.4 and 4.6, the Company Board has taken all action necessary to render Section 203 of the DGCL inapplicable to the Offer, the Top-Up Option, and the Merger and all of the transactions contemplated by this Agreement. The Company has amended the Company Rights Agreement to provide that neither Parent nor Purchaser shall be deemed to be an Acquiring Person (as such term is defined in the Company Rights Agreement), that neither a Distribution Date nor a Stock Acquisition Date (as such terms are defined in the Company Rights Agreement) shall be deemed to occur and that the Company Rights will not separate from the Company Shares as a result of the execution, delivery or performance of this Agreement, and that the Company Rights shall terminate in accordance with the Company Rights Agreement immediately prior to the Effective Time.

3.28. Opinion of Financial Advisor. The Company Board has received the opinion of ▇▇▇▇▇▇▇, ▇▇▇▇▇ & Co. to the effect that, as of the date of such opinion, subject to various qualifications and assumptions, the Offer Price (as such term is defined in this Agreement) is fair, from a financial point of view, to the holders of Company Shares (other than Parent, Purchaser and any of their affiliates), and such opinion has not been modified or withdrawn prior to the date of this Agreement.

3.29. Brokers. No broker, finder or investment banker (other than ▇▇▇▇▇▇▇, Sachs & Co.) is entitled to any brokerage, finder’s or other similar fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of the Company. The Company has delivered to Parent complete and correct copies of all Contracts under which any such fees or commissions are payable and all indemnification and other Contracts related to the engagement of the Persons to whom such fees are payable. The methodology, basis and formula for calculating fees and expenses of any accountant, broker, financial advisor, consultant, legal counsel, proxy solicitor or other Person retained by or on behalf of the Company or any Company Subsidiary in connection with this Agreement or the transactions contemplated hereby are set forth in Part 3.29 of the Company Disclosure Schedule.

3.30. ▇▇▇▇▇▇▇ Merger Agreement. The Company has paid to ▇▇▇▇▇▇▇ the termination fee payable pursuant to the ▇▇▇▇▇▇▇ Merger Agreement (the “Company Termination Fee”). The ▇▇▇▇▇▇▇ Merger Agreement has been validly terminated and, except for Sections 7.2, 7.3 and 8 thereof, the ▇▇▇▇▇▇▇ Merger Agreement is of no further force or effect.

SECTION 4. REPRESENTATIONS AND WARRANTIES OF PARENT AND PURCHASER

Parent and Purchaser hereby jointly and severally represent and warrant to the Company that:

4.1. Due Organization. Each of Parent and Purchaser is a corporation duly organized, validly existing and in good standing under the laws of Delaware and has all requisite corporate power and authority necessary to carry on its business as it is now being conducted except where the failure to be so organized, existing or in good standing, individually or in the aggregate, would not be reasonably likely to prevent or materially delay the consummation of any of the transactions contemplated herein. Since its date of incorporation, Purchaser has not carried on any business or conducted any operations other than the execution of this Agreement, the performance of its obligations hereunder and matters ancillary thereto.

4.2. Authority; Binding Nature of Agreement. Parent has the requisite corporate power and authority to enter into and to perform its obligations under this Agreement. The board of directors of Parent, at a meeting duly called and held, has authorized and approved the execution, delivery and performance of this Agreement by Parent. The execution and delivery of this Agreement by Parent and the consummation

by Parent of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate action on the part of Parent, and no other corporate proceedings on the part of Parent are necessary to authorize this Agreement. This Agreement has been duly and validly executed and delivered by Parent and, assuming the due authorization, execution and delivery of this Agreement by the Company, constitutes the valid and binding obligation of Parent, enforceable against Parent in accordance with its terms, subject to: (i) laws of general application relating to bankruptcy, insolvency and the relief of debtors; and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies. Purchaser is a newly formed, wholly-owned Subsidiary of Parent and has the requisite corporate power and authority to enter into and to perform its obligations under this Agreement. The board of directors of Purchaser has authorized and approved the execution, delivery and performance of this Agreement by Purchaser. The execution and delivery of this Agreement by Purchaser and the consummation by Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate action on the part of Purchaser, and no other corporate proceedings on the part of Purchaser are necessary to authorize this Agreement other than, with respect to the Merger, the filing of the appropriate merger documents as required by the DGCL. Parent, as the sole stockholder of Purchaser, will vote to adopt this Agreement immediately after the execution and delivery of this Agreement. This Agreement has been duly executed and delivered by Purchaser and, assuming the due authorization, execution and delivery of this Agreement by the Company, constitutes the valid and binding obligation of Purchaser, enforceable against Purchaser in accordance with its terms, subject to: (1) laws of general application relating to bankruptcy, insolvency and the relief of debtors; and (2) rules of law governing specific performance, injunctive relief and other equitable remedies.

4.3. Non-Contravention; Consents; Certain Contract Matters. The execution and delivery of this Agreement by Parent and Purchaser, and the consummation by Parent or Purchaser of the Offer, the Merger and the other transactions contemplated by this Agreement, will not: (a) cause a violation of any of the provisions of the certificate of incorporation or bylaws of Parent or Purchaser; or (b) cause a violation by Parent or Purchaser of any Legal Requirement applicable to Parent or Purchaser; except in the case of clause (b) as would not be reasonably likely to prevent or materially delay the consummation of any of the transactions contemplated herein. Except (i) as may be required by the Securities Act, the Exchange Act, the DGCL, the HSR Act or the antitrust or competition laws of foreign jurisdictions, or (ii) as set forth on Part 4.3 of the disclosure schedule delivered to the Company on the date of this Agreement (the “Parent Disclosure Schedule”), Parent is not required to make any filing with or to obtain any consent from any Person in connection with the execution and delivery of this Agreement by Parent or Purchaser or, the consummation by Parent or Purchaser of any of the transactions contemplated by this Agreement, except where the failure to make any such filing or obtain any such consent would not be reasonably likely to prevent or materially delay the consummation of any of the transactions contemplated herein. No vote of Parent’s stockholders is necessary to adopt this Agreement or to approve any of the transactions contemplated by this Agreement. Part 4.3 of the Parent Disclosure Schedule sets forth the name of any Person who, to the Parent’s knowledge, is offering products of the type set forth in such Part 4.3 thereon to whom Parent or any Subsidiary of Parent has licensed its Intellectual Property Rights for use in such products.

4.4. Not an Interested Stockholder. Neither Parent nor any of its Affiliates is an “interested stockholder” (as such term is defined in Section 203 of DGCL) of the Company.

4.5. Financing. Parent has available cash resources and financing in an amount sufficient to enable Purchaser to purchase Company Shares pursuant to the Offer, to consummate the Merger and to otherwise perform its obligations under this Agreement. Without limiting the foregoing, Purchaser has delivered to the Company true and complete copies of executed commitment letters, dated May 14, 2007 from General Electric Capital Corporation, UBS Loan Finance LLC and UBS Securities LLC (the “Debt Commitment Letters”), pursuant to which the lender parties thereto have committed, subject to the terms and conditions thereof, to lend the amounts set forth therein for the purpose of funding the consideration payable by Parent and the Purchaser in respect of the Company Shares and Company Options (the “Debt Financing”). As of the date of this Agreement: (i) the Debt Commitment Letters have not been amended or modified; and (ii) none of the commitments contained in the Debt Commitment Letters have been withdrawn or rescinded in any respect. There are no conditions precedent or other contingencies related to the funding by such lenders of the full amount of the Debt Financing, other than as set forth in or contemplated by the Debt Commitment Letters. As of the date of this Agreement, and assuming the accuracy of the Company’s representations set forth in this Agreement and the Company’s compliance with its covenants set forth in this Agreement, in each case such that the conditions to the Debt Financing contemplated by the Debt Commitment Letters are satisfied, neither Parent nor Purchaser has any reason to believe that it will be unable to satisfy on a timely basis any term or condition to be satisfied by it contained in the Debt Commitment Letters. Parent or Purchaser will fully pay any and all commitment fees that are incurred and are due and payable in connection with the Debt Financing as and when they become payable.

4.6. Ownership of Company Shares. As of the date hereof, Parent and its Affiliates directly and indirectly own 750,000 Company Shares, beneficially or otherwise, including any securities, contracts or obligations convertible into or exercisable or exchangeable for Company Shares.

4.7. Offer Documents. The Offer Documents will comply as to form in all material respects with the requirements of the Exchange Act. On the date filed with the SEC, on the date first published, sent or given to holders of Company Shares or at any other time at or prior to the Acceptance Time, the Offer Documents will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that no representation, warranty or covenant is made by Parent or Purchaser with respect to statements made or incorporated therein based on any written information supplied by the Company expressly for inclusion or incorporation by reference in the Offer Documents.

4.8. Information in Schedule 14D-9 and Proxy Statement. None of the written information supplied or to be supplied by or on behalf of Parent expressly for inclusion in the Schedule 14D-9 will, at the time the Schedule 14D-9 is mailed to the

stockholders of the Company, or at any other time at or prior to the Acceptance Time, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they are made, not misleading. If the Special Meeting is to be held pursuant to Section 5.4, none of the written information supplied or to be supplied by or on behalf of Parent expressly for inclusion in the Proxy Statement will, at the time the Proxy Statement is mailed to the stockholders of the Company or at the time of the Special Meeting (or any adjournment or postponement thereof), contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they are made, not misleading.

SECTION 5. COVENANTS

5.1. Interim Operations of the Company. Except: (i) to the extent Parent shall otherwise consent in writing (which consent may be withheld or delayed in Parent’s sole discretion, except in the case of Section 5.1(f), 5.1(m), 5.1(n), 5.1(o), or 5.1(u), for which Parent may not unreasonably withhold or delay its consent); (ii) as set forth in Part 5.1 of the Company Disclosure Schedule; or (iii) as expressly required by this Agreement, the Company agrees that, during the period from the date of this Agreement through the earlier of the time the designees of Parent have been elected to, and shall constitute a majority of, the Company Board pursuant to Section 1.4 or the date of the valid termination of this Agreement in accordance with Section 7.1, the Company shall and shall cause each Company Subsidiary to use commercially reasonable efforts to: (A) conduct their businesses in the Ordinary Course of Business, (B) preserve intact their present business organizations, (C) maintain satisfactory relations with and keep available the services of their current officers and other key employees, (D) preserve existing relationships with material customers, lenders, suppliers, distributors and others having material business relationships with the Company and or any Company Subsidiary and (E) not:

(a) amend its certificate of incorporation or bylaws (except as required under Section 1.4) or equivalent organizational documents;

(b) split, combine, subdivide or reclassify any shares of its capital stock;

(c) declare, set aside or pay any dividend (whether payable in cash, stock or property) with respect to any shares of its capital stock (except with respect to shares of the capital stock of a Company Subsidiary that is directly or indirectly wholly-owned by the Company);

(d) form any Subsidiary;

(e) issue, sell, pledge, transfer, deliver, dispose of or encumber any shares of, or securities convertible or exchangeable for, or options or rights to acquire, any shares of its capital stock, voting securities, phantom stock, phantom stock rights,

stock based performance units or other securities that derive their value by reference to such capital stock or voting securities, other than: (i) the issuance of Company Shares upon the exercise of Company Options outstanding as of the date of this Agreement and listed in Part 3.5 of the Company Disclosure Schedule in accordance with their present terms; (ii) the issuance of Company Shares upon the exercise of Company Rights; (iii) the grant of Company Options, with a per share exercise price equal to the closing price of a Company Share on the date of grant, to employees in the Ordinary Course of Business, not to exceed options to purchase more than 75,000 Company Shares in the aggregate; and (iv) the issuance of Company Shares under the Company ESPP;

(f) transfer, lease, or license to any third party, or Encumber (except for Permitted Encumbrances), any material assets of the Company or any Company Subsidiary other than: (i) sales in the Ordinary Course of Business; (ii) leases or rentals of equipment in the Ordinary Course of Business; (iii) dispositions of obsolete equipment; or (iv) Encumbrances permitted by Section 5.1 (j)(iv) below;

(g) repurchase, redeem or otherwise acquire or offer to repurchase, redeem or otherwise acquire any shares of its capital stock, except shares repurchased from employees or former employees of the Company or any Company Subsidiary upon the exercise of repurchase rights pursuant to and in accordance with the terms of a Contract in effect on the date of this Agreement (a true and complete copy of which has been made available to Parent);

(h) acquire (whether pursuant to merger, stock or asset purchase or otherwise) or lease (i) any asset or assets in one transaction or any series of related transactions involving payments (whether to be made at or after the time of such transaction or transactions) in excess of $1,000,000 individually or $10,000,000 in the aggregate or that would adversely affect the ability of Parent or the Company to obtain approval of the Merger under the HSR Act or the antitrust or anti-competition Legal Requirements of foreign countries, except for (A) purchases of raw materials, equipment and supplies in the Ordinary Course of Business or (B) capital expenditures (which are subject to subsection (u) below), or (ii) any equity interests in any Person or any business or division of any Person (except for marketable securities acquired by the Company from time to time in connection with its normal cash management activities) or all or substantially all of the assets of any Person (or business or division thereof);

(i) merge or consolidate with any Person (other than a merger among wholly-owned Company Subsidiaries), or enter into any agreement with respect to the voting of its capital stock or other securities held by the Company or any Company Subsidiary;

(j) incur, issue, repurchase, modify or assume any Indebtedness or guarantee any such Indebtedness, except for: (i) short-term borrowings incurred in the Ordinary Course of Business made or incurred in connection with the purchase of raw materials, equipment and supplies and on terms consistent with past practices; and (ii) borrowings pursuant to existing credit facilities, or pursuant to any modification, renewals or replacements of any such credit facilities that do not exceed $500,000 in the

aggregate; (iii) borrowings under any new credit facility that do not exceed $500,000 in the aggregate; and (iv) entry into capital leases in the Ordinary Course of Business (and the grant of security interests in the Ordinary Course of Business in connection therewith).

(k) assume, guarantee, endorse or otherwise become liable or responsible (whether directly, contingently or otherwise) for the obligations of any other Person; or make any loans, advances or capital contributions to, or investments in, any other Person other than (A) loans, advances or capital contributions to, or investments in, a Company Subsidiary that is directly or indirectly wholly-owned by the Company in the Ordinary Course of Business, (B) advances to employees in respect of travel and other expenses in the Ordinary Course of Business, and (C) investments made by the Company in marketable securities in connection with its normal cash management activities;

(l) (A) increase benefits under any Company Plan, (B) increase or otherwise change the method for funding or insuring benefits under any Company Plan, except as required by applicable Legal Requirements, (C) (i) establish, adopt, enter into, amend or terminate any Company Plan that is an “employee benefit plan” as defined in Section 3(3) of ERISA or other any other arrangement that would be an employee benefit plan under ERISA if it were in existence as of the date of this Agreement, except as required by applicable Legal Requirements, or (ii) establish, adopt, enter into, amend or terminate any collective bargaining agreement, Company Plan that is not an employee benefit plan under ERISA or any plan, agreement, program, policy, trust, fund or other arrangement that would be a Company Plan that is not an employee benefit plan under ERISA if it were in existence as of the date of this Agreement, except in the Ordinary Course of Business or as required by applicable Legal Requirements, (D) grant any increase in the rates of salaries, compensation or fringe or other benefits payable to any Executive (other than as required by applicable Legal Requirements or pursuant to non-discretionary provisions of Contracts in effect as of the date hereof that have been disclosed to Parent and, even in the event of Parent’s consent to any such increase, only to the extent that the Compensation Committee has duly approved such action as an Employment Compensation Arrangement), (E) grant any increase in the rates of salaries, compensation or fringe or other benefits payable to any employee other than an Executive, except (i) regular cost of living increases in the Ordinary Course of Business, (ii) merit based increases in the Ordinary Course of Business or (iii) equity adjustments (i.e. market based increases) in an amount that does not exceed the lesser of (x) 10% of the employee’s base salary before the increase or (y) $10,000 and, in any event, to no more than 20% of the Company’s or any Company Subsidiary’s employees as of the date of this Agreement) and except, with respect to all of the foregoing, for increases that are required by Legal Requirements or pursuant to non-discretionary provisions of Contracts in effect as of the date hereof that have been disclosed to Parent, (F) grant or pay any bonus of any kind or amount whatsoever to any current or former director or officer or any employee of the Company or any Company Subsidiary (other than commissions payable to sales personnel in accordance with plans in effect as of the date of this Agreement and consistent with past practice and, with respect to employees that are not officers, pursuant to the non-discretionary provisions of Contracts in effect as of the date of this Agreement), (G) grant or pay any severance or termination pay or increase in any

manner the severance or termination pay of any current or former director, officer, employee or consultant of the Company or any Company Subsidiary outside the Ordinary Course of Business and other than as required by applicable Legal Requirements or pursuant to non-discretionary provisions of Contracts in effect as of the date hereof that have been disclosed to Parent, (H) waive any material restrictions in any Company Plan or agreements or awards made thereunder, (I) amend or modify any Company Option, except as required pursuant to this Agreement or by applicable Legal Requirements, (J) take any action to secure, accelerate or accelerate the vesting of the payment after the Effective Time of compensation or benefits under any employee plan, Contract or Company Plan, other than as required by applicable Legal Requirements or pursuant to non-discretionary provisions of Contracts in effect as of the date hereof that have been disclosed to Parent, (K) fail to take such action as would be reasonable under the circumstances to enforce any rights of the Company or any Company Subsidiary under any employment agreement, severance agreement, noncompete agreement, nonsolicitation agreement, covenant not to disclose, confidential information or other similar agreement with respect to any current or former employee or independent contractor of the Company or any Company Subsidiary in effect as of the date of this Agreement, or (L) materially change any actuarial or other assumption used to calculate funding obligations with respect to any Company Plan or change the manner in which contributions to any Company Plan are made or the basis on which such contributions are determined;

(m) plan, announce, implement or effect any material reduction in labor force, lay-off, early retirement program, or severance program involving the termination of employment of employees of the Company or any Company Subsidiary other than routine employee performance-related terminations;

(n) settle or compromise any Legal Proceeding (whether or not commenced prior to the date of this Agreement), other than settlements or compromises of Legal Proceedings where the amount paid (after giving effect to insurance proceeds actually received) in settlement or compromise does not exceed the Company’s reserves on its books therefor by more than $500,000, or for any Legal Proceeding for which the Company has not yet reserved, in an amount therefor that does not exceed $500,000;

(o) except as expressly permitted under Section 5.1(l), enter into any new, or materially amend or prematurely terminate any current, Material Contract or waive, release or assign any material rights or claims under any Material Contract (except in the Ordinary Course of Business or where the failure to amend or terminate a Material Contract would, in the reasonable judgment of the Company Board, have a material adverse impact on the Company);

(p) enter into any new or renew or amend any existing Contract relating to the distribution of the Company’s or any of the Company Subsidiaries’ products under which the Company or a Company Subsidiary is obligated or could be expected to pay or receive more than $250,000 in any fiscal year and that is not terminable or cancelable by the Company on less than 91 days notice after the Acceptance Time.

(q) fail to maintain any material Intellectual Property Rights of the Company or fail to take such actions as are reasonable to enforce or prosecute the Intellectual Property Rights of the Company in any material respect;

(r) change any of its methods of accounting or accounting practices in any material respect, other than changes required under GAAP;

(s) revalue in any material respect any of its assets, including writing down the value of inventory or writing down notes or accounts receivable, other than in the Ordinary Course of Business or as required under GAAP or any Legal Requirement;

(t) except as provided in Part 5.1(t) of the Company Disclosure Schedule, (i) make or amend any material Tax election, (ii) settle any material Tax liability, (iii) change any annual Tax accounting period, (iv) change any method of Tax accounting, (v) file any material amendment to a Tax Return, enter into any closing agreement relating to any material Tax, (vi) surrender any right to claim a material Tax refund, or (vii) consent to any extension or waiver of the statute of limitations period applicable to any material Tax claim or assessment;

(u) make any capital expenditure (including pursuant to leases) that is not contemplated by the capital expenditure budget set forth in Part 5.1(u) of the Company Disclosure Schedule (a “Non-Budgeted Capital Expenditure”), except that the Company or any Subsidiary of the Company: (i) may make any Non-Budgeted Capital Expenditure that does not individually exceed $100,000 in amount; and (ii) may make any Non-Budgeted Capital Expenditure that, when added to all other Non-Budgeted Capital Expenditures made by the Company and the Company Subsidiaries since the date of this Agreement, would not exceed $500,000 in the aggregate;

(v) waive, release or assign any claims or rights of material value;

(w) take any action to exempt any Person from, or make any Person not subject to, any state takeover law or state law that purports to limit or restrict business combinations or the ability to acquire or vote shares (other than Parent, Purchaser or any Subsidiary of Parent or Purchaser);

(x) adopt a plan of complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization of the Company or any Company Subsidiary (other than the Merger);

(y) take any action which would, directly or indirectly, restrict or impair the ability of Parent or Purchaser to vote, or otherwise to exercise the rights and receive the benefits of a stockholder with respect to, securities of the Company acquired or controlled or to be acquired or controlled by Parent or Purchaser;

(z) change (including by way of amendment, modification, or failure to renew) any insurance coverage in any material respect, including providing for self insurance by the Company or any Company Subsidiary for risks and liabilities for which the Company or any Company Subsidiary formerly held third party insurance;

(aa) take, or agree in writing or otherwise to take, any action that would or is reasonably likely to result in any of the conditions to the Merger set forth in Section 6 hereof or any of the conditions or requirements to the Offer set forth in Annex I not being satisfied, or would make any representation or warranty of the Company contained herein inaccurate in any material respect at, or as of any time prior to, the Effective Time, or that would materially impair the ability of the Company to consummate the Merger in accordance with the terms hereof or materially delay such consummation;

(bb) pay any success fee to its advisors or agents in connection with the execution and delivery of this Agreement or the completion of the transactions contemplated hereby, except pursuant to non-discretionary provisions of Contracts in effect as of the date of this Agreement; or

(cc) except as permitted in Section 7.1(f), authorize or enter into a Contract or arrangement to take any of the actions described in clauses “(a)” through “(bb)” of this sentence.

5.2. No Solicitation.

(a) At all times during the period commencing with the execution and delivery of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to Section 7.1 hereof and the Acceptance Time, the Company shall not, and shall cause all of the Company Subsidiaries and the Company’s and such Company Subsidiaries’ directors, officers, employees, Affiliates, investment bankers, attorneys or other agents or representatives (collectively, “Representatives”) not to (and in any event the Company shall not authorize any of such Persons to), directly or indirectly (i) solicit, initiate, knowingly encourage, knowingly induce or knowingly facilitate the making, submission or announcement of an Acquisition Proposal or Acquisition Inquiry; (ii) furnish to any Person any non-public information relating to the Company in response to or in connection with an Acquisition Proposal or Acquisition Inquiry (for avoidance of doubt, it being understood that the foregoing shall not prohibit the Company from furnishing, in the Ordinary Course of Business, any non-public information to (A) any actual or potential customer, supplier, distributor, licensor, licensee, partner or other Person to the extent necessary to facilitate any business dealings between the Company and such actual or potential customer, supplier, distributor, licensor, licensee, partner or other Person that are unrelated to any Acquisition Proposal or any Acquisition Inquiry and are not prohibited by the terms of Section 5.1, or (B) a Governmental Entity); (iii) participate or engage in discussions or negotiations with any Person with respect to an Acquisition Proposal or Acquisition Inquiry (for avoidance of doubt, it being understood that the foregoing shall not prohibit the Company or any of its advisors or representatives from making such Person aware of the restrictions of this Section 5.2 in response to the receipt of an Acquisition Proposal, nor shall it prohibit the Company from engaging in discussions with its advisors or representatives to the extent reasonably necessary to assist the Company in determining how to properly respond to such Acquisition Proposal or Acquisition Inquiry); or (iv) except as permitted pursuant to Section 5.3, approve, endorse or recommend to the Company’s stockholders any Acquisition Proposal; provided, however, that notwithstanding anything to the contrary

contained in this Agreement, at any time prior to the Acceptance Time, the Company may, directly or indirectly through its Representatives, (A) engage or participate in discussions or negotiations with any Person (and may engage or participate in discussions or negotiations with such Person’s Representatives and potential financing sources) that has (1) made a bona fide Acquisition Proposal in writing that the Company Board determines in good faith After Consultation constitutes or is reasonably likely to lead to a Superior Proposal and (2) to the extent the Company is prohibited from disclosing such discussions or negotiations or the information exchanged in connection therewith, provided the Company with written acknowledgement that such discussions or negotiations and the information exchanged in connection therewith will be disclosed to Parent and its Representatives, and (B) furnish to any such Person described in clause (A) above (including to such Person’s Representatives and potential financing sources) any non-public information relating to the Company and its Subsidiaries pursuant to a confidentiality agreement (whether executed before or after the date of this Agreement), the terms of which are no less favorable in any material respect to the Company than those contained in the Confidentiality Agreement (provided that, for the avoidance of doubt such Confidentiality Agreement is not required to contain standstill provisions) (it being understood that none of the actions described in this proviso, shall, to the extent taken in accordance with this proviso, be prohibited by the preceding terms of this Section 5.2(a)); and provided further, that in the case of any action taken pursuant to clause (A) or clause (B) above, (1) the Company Board received such Acquisition Proposal other than as a result of a breach or violation of the terms of this Section 5.2, (2) the Company Board shall first have determined in good faith, After Consultation, that the failure to take such action does or would reasonably be likely to constitute a breach of its fiduciary obligations to the Company’s stockholders under applicable Legal Requirements; (3) at least 48 hours prior to initially engaging or participating in any such discussions or negotiations with, or initially furnishing any non-public information to, such Person, the Company gives Parent written notice of the identity of such Person and all of the material terms and conditions of such Acquisition Proposal and of the Company’s intention to engage or participate in discussions or negotiations with, or furnish non-public information to, such Person, and (4) contemporaneously with furnishing any non-public information to such Person, the Company furnishes such non-public information to Parent (to the extent such information has not been previously furnished by the Company to Parent). Without limiting the generality of the foregoing, the Company acknowledges and agrees that if any Company Subsidiary or Representative of the Company or Company Subsidiary (whether or not such Person is purporting to act on behalf of the Company) takes any action that, if taken by the Company, would constitute a breach of this Section 5.2(a) by the Company, then such action shall be deemed to constitute a breach of this Section 5.2(a) by the Company.

(b) In addition to the obligations of the Company set forth in Section 5.2(a) hereof, the Company shall promptly, and in all cases within one business day of its receipt, advise Parent orally (to be confirmed in writing as soon as practicable thereafter) of the receipt by the Company of any Acquisition Proposal or Acquisition Inquiry, including the material terms and conditions of such Acquisition Proposal or Acquisition Inquiry and the identity of the Person or group making any such Acquisition Proposal or Acquisition Inquiry. The Company shall keep Parent informed as promptly as practicable

(and in any event within 24 hours) of any material change in the status of or material change in the proposed terms and conditions of (including all material amendments or proposed material amendments to), any such Acquisition Proposal or Acquisition Inquiry. In fulfilling its obligations under this Section 5.2(b), the Company shall provide or make available promptly (and in any event within 24 hours) to Parent copies of all written correspondence or other written material, including material in electronic form, between the Company, any Company Subsidiary or their respective Representatives and such third party or its Representatives delivered in connection with any Acquisition Proposal or Acquisition Inquiry.

(c) Upon the execution and delivery of this Agreement, the Company shall immediately cease and cause to be terminated any existing discussions with any Person that relate to any Acquisition Proposal or Acquisition Inquiry.

(d) Unless the Company Board shall first have determined in good faith, After Consultation, that the failure to take the following actions does or would reasonably be likely to constitute a breach of its fiduciary obligations to the Company’s stockholders under applicable Legal Requirements, the Company (i) agrees not to release or permit the release of any Person from, or to waive or permit the waiver of any provision of, any confidentiality, standstill or similar agreement to which the Company is a party or under which the Company has any rights and (ii) will use its best efforts to enforce or cause to be enforced each such agreement at the request of Parent; provided, however, that the expiration or termination of such agreement or provision of such agreement by its own terms shall not be considered to be a violation of the foregoing clause “(i)” or “(ii)” by the Company. The Company also shall promptly (but in no event later than five business days after the execution of this Agreement) request each Person that since January 1, 2005 has executed a confidentiality agreement in connection with its consideration of a possible Acquisition Transaction or equity investment in the Company to return (or destroy, to the extent permitted by the terms of the applicable confidentiality agreement) all confidential information heretofore furnished to such Person by or on behalf of Company, subject to the terms of the applicable confidentiality agreement; provided however, that the Company need not take the actions described in this sentence with respect to any Person if, prior to the date of this Agreement, the Company has made a request to such Person of the type described in this sentence and on or after the date of such request the Company has not furnished any additional Confidential Information to such Person.

5.3. Board Recommendation.

(a) Subject to the terms of Section 5.3(c) hereof, the Company Board shall (i) recommend that the holders of the Company Shares accept the Offer, tender their Shares to Purchaser pursuant to the Offer and, if required to consummate the Merger, adopt this Agreement and the Merger in accordance with the applicable provisions of DGCL (the “Company Recommendation”), and (ii) include the Company Recommendation in the Schedule 14D-9 and permit Parent to include the Company Recommendation in the Offer Documents.

(b) Subject to Section 5.3(c), neither the Company Board nor any committee thereof shall (i) withdraw, qualify, modify, change or amend in any manner adverse to the transactions contemplated by this Agreement, Parent or Purchaser (including pursuant to the Schedule 14D-9 or any amendment thereto), the Company Recommendation, the approval by the Company Board of this Agreement and the transactions contemplated hereby, including the Offer and the Merger, or the approval by the Compensation Committee of the Company Compensation Arrangements for purposes of satisfying the requirements of the non-exclusive safe-harbor in accordance with Rule 14d-10(d)(2) under the Exchange Act, (ii) fail to reconfirm the Company Recommendation or its approval of this Agreement, the Offer, the Merger or any other transaction contemplated by this Agreement promptly, and in any event within two business days, following Parent’s request to do so (A) if Parent makes such request following the time at which an Acquisition Proposal made by a third party shall have been publicly announced or shall otherwise have become public (provided that Parent may not make such a request on more than one occasion with respect to any particular Acquisition Proposal unless, since any prior such request by Parent, the price or other material terms of such Acquisition Proposal have changed) or (B) if one or more members of the Company Board shall have taken any action publicly or that shall have become public that indicates that such member or members of the Company Board do not unanimously support the Offer or the Merger), (iii) approve or recommend (or propose publicly to approve or recommend) any Acquisition Proposal, (iv) if a tender offer or exchange offer that, if successful, would result in any Person or “group” (as defined under Section 13(d) of the Exchange Act) becoming a beneficial owner of ten percent (10%) or more of the outstanding Company Shares is commenced (other than by Parent or Purchaser), fail to recommend that the Company’s stockholders not tender their Shares in such tender or exchange offer within five business days following such commencement, (v) except in connection with a termination of this Agreement pursuant to Section 7.1(f), permit the Company or any Company Subsidiary to enter into any Contract (other than a confidentiality agreement as contemplated by Section 5.2(d)), including any letter of intent or understanding, with respect to any Acquisition Proposal, or (vi) except in connection with a termination of this Agreement pursuant to Section 7.1(f), resolve or propose to take any action described in clauses (i) through (v) (each of the foregoing actions described in clauses (i) through (vi) being referred to as a “Company Change in Recommendation”).

(c) Notwithstanding anything to the contrary contained in this Agreement, the Company Board may effect a Company Change in Recommendation at any time (but in the case of a Company Change in Recommendation specified in clauses “(ii),” “(iii),” or “(v)” of such definition, only prior to the Acceptance Time), if and only if (i) the Company Board has determined in good faith (After Consultation and after considering in good faith any counter-offer or proposal made by Parent pursuant to this Section 7.1(f)), that the Company Board is required to effect a Company Change in Recommendation in order to comply with its fiduciary duties to the Company’s stockholders in accordance with applicable Legal Requirements, (ii) prior to effecting such Company Change in Recommendation, the Company provides to Parent a written notice (a “Notice of Recommendation Change”) at least three business days (or, if the Offer is scheduled to expire in a shorter period after the date the Notice of

Recommendation Change is provided, then such shorter period) prior to making such Company Change in Recommendation of its intention to make a Company Change in Recommendation. Notwithstanding the foregoing, the Company shall not enter into any Contract (other than a confidentiality agreement as contemplated by Section 5.2(d)), with respect to a Superior Proposal unless this Agreement has been or concurrently is validly terminated by its terms pursuant to Section 7.1 and Parent has received, by wire transfer of immediately available funds, any amounts due to Parent pursuant to Section 7.3.

(d) Without limiting any rights or remedies of Parent or Purchaser set forth in this Agreement that might exist as a consequence of any such action, nothing in this Agreement shall prohibit the Company Board from (i) taking and disclosing to the Company’s stockholders a position contemplated by Rule 14e-2(a) promulgated under the Exchange Act or complying with the provisions of Rule 14d-9 promulgated under the Exchange Act or (ii) making any disclosures to the Company’s stockholders that the Company Board determines in good faith After Consultation that the Company Board is required to make in order to comply with its fiduciary duties to the Company’s stockholders under Delaware Law.

5.4. Meeting of the Company’s Stockholders.

(a) If, following the Acceptance Time, the expiration of any subsequent offering period provided in accordance with Rule 14d-11 under the Exchange Act, and any exercise of the Top-Up Option, the approval of the Company’s stockholders is required to effect the Merger, the Company will prepare a Proxy Statement relating to the adoption of this Agreement and approval of the Merger and shall file the Proxy Statement with the SEC as promptly as practicable; provided that Parent, Purchaser and their counsel shall be given a reasonable opportunity to review the Proxy Statement before it is filed with the SEC and the Company shall give due consideration to all reasonable additions, deletions or changes suggested thereto by Parent, Purchaser and their counsel with the intention that the Proxy Statement be in a form ready to print and mail to the stockholders of the Company as soon as reasonably practicable following the Acceptance Time. Unless the Company shall have effected a Company Change in Recommendation in accordance with Section 5.3(c), the Company shall include in the Proxy Statement the recommendation of the Company Board that stockholders of the Company vote in favor of the adoption of this Agreement and the approval of the Merger. The Company shall use its best efforts to obtain and furnish the information required to be included by the SEC in the Proxy Statement and, after consultation with Parent and Purchaser, respond promptly to any comments made by the SEC with respect to the Proxy Statement. The Company shall provide Parent, Purchaser and their counsel with copies of any written comments, and shall inform them of any oral comments, that the Company or its counsel may receive from time to time from the SEC or its staff with respect to the Proxy Statement promptly after the Company’s receipt of such comments, and any written or oral responses thereto. Parent, Purchaser and their counsel shall be given a reasonable opportunity to review any such written responses and the Company shall give due consideration to all reasonable additions, deletions or changes suggested thereto by Parent, Purchaser and their counsel. The Company, on the one hand, and Parent and Purchaser, on the other hand, agree to promptly correct any information

provided by it for use in the Proxy Statement if and to the extent that it shall have become false or misleading in any material respect or as otherwise required by law and, the Company further agrees to take all steps necessary to cause the Proxy Statement, as so corrected (if applicable), to be filed with the SEC and, if any such correction is made following the mailing of the Proxy Statement as provided in Section 5.4(b)(ii), mailed to holders of Company Shares, in each case as and to the extent required by the Exchange Act.

(b) The Company, acting through the Company Board, shall, promptly following the Acceptance Time and in accordance with applicable Legal Requirements:

(i) (A) duly set a record date for, call and establish a date for, and give notice of, the Special Meeting (with the record date and meeting date each set for a date as soon as reasonably practicable after the Acceptance Time and in consultation with Purchaser), and (B) convene and hold the Special Meeting;

(ii) if required by applicable Legal Requirements, cause the definitive Proxy Statement to be mailed to its stockholders; and

(iii) unless the Company has effected a Company Change in Recommendation in accordance with Section 5.3(c), use its best efforts to solicit from its stockholders proxies in favor of the adoption of this Agreement and the approval of the Merger and take all other action reasonably necessary or advisable to secure the approval of stockholders required by the DGCL and any other applicable Legal Requirements to effect the Merger.

At the Special Meeting, Parent shall ensure that all Company Shares owned beneficially or of record by Parent, Purchaser or any of Parent’s other Affiliates will be voted in favor of the adoption of this Agreement and approval of the Merger.

(c) Notwithstanding anything to the contrary contained in this Agreement, if, at any time after the Acceptance Time, the Company Shares beneficially owned by Purchaser, together with any Company Shares beneficially owned by Parent and Parent’s other Affiliates, shall collectively represent at least 90% of the outstanding Company Shares, then Parent shall take all actions necessary and appropriate to cause the Merger to become effective as soon as practicable without a meeting of the Company’s stockholders in accordance with Section 253 of the DGCL.

5.5. Filings; Other Action.

(a) Each of the Company, Parent and Purchaser shall: (i) promptly make and effect all registrations, filings and submissions required to be made or effected by it pursuant to the HSR Act, the Exchange Act and other applicable Legal Requirements with respect to the Offer and the Merger, and in any event, filings under the HSR Act, shall be made within five (5) calendar days of the date hereof (or, in each case, the next succeeding business day); and (ii) use their commercially reasonable efforts to cause to be taken, on a timely basis, all other actions necessary or appropriate for the purpose of consummating and effectuating the transactions contemplated by this Agreement. Without limiting the generality of the foregoing, each

of Parent and Purchaser: (A) shall promptly provide all information requested by any Governmental Entity in connection with the Offer, the Merger or any of the other transactions contemplated by this Agreement; (B) shall use its commercially reasonable efforts to promptly take, and cause its Affiliates to take, all actions and steps necessary to obtain any clearance or approval required to be obtained from the U.S. Federal Trade Commission, the U.S. Department of Justice, the U.S. Department of State, the U.S. Department of Defense, any state attorney general, any foreign competition authority or any other Governmental Entity in connection with the transactions contemplated by this Agreement; and (C) shall, if requested by the Company at any time prior to the expiration of the initial waiting period under the HSR Act, withdraw its HSR filing with respect to the Offer and the Merger and resubmit an updated version of such filing to the U.S. Department of Justice and the U.S. Federal Trade Commission within two business days. Notwithstanding anything set forth in this Agreement, in connection with the receipt of any necessary approvals or clearances of a Governmental Entity (including under the HSR Act), neither Parent nor the Company shall be required to sell, hold separate or otherwise dispose of or conduct their business in a specified manner, or agree to sell, hold separate or otherwise dispose of or conduct into or agree to enter into a voting trust arrangement, proxy arrangement, “hold separate” agreement or arrangement or similar agreement or arrangement with respect to the assets, operations or conduct of their business in a specified manner, or permit the sale, holding separate or other disposition of, any assets of Parent, the Company or their respective Subsidiaries.

(b) Without limiting the generality of anything contained in Section 5.5(a) or 5.5(c), each party hereto shall: (i) give the other parties prompt notice of the making or commencement of any request, inquiry, investigation, action or Legal Proceeding by or before any Governmental Entity with respect to the Offer or the Merger or any of the other transactions contemplated by this Agreement; (ii) keep the other parties informed as to the status of any such request, inquiry, investigation, action or Legal Proceeding; and (iii) promptly inform the other parties of any communication to or from the Federal Trade Commission, the Department of Justice or any other Governmental Entity regarding the Offer or the Merger. Each party hereto will consult and cooperate with the other parties and will consider in good faith the views of the other parties in connection with any analysis, appearance, presentation, memorandum, brief, argument, opinion or proposal made or submitted in connection with any such request, inquiry, investigation, action or Legal Proceeding. In addition, except as may be prohibited by any Governmental Entity or by any Legal Requirement, in connection with any such request, inquiry, investigation, action or Legal Proceeding, each party hereto will permit authorized representatives of the other parties to be present at each meeting or conference relating to such request, inquiry, investigation, action or Legal Proceeding and to have access to and be consulted in connection with any document, opinion or proposal made or submitted to any Governmental Entity in connection with such request, inquiry, investigation, action or Legal Proceeding.

(c) Without limiting the generality of anything contained in Section 5.5(a) or 5.4(b), but subject thereto, Parent and Purchaser shall use their commercially reasonable efforts to cause all Offer Conditions to be satisfied on a timely basis (to the extent the satisfaction of such Offer Conditions is within Parent’s or Purchaser’s direct or indirect control) and to cause Purchaser to purchase Company Shares pursuant to the Offer on the earliest possible date.

5.6. Access. Upon reasonable notice, the Company shall, and shall cause its Subsidiaries to, afford Parent and Parent’s Representatives reasonable access, during normal business hours throughout the period prior to the Effective Time, to its books and records and, during such period, the Company shall, and shall cause its Subsidiaries to, furnish promptly to Parent all readily available information concerning its business as Parent may reasonably request; provided, however, that none of the Company or any of its Subsidiaries shall be required to permit any inspection or other access, or to disclose any information, that in its reasonable judgment would: (a) constitute, or result in any, disclosure (whether or not to a third party) of any trade secrets concerning its technical processes, including formulas, compositions of reagents, methods for production and use of reagents, computer processes (including source code) used for research purposes, methods for production of polypeptides or nucleic acids (including antibodies), and sequences of specific polypeptides or nucleic acids (including antibodies); (b) result in the disclosure of any trade secrets of third parties; (c) violate any of its obligations with respect to confidentiality; (d) jeopardize protections afforded it under the attorney-client privilege or the attorney work product doctrine; (e) violate any Legal Requirement; or (f) materially interfere with the conduct of its business; provided, however, that in each of the forgoing cases, the Company shall use commercially reasonable efforts to provide Parent with any such inspection, access or disclosure (except for inspection, access and disclosure with respect to the Confidential Agreement), provided to (i) any third party as set forth in Item 4(b) of the Company’s Schedule 14D-9 filed with the SEC on April 2, 2007, as amended from time to time, and/or (ii) any third party in compliance with the terms of this Agreement, including Section 5.2 hereof. All information obtained by Parent or and its Representatives pursuant to this Section 5.6 shall be treated as “Confidential Information” for purposes of the Confidentiality Agreement and shall not affect or be deemed to modify any representation or warranty made by the Company in this Agreement. The Company shall furnish promptly to Parent a copy of each report, schedule, registration statement and other document filed by it or its Subsidiaries during such period pursuant to the requirements of federal or state securities Legal Requirements to the extent that such report, schedule, registration statement or other document is not publicly available on ▇▇▇▇▇.

5.7. Interim Operations of Purchaser. During the period of time between the date of this Agreement and the Effective Time, Purchaser shall not engage in any activities of any nature except as provided in or contemplated by this Agreement.

5.8. Publicity. Except as otherwise required by Legal Requirements, the initial press release relating to this Agreement shall be a joint press release issued by the Company and Parent, and thereafter the parties hereto shall consult with each other and give due consideration to any reasonable additions, deletions or changes suggested by the other party and its counsel prior to issuing any press releases or otherwise making public statements with respect to the transactions contemplated by this Agreement and prior to making any filings with any Governmental Entity with respect to the transactions contemplated by this Agreement; provided, however, that the Company need not consult with Parent in connection with any press release or public statement to be issued or made with respect to any Acquisition Proposal or with respect to any Company Change in Recommendation. The Company and its counsel shall be given a reasonable opportunity

to review and comment on any materials that are to be presented during any road shows conducted in connection with the financing of the transactions contemplated herein, and Parent shall give due consideration to all reasonable additions, deletions or changes suggested thereto by the Company and its counsel. Notwithstanding anything to the contrary contained in this Section 5.8, Parent and Purchaser may utilize such materials in substantially the form presented (after consideration of any comments received from the Company or its counsel) and make public statements consistent with such materials during the road show, without any further consultation, approval, review or commentary from the Company or its counsel.

5.9. Stock Options/ESPP.

(a) Pursuant to this Agreement, each Company Option (other than any options granted under the Company ESPP) outstanding immediately prior to the Effective Time shall become fully vested and exercisable at the Effective Time; provided, however, that, to the extent consistent with applicable Legal Requirements, any Company Option held by a person who, immediately prior to the Effective Time, does not have a status that entitles such person to accrue service towards increased vesting in such Company Option (such as a person on a leave of absence or a part-time employee) shall not become fully vested and exercisable unless and until such person returns to a status that would entitle such person to accrue service towards increased vesting in such Company Option. Except as provided in Section 5.9(b) below, each Company Option outstanding as of the Effective Time shall be assumed by Parent and converted into a fully vested and exercisable option to acquire Parent Shares (any Company Options that are assumed pursuant to this Section 5.9(a) are referred to as the “Assumed Options”). Each Assumed Option shall continue to be subject to the terms and conditions (other than vesting and exercisability terms as modified by this Section 5.9(a)) set forth in the applicable Company Option Plan and the option agreement evidencing such Company Option, except that the exercise price and number of Parent Shares subject to each Assumed Option shall be determined as follows: (i) the number of Parent Shares subject to such Assumed Option shall be equal to the product of (x) the number of Company Shares subject to the original Company Option and (y) the Option Conversion Ratio, with fractional shares rounded down to the nearest whole share and (ii) the per-share exercise price of such Assumed Option shall be equal to (x) the per-share exercise price of the original Company Option immediately prior to the Effective Time divided by (y) the Option Conversion Ratio, rounded up to the nearest whole cent. The Company shall, prior to the Acceptance Time, take all action and give any notices necessary to effect the treatment of the Assumed Options contemplated by this Section 5.9(a), including ensuring that the Compensation Committee has duly approved the accelerated vesting and assumption of the Assumed Options as an Employment Compensation Arrangement. It is the intention of the parties that, to the extent possible under the circumstances, each Assumed Option shall qualify following the Effective Time as an incentive stock option as defined in Section 422 of the Code to the extent such Assumed Option qualified as an incentive stock option prior to the Effective Time.

(b) Notwithstanding anything to the contrary in Section 5.9(a) above, in the event that the conversion of a Company Option as set forth in Section 5.9(a) above

would result in a per-share exercise price of the corresponding Assumed Option of less than three percent (3%) of the Parent Share Price at the Effective Time, then such Company Option shall be cancelled and terminated in exchange for a cash payment (without interest) equal to the aggregate excess, if any, of the Offer Price over the exercise price of such Company Option immediately prior to the Effective Time. The Company shall, prior to the Acceptance Time, take all action and give any notices necessary to effect the treatment of the Company Options contemplated by this Section 5.9(b), including ensuring that the Compensation Committee has duly approved the accelerated vesting and cash settlement of such Company Options as an Employment Compensation Arrangement.

(c) The Company shall amend the Company ESPP, as necessary, (i) to provide that prior to the Effective Time, outstanding purchase rights under the Company ESPP shall be exercised in accordance with the terms of the Company ESPP and each Company Share purchased pursuant to such exercise shall by virtue of the Merger, and without any action on the part of the holder thereof, be converted into the right to receive the Merger Consideration, and (ii) to provide that, as and after the date hereof, no further offering periods or purchase periods shall commence.

(d) Parent shall file with the SEC, as soon as practicable, but in no event later than 10 business days, following the Effective Time, a registration statement on Form S-8 with respect to Parent Shares issuable under any Assumed Options issued under this Section 5.9 and shall use commercially reasonable efforts to maintain the effectiveness of such registration statement for as long as there are any Parent Shares issuable thereunder.

5.10. Other Employee Benefits.

(a) Following the Effective Time, any employee who as of the Effective Time is employed by the Company and the Company Subsidiaries (referred to herein individually as a “Continuing Employee” and collectively as the “Continuing Employees”) shall continue in the employment of the Parent, the Surviving Corporation or any Subsidiary of the Parent or Surviving Corporation after the Effective Time, provided, that to the extent such employment was “at-will” immediately prior to the Effective Time, such employment shall continue to be at-will and subject to termination at any time for any or no reason. Nothing in this Agreement shall be construed to create a right in any Continuing Employee to employment with Parent, the Surviving Corporation, or any of their respective Subsidiaries. For the period beginning on the Effective Time through the end of the calendar year in which the Effective Time occurs, Parent shall provide, or cause to be provided, to each Continuing Employee compensation and employee benefits under either the Company Plans or under employee benefit plans and programs of Parent, the Surviving Corporation or any Subsidiary of Parent or the Surviving Corporation (the “Parent Plans”), or under any combination of the Company Plans and the Parent Plans.

(b) With respect to any Parent Plans that provide group medical, dental, disability or prescription drug coverage in which any Continuing Employees

become eligible to participate after the Effective Time, Parent shall, or shall cause the Surviving Corporation or their respective Subsidiaries to: (i) waive (to the extent such Parent Plan is self-insured), or use commercially reasonable efforts to waive (to the extent such Parent Plan is insured), any exclusions for pre-existing conditions under such Parent Plans that would result in a lack of coverage for any condition for which the applicable Continuing Employee would have been entitled to coverage under the corresponding Company Plan in which such Continuing Employee was an active participant immediately before his or her transfer to the Parent Plan; (ii) waive any coverage waiting periods under any such Parent Plans to the extent that such periods exceed the corresponding waiting period under the corresponding Company Plan in which any applicable Continuing Employee was an active participant immediately before his or her transfer to any such Parent Plans (after taking into account any prior service with the Company or its Subsidiaries credited under such Company Plan for purposes of satisfying such waiting period); (iii) provide each applicable Continuing Employee with credit for any co-payments deductibles and premiums for voluntary coverage paid by such Continuing Employee before his or her transfer to any such Parent Plans (to the same extent such credit was given under the analogous Company Plans before such transfer) in satisfying any applicable deductible, out-of-pocket requirements or coverage levels under any such Parent Plans for the plan year that includes such transfer; provided that, such Continuing Employee shall be responsible for any applicable co-payments or premiums for voluntary coverage required to be made under such Parent Plans, and (iv) provide each applicable Continuing Employee with credit for any unused account balance in each Company Plan that includes a flexible spending account before his or her transfer to any analogous Parent Plan for the plan year that includes such transfer.

(c) Following the Effective Time, Continuing Employees shall be eligible to participate in a qualified cash or deferred arrangement or arrangements under Section 401(k) of the Code sponsored by Parent or a Subsidiary of Parent for the benefit of their eligible employees, provided that Continuing Employees shall not be entitled to receive credit for past service with the Company or its Subsidiaries for purposes of determining the amount of company contributions or vesting under any qualified defined contribution or defined benefit retirement plans sponsored or maintained by Parent, the Surviving Corporation, or their respective Subsidiaries. Without limiting the generality of the foregoing, Continuing Employees shall not be eligible to participate in any Parent Plans under which new Parent employees are not currently eligible to participate.

(d) Following the Effective Time, Continuing Employees shall receive credit for past service (calculated under the method applicable to Parent’s similarly-situated employees) with the Company and its Subsidiaries for purposes of eligibility to participate in the generally applicable severance plan currently maintained by Parent for its and its Subsidiaries’ employees, provided that Continuing Employees shall be required to enter into Parent’s standard release as a condition to the receipt of any benefits under Parent’s severance plan and shall not be entitled to receive the additional severance benefits under such plan otherwise provided in consideration for entering into a release. Continuing Employees covered by a Company Plan providing severance benefits following a change of control shall be covered by such Company Plan according to its terms, and following the period of coverage in such Company Plan, shall participate in the generally applicable severance plan currently maintained by Parent for its and its Subsidiaries’ employees according to the preceding sentence.

(e) Following the Effective Time, Continuing Employees shall be entitled to carryover or otherwise receive credit under any applicable Parent Plans they may participate in for any vacation days, sick days, or other paid time off that is accrued but unused at the Effective Time under the Company Plans. Vacation days, sick days, or other paid time off that is accrued but unused at the Effective Time under the Company Plans shall not be reduced as of the Effective Time, but accruals of Continuing Employees following the Effective Time may be limited to comply with the applicable policies and programs of Parent and its Subsidiaries.

(f) Except as specifically provided in this Section 5.10, Continuing Employees shall not receive credit for past service with the Company or its Subsidiaries for purposes of eligibility to participate in or receive benefits under any Parent Plans.

(g) Nothing contained in this Section 5.10: (i) shall be construed to establish, amend or modify any benefit plan, program, agreement or arrangement, (ii) shall alter or limit Parent’s ability to amend, modify or terminate any benefit plan, program, agreement or arrangement at any time assumed, established, sponsored or maintained by Parent, (iii) is intended to confer upon any current or former employee any right to employment or continued employment for any period of time by reason of this Agreement, or any right to a particular term or condition of employment, or (iv) is intended to confer upon any individual (including employees, retirees, or dependents or beneficiaries of employees or retirees) any right as a third-party beneficiary of this Agreement.

5.11. Indemnification; Directors’ and Officers’ Insurance.

(a) From and after the Acceptance Time, Parent will cause the Surviving Corporation to honor in all respects the obligations of the Company and the Company Subsidiaries pursuant to (i) each indemnification agreement in effect on the date of this Agreement between the Company or any of the Company Subsidiaries and any Indemnified Party; and (ii) any indemnification provision and any exculpation provision in favor of an Indemnified Party that is set forth in the certificate of incorporation or bylaws of the Company and the equivalent organizational documents of any Company Subsidiary in effect as of the date of this Agreement.

(b) Through the sixth anniversary of the Effective Time, Parent will cause Surviving Corporation to be maintain in effect, for the benefit of the Company’s directors and officers that are insured under the Company’s current directors’ and officers’ liability insurance policy in effect as of the date of this Agreement (the “D&O Insurance Policy”), the current level and scope of directors’ and officers’ liability insurance coverage as set forth in the D&O Insurance Policy; provided, however, that in no event shall the Surviving Corporation be required pursuant to this Section 5.11(b) to expend an aggregate amount in excess of 200% of the annual premium currently payable by the Company with respect to such current D&O Insurance Policy, it being understood

that if the annual premiums payable for such insurance coverage exceed such amount, the Surviving Corporation shall be obligated to obtain a policy with the greatest coverage available for a cost equal to such amount. At any time prior to the Effective Time, notwithstanding anything to the contrary set forth in this Agreement, the Company may purchase, and shall purchase at the request of Parent, a “tail” prepaid policy on the D&O Insurance Policy covering a period of six years from the Effective Time; provided that the aggregate amount of such “tail” policy is less than 200% of the annual premium currently payable by the Company with respect to its current D&O Insurance Policy. In the event that the Company shall purchase such a “tail” policy prior to the Effective Time, Parent will cause the Surviving Corporation to maintain such “tail” policy in full force and effect and continue to honor its respective obligations thereunder, in lieu of all other obligations of Parent under the first sentence of this Section 5.11(b) for so long as such “tail” policy shall be maintained in full force and effect.

(c) This Section 5.11 shall survive the Acceptance Time and shall also survive consummation of the Merger and the Effective Time. This Section 5.11 is intended to benefit, and may be enforced by, the Indemnified Parties and their respective heirs, representatives, successors and assigns, and shall be binding on all successors and assigns of the Surviving Corporation. In the event of any merger, consolidation or other similar transaction involving the Surviving Corporation, or in the event of any sale by the Surviving Corporation of all or substantially all of its assets, the Surviving Corporation shall ensure that an Entity no less financially viable than the Surviving Corporation remains responsible for the obligations of the Surviving Corporation under this Section 5.11.

(d) For purposes of this Agreement, each individual who is an officer or director of the Company at the date of this Agreement or was an officer or director of the Company within the six years prior to the date of this Agreement shall be deemed to be an “Indemnified Party.”

5.12. Section 16 Matters. Prior to the Effective Time, Parent and the Company shall take all such steps as may be required to cause any dispositions of Company Shares (including derivative securities with respect to Company Shares) resulting from the Merger by each individual who is subject to the reporting requirements of Section 16(a) of the Exchange Act with respect to the Company or will become subject to such reporting requirements with respect to Parent, to be exempt under Rule 16b-3 promulgated under the Exchange Act.

5.13. Rule 14d-10(d). Prior to the Acceptance Time, the Company (acting through its Compensation Committee) will take all such steps as may be required to cause each Company Compensation Arrangement entered into by the Company or the Company Subsidiaries on or after the date hereof with any holder of Company Shares, including any of the Company’s officers, directors or employees, pursuant to which consideration is paid to such holder, officer, director or employee to be approved as an Employment Compensation Arrangement and to satisfy the requirements of the non-exclusive safe harbor set forth in Rule 14d-10(d) of the Exchange Act.

5.14. Cooperation Regarding Transition of Business. After the Acceptance Time, if requested by Parent, the Company will take commercially reasonable action to cooperate with Parent in the planning and preparation of the integration of the Company’s and Parent’s business, including with respect to the matters identified in Part 5.14 of the Company Disclosure Schedule following the Acceptance Time. Nothing in this Section 5.14 will require the Company to take any action in violation of Legal Requirements.

5.15. Termination of Certain Company Plans. At the request of Parent and prior to the Acceptance Time, the Company will take all necessary corporate actions to approve and effect the termination of any and all Company Plans intended to qualify as a qualified cash or deferred arrangement under Section 401(k) of the Code effective immediately preceding the Acceptance Time (provided that such termination shall not cause the Continuing Employees to fail to be covered by a qualified cash or deferred arrangement under Section 401(k) of the Code). Following the Effective Time, Parent shall use commercially reasonable efforts to cause the Company to continue in effect the Company’s Nonqualified Deferred Compensation Plan, 409A Nonqualified Deferred Compensation Plan, Director Fee Deferral Program under the Amended and Restated 1996 Stock Incentive Plan, provided that, Parent may elect to cause the Company to terminate participant’s ability to make future contributions under such plans. At the request of Parent and prior to the Acceptance Time, the Company shall take all necessary corporate action to approve and effect the termination of any substantially similar deferred compensation arrangements within the meaning of Section 409A of the Code effective immediately preceding the Acceptance Time, and the payment of all amounts deferred under such plans (including payment in respect of any stock units granted under the Amended and Restated 1996 Stock Incentive Plan) as soon as practicable following the Effective Time and in any event within 12 months of the Acceptance Time. The Company will provide Parent with evidence that any such plans terminated pursuant to this Section 5.15 have been so terminated pursuant to resolutions duly adopted by the Company Board or other duly-designated authority.

5.16. Financing.

(a) Parent and the Purchaser shall use their commercially reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable to arrange and obtain the Debt Financing on the terms and conditions described in the Debt Commitment Letters, including using commercially reasonable efforts to (i) maintain in effect the Debt Commitment Letters and negotiate and enter into definitive agreements with respect to the Debt Financing on the terms and conditions reflected in the Debt Commitment Letters or on other terms reasonably acceptable to Parent and the Purchaser, (ii) satisfy on a timely basis all material conditions applicable to Parent and the Purchaser in such definitive agreements that are within their control, (iii) consummate the Debt Financing at such time or from time to time as is necessary for Purchaser to satisfy its obligations under this Agreement, and (iv) enforce its rights under the Debt Commitment Letters; provided, however, that Parent or Purchaser shall have the right to substitute alternative financing for the Debt Commitment Letters with a different letter or a letter from alternative lenders so long as

such substitute letter is subject to financing conditions that are at least as favorable to Parent and Purchaser as the financing conditions set forth in the Debt Commitment Letters. In the event any portion of the Debt Financing becomes unavailable on the terms and conditions contemplated in the Debt Commitment Letters for any reason, Parent and the Purchaser shall use their commercially reasonable efforts to obtain alternative financing on terms no less favorable to Parent and Purchaser than the Debt Financing from alternative sources (“Alternative Financing”) as promptly as practicable following the occurrence of such event. Parent shall promptly notify the Company in writing of: (A) the occurrence or existence of any event, condition, fact or circumstance that could adversely impact the availability to Parent or Purchaser of the cash resources and/or financing sufficient to enable Purchaser to acquire the Company Shares pursuant to the Offer, and otherwise perform its obligations under this Agreement; (B) any amendment, withdrawal, rescission, breach, violation or non-satisfaction of any of the covenants, conditions or other terms contained in the Debt Commitment Letters or any documents incorporated by reference therein; or (C) any allegation with respect to any of the matters described in clause “(B)” of this sentence. No notification given to the Company pursuant to this Section 5.16(a) shall limit or otherwise affect the covenants or obligations of Parent or Purchaser contained in this Section 5.16(a). For the avoidance of doubt, Parent’s and the Purchaser’s obligation to consummate the Offer, the Merger and the other transactions contemplated by this Agreement are not (and shall not be) subject to any financing condition.

(b) In the period between the date of this Agreement and the Effective Time, upon request of Parent, the Company shall, and shall use commercially reasonable efforts to cause its Subsidiaries, and its and their Affiliates and Representatives to, reasonably cooperate with Parent in connection with its financing of the transactions contemplated in this Agreement, including using commercially reasonable efforts to (i) participate in meetings and road shows, if any; (ii) provide information reasonably requested by Parent relating to such financing; (iii) assist in the preparation of offering memoranda, private placement memoranda, prospectuses and similar documents of Parent; and (iv) obtain the consent of, and customary comfort letters from, Ernst & Young, LLP (including by providing customary management letters and requesting legal letters to obtain such consent) if necessary or desirable for Parent’s use of the Company’s financial statements. Parent shall promptly, upon request by the Company, reimburse the Company for all documented out-of-pocket expenses incurred by the Company or its Affiliates or Representatives in connection with such cooperation.

5.17. Tax Matters. Upon Parent’s request, the Company shall promptly deliver or make available to Parent complete and accurate copies of all Tax Returns of the Company and each Company Subsidiary and complete and accurate copies of all examination reports and statements of deficiencies assessed against or agreed to by the Company, any Company Subsidiary or any of their predecessors since its last open Tax year.

5.18. Inverness Payment.

(a) Immediately following the execution of this Agreement, Parent shall pay to the Company, as reimbursement for its payment of the Company Termination Fee, without deduction or setoff of any nature, by wire transfer of immediately available funds to an account designated by the Company, an amount in cash equal to $54,000,000 (the “Inverness Payment”).

(b) If this Agreement is validly terminated by Parent pursuant to Section 7.1(g) or if this Agreement is validly terminated in circumstances requiring payment of the Termination Fee to Parent pursuant to Section 7.3(a), 7.3(b) or 7.3(c), then the Company shall reimburse Parent for, and in an amount in cash equal to, the Inverness Payment. Any such reimbursement by the Company shall be made by wire transfer of same day funds (i) as promptly as possible, following, and in any event within one business day of, termination pursuant to Section 7.1(g), and (ii) at the time that the Termination Fee is paid to Parent in the case of a termination of this Agreement in circumstances requiring payment of the Termination Fee.

(c) The Company shall provide Parent with a copy of the written termination notice delivered to ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ in accordance with the terms of the ▇▇▇▇▇▇▇ Merger Agreement within 24 hours of the Company’s delivery of such notice to ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇.

SECTION 6. CONDITIONS TO EACH PARTY’S OBLIGATION TO EFFECT THE MERGER

The obligation of each party to effect the Merger shall be subject to the satisfaction or waiver of the following conditions prior to the Effective Time:

6.1. Stockholder Approval. If adoption of this Agreement by the holders of Company Shares is required by applicable Legal Requirements, the Merger Agreement shall have been adopted by the requisite vote of such holders.

6.2. No Injunctions; Laws. (a) No lawsuit shall have been commenced by a Governmental Entity against the Company or Parent that remains pending and seeks to prohibit the consummation of the Merger; (b) no injunction shall have been issued by a court of competent jurisdiction and shall be continuing that prohibits the consummation of the Merger (an “Order”); and (c) no Legal Prohibition shall have been enacted since the date of this Agreement and shall remain in effect.

6.3. Government Consents. Any applicable waiting period under the HSR Act relating to the Merger shall have expired or been terminated, any antitrust or competition Legal Requirements applicable to the Merger of any other applicable jurisdiction shall have expired or been terminated and all other foreign antitrust and competition approvals required to consummate the Merger shall have been obtained (in the case of foreign Legal Requirements or approvals, only if such Legal Requirements or approvals: (a) would have suspensory effect, (b) if not obtained would reasonably be expected to result in material limitations on the ownership or operation by Parent of the assets of Parent, its Subsidiaries or the Surviving Corporation or (c) if not obtained, would subject Parent or Purchaser to the payment of a material fine or penalty.

6.4. Offers Purchased. Purchaser shall have purchased the Company Shares pursuant to the Offer (provided that this shall not be a condition to Parent’s and Purchaser’s obligations if Purchaser shall have failed to purchase or exchange such Company Shares in violation of this Agreement, notwithstanding the satisfaction or waiver by Purchaser of all of the conditions to the Offer set forth in Annex I attached).

SECTION 7. TERMINATION

7.1. Termination. This Agreement may be terminated and the Merger may be abandoned (before or after the adoption of the Merger Agreement by the stockholders of the Company):

(a) by mutual consent of the Company (subject to Section 1.5) and Parent at any time prior to the Acceptance Time;

(b) by Parent or the Company at any time after September 30, 2007 (the “Outside Date”) if the Acceptance Time shall not have occurred on or before the Outside Date; (provided that if the Acceptance Time has not occurred by September 30, 2007, solely by reason of non-satisfaction of the conditions set forth in clause (2) of the introductory paragraph of Annex I, then the Company may extend the Outside Date one or more times up to and including December 31, 2007; (provided that the right to terminate this Agreement pursuant to this Section 7.1(b) shall not be available to any party where the failure of such party (or any Affiliate of such party) to fulfill any obligation under this Agreement has resulted in the failure of the Acceptance Time to have occurred on or before the Outside Date);

(c) by Parent or the Company if there shall be any Legal Prohibition in effect against, prior to the Acceptance Time, the acceptance for payment of Company Shares tendered pursuant to the Offer or against, prior to the Effective Time, the consummation of the Merger; provided, however, that a party shall not be permitted to terminate this Agreement pursuant to this Section 7.1(c) if the existence of the Legal Prohibition is attributable to the failure of such party (or any Affiliate of such party) to perform in any material respect any covenant in this Agreement required to be performed by such party (or any Affiliate of such party) at or prior to the Acceptance Time or the Effective Time, as applicable and provided, further, that the party seeking to terminate this Agreement pursuant to this Section 7.1(c) shall have used its commercially reasonable efforts to prevent such Legal Prohibition and to cause any such Legal Prohibition to be vacated or otherwise rendered of no effect;

(d) by Parent or the Company if the Offer (as it may have been extended pursuant to Section 1.1) expires as a result of the non-satisfaction of any Offer Condition, or is terminated or withdrawn prior to the Acceptance Time, without Purchaser having accepted for payment any Company Shares tendered pursuant to the Offer; provided, however, that a party shall not be permitted to terminate this Agreement pursuant to this Section 7.1(d) if the non-satisfaction of any Offer Condition or the termination or withdrawal of the Offer is attributable to the failure of such party (or any Affiliate of such party) to fulfill its obligations under this Agreement;

(e) by Parent at any time prior to the Acceptance Time if: (i) the Company Board or any committee thereof shall have made a Company Change in Recommendation; (ii) the Company shall have violated or breached (or be deemed pursuant to the terms thereof, to have violated or breached) any provisions of Section 5.2(a) or Section 5.2(d) and such breach has led to or resulted in an Acquisition Proposal being made, or (iii) the Company shall have failed to include the Company Recommendation in the Schedule 14D-9 or to permit Parent to include the Company Recommendation in the Offer Documents;

(f) by the Company at any time prior to the Acceptance Time if the Company Board authorizes the Company, subject to complying with the terms of this Agreement, to accept (or to enter into a written agreement for a transaction constituting) a Superior Proposal; provided that: (i) the Company received such Superior Proposal other than as a result of a breach of or violation of the terms of Section 5.2, (ii) the Company has not breached or violated in any material respect the terms of Section 5.2 or Section 5.3 in connection with such Superior Proposal (or any Acquisition Proposal that was a precursor thereto), (iii) the Company has provided Parent at least three business days (the “Matching Period”) prior written notice indicating that the Company intends to accept such Superior Proposal, (iv) prior to the expiration of such Matching Period, Parent does not make a binding offer that the Company Board determines in good faith, After Consultation, is at least as favorable to the Company’s stockholders as such Superior Proposal, (v) immediately prior to (or contemporaneous with) the termination of this Agreement, the Company pays to Parent the Termination Fee payable pursuant to Section 7.3(c), and (vi) immediately following the termination of this Agreement, the Company enters into a definitive agreement to effect such Superior Proposal;

(g) by Parent at any time prior to the Acceptance Time if: (i) there shall be an Uncured Inaccuracy in any representation or warranty of the Company contained in this Agreement or breach of any covenant of the Company or any of its Affiliates contained in this Agreement, in any case, such that any Offer Condition contained in paragraph (a) or (b) of Annex I is not or would reasonably be likely to not be satisfied, (ii) Parent shall have delivered to the Company written notice of such Uncured Inaccuracy or breach, and (iii) at least 30 days shall have elapsed since the date of delivery of such written notice to the Company and such Uncured Inaccuracy or breach shall not have been cured in all material respects;

(h) by Parent at any time prior to the Acceptance Time if: (i) there shall have occurred any adverse event or development which, individually or in the aggregate, has had, and continues to have, a Company Material Adverse Effect, (ii) Parent shall have delivered to the Company written notice of such Company Material Adverse Effect, and (iii) either (A) such Company Material Adverse Effect is not reasonably likely to be cured prior to the Outside Date or (B) the Company is not using its reasonable best efforts to cure such Material Adverse Effect prior to the Outside Date;

(i) by the Company at any time prior to the Acceptance Time if: (i)(A) there shall be an Uncured Inaccuracy in any representation or warranty of Parent or Purchaser contained in this Agreement or breach of any covenant of Parent, Purchaser or

any of their Affiliates contained in this Agreement that shall have had or is reasonably like to have, individually or in the aggregate, a material adverse effect upon Parent’s or Purchaser’s ability to consummate the Offer or Merger, or (B) since the date of this Agreement, there shall have occurred any adverse event or development which, individually or in the aggregate, has had, and continues to have, a material adverse effect upon Parent’s or Purchaser’s ability to consummate the Offer, (ii) the Company shall have delivered to Parent written notice of such Uncured Inaccuracy, breach or material adverse effect; and (iii) at least 30 days shall have elapsed since the date of delivery of such written notice to Parent and such Uncured Inaccuracy, breach or material adverse effect shall not have been cured in all material respects;

(j) by the Company at any time prior to the Acceptance Time, if Parent shall have failed to fully comply with Section 5.18(a) of this Agreement within 24 hours or, if later, one full business day following the execution and delivery of this Agreement;

provided, however, that notwithstanding anything to the contrary contained in this Section 7.1: (1) Parent shall not be permitted to terminate this Agreement pursuant to Section 7.1(g) if: (A) any material covenant of Parent or Purchaser contained in this Agreement shall have been breached in any material respect, and such breach shall not have been cured in all material respects; or (B) there shall be an Uncured Inaccuracy in any representation or warranty of Parent or Purchaser contained in this Agreement; and (2) the Company shall not be permitted to terminate this Agreement pursuant to Section 7.1(i) if: (A) any material covenant of the Company contained in this Agreement shall have been breached in any material respect, and such breach shall not have been cured in all material respects; or (B) there shall be an Uncured Inaccuracy in any representation or warranty of the Company contained in this Agreement.

7.2. Effect of Termination. In the event of the termination of this Agreement as provided in Section 7.1, written notice thereof shall forthwith be given to the other party or parties specifying the provision hereof pursuant to which such termination is made and this Agreement shall be of no further force or effect; provided, however, that: (a) Section 5.18, this Section 7.2, Section 7.3 and Section 8 shall survive the termination of this Agreement and shall remain in full force and effect; and (b) the termination of this Agreement shall not relieve any party from any liability for any breach of any covenant (including, for the avoidance of doubt, Parent’s obligations pursuant to Section 5.18(a) of this Agreement and the Company’s obligations pursuant to Section 5.18(b) of this Agreement) or willful breach of any representation or warranty contained in this Agreement.

7.3. Termination Fee.

(a) If: (i) this Agreement is validly terminated by Parent or the Company pursuant to Section 7.1(d); (ii) at or prior to the time of the termination of this Agreement an Acquisition Proposal shall have been publicly announced or shall have become publicly known; (iii) the number of Company Shares tendered (and not validly withdrawn) pursuant to the Offer shall not have satisfied the Minimum Condition; and (iv) within 12 months after the date of termination of this Agreement, the Company or any Company Subsidiary consummates an Acquisition Transaction or enters into a

Contract to consummate an Acquisition Transaction that is subsequently consummated, then, within two business days after such Acquisition Transaction is consummated, the Company shall cause a termination fee in the amount of $54,000,000 (the “Termination Fee”) to be paid to Parent; provided, however, that solely for purposes of this Section 7.3(a), the term “Acquisition Transaction” shall have the meaning set forth in the definition of Acquisition Transaction contained in Exhibit A except that all references to “15%” shall be deemed to be references to “40%” and all references to “85%” shall be deemed to be references to “60%”.

(b) If this Agreement is validly terminated by Parent pursuant to Section 7.1(e) then, within two business days after such termination, the Company shall cause the Termination Fee to be paid to Parent.

(c) If this Agreement is terminated by the Company pursuant to Section 7.1(f), prior to (or contemporaneously with) and as a condition to the effectiveness of such termination, the Company shall pay the Termination Fee to Parent.

(d) Any payments made under this Section 7.3 shall be made by wire transfer of immediately available funds to an account designated by the party entitled thereto. The Company acknowledges and agrees that the agreements contained in this Section 7.3 are an integral part of the transactions contemplated by this Agreement, and that, without these agreements, Parent would not enter into this Agreement. Accordingly, if the Company fails promptly to pay any amount due to the Parent, pursuant to this Section 7.3, and, in order to obtain such payment, Parent commences a suit that results in a judgment against the Company for the Termination Fee, the Company shall pay to Parent its costs and expenses (including attorneys’ fees and expenses) in connection with such suit, together with interest on the amount due pursuant to this Section 7.3 from the date such payment was required to be made until the date of payment at a rate of 10% per annum, or, if lower, the maximum rate permitted to be charged by applicable Legal Requirements. Except to the extent required by applicable Legal Requirements, the Company shall not withhold any withholding taxes on any payment made to Parent under this Section 7.3.

SECTION 8. MISCELLANEOUS PROVISIONS

8.1. Amendment. Subject to Section 1.5, this Agreement may be amended with the written approval of the respective parties at any time prior to the Effective Time; provided, however, that after any adoption of this Agreement by the Company’s stockholders, no amendment shall be made which by applicable Legal Requirements or any rule of any relevant stock exchange requires further approval of the stockholders of the Company, without such further approval.

8.2. Waiver.

(a) No failure on the part of any party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a

waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.

(b) No party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such party; and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.

8.3. No Survival of Representations and Warranties. None of the representations, warranties, covenants and other agreements of the parties contained in this Agreement, or contained in any certificate delivered pursuant to this Agreement or in connection with any of the transactions contemplated by this Agreement, or any claim with respect thereto, shall survive the Acceptance Time, except for those covenants, agreements and other provisions contained herein that by their terms apply or are to be performed in whole or in part after the Acceptance Time.

8.4. Entire Agreement; Counterparts. This Agreement, the other agreements referred to herein and the Confidentiality Agreement constitute the entire agreement of the parties hereto and supersede all prior agreements and understandings, both written and oral, among or between any of the parties hereto with respect to the subject matter hereof and thereof. Without limiting the generality of the foregoing: (a) Parent and Purchaser acknowledge that the Company has not made and is not making any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except as provided in this Agreement or the Company Disclosure Schedule and that they are not relying and have not relied on any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except as provided in this Agreement and the Company Disclosure Schedule; and (b) the Company acknowledges that Parent and Purchaser have not made and are not making any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except as provided in this Agreement, and that it is not relying and has not relied on any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except as provided in this Agreement. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument.

8.5. Applicable Law; Jurisdiction; Waiver of Jury Trial.

(a) This Agreement is made under, and shall be construed and enforced in accordance with, the Legal Requirements of the State of Delaware applicable to agreements made and to be performed solely therein, without giving effect to principles of conflicts of law. The parties hereto agree that any suit, action or proceeding seeking to enforce any provision of, or based on any matter arising out of or in connection with, this Agreement or the transactions contemplated hereby shall be brought in the Court of Chancery of the State of Delaware, and each of the parties hereby

irrevocably consents to the jurisdiction of such court (and of the appropriate appellate courts therefrom) in any such suit, action or proceeding and irrevocably waives, to the fullest extent permitted by Legal Requirements, any objection that it may now or hereafter have to the laying of the venue of such suit, action or proceeding in any such court or that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Legal Requirements. Each party to this Agreement irrevocably consents to service of process in the manner provided for notices in Section 8.8. Nothing in this Agreement will affect the right of any party to this Agreement to serve process in any other manner permitted by Legal Requirements. Each party hereto agrees not to commence any legal proceedings relating to or arising out of this Agreement or the transactions contemplated hereby in any jurisdiction or courts other than as provided herein.

(b) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT AND ANY OF THE AGREEMENTS DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE EITHER OF SUCH WAIVERS, (B) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVERS, (C) IT MAKES SUCH WAIVERS VOLUNTARILY, AND (D) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 8.5(b).

8.6. Payment of Expenses. Except as set forth in Section 7.3, whether or not Company Shares are exchanged pursuant to the Offer and whether or not the Merger is consummated, each party hereto shall pay its own expenses incident to preparing for, entering into and carrying out this Agreement and the transactions contemplated hereby. Nothing contained in this Agreement shall be deemed to limit the right or ability of any party to this Agreement to pay such expenses, as and when due and payable.

8.7. Assignability; No Third Party Rights. This Agreement shall be binding upon, and shall be enforceable by and inure to the benefit of, the parties hereto and their respective successors and assigns. Except as set forth in Section 5.11 with respect to the Indemnified Parties, nothing in this Agreement, express or implied, is intended to or shall confer upon any Person, other than the parties hereto, any right, benefit or remedy of any nature.

8.8. Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given or made as follows: (a) if sent by registered or certified mail in the United States return receipt requested, upon receipt; (b) if sent designated for overnight delivery by nationally recognized overnight air courier (such as DHL or Federal Express), upon receipt of proof of delivery; (c) if sent by facsimile transmission before 5:00 p.m. in California, when transmitted and receipt is confirmed; (d) if sent by facsimile transmission after 5:00 p.m. in California and receipt is confirmed, on the following business day; and (e) if otherwise actually personally delivered, when delivered, provided that such notices, requests, demands and other communications are delivered to the address set forth below, or to such other address as any party shall provide by like notice to the other parties to this Agreement:

if to Parent or Purchaser:

Inverness Medical Innovations, Inc.

▇▇ ▇▇▇▇▇▇ ▇▇▇▇

▇▇▇▇▇ ▇▇▇

▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇

Attention: General Counsel

Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇

with a copy (which shall not constitute notice) to:

▇▇▇▇▇▇▇ Procter LLP

Exchange Place

Boston, MA

Attention: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇, Esq.

Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇

if to the Company:

Biosite Incorporated

▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇

▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇

Attention: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇, Vice President, Legal Affairs

Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇

with a copy to:

▇▇▇▇▇▇ Godward Kronish LLP

▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇

▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇

Attention: ▇▇▇▇ ▇▇▇▇, Esq.

Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇

8.9. Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit the term or provision, to delete specific words or phrases or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term.

8.10. Obligation of Parent. Parent shall ensure that each of Purchaser and the Surviving Corporation duly performs, satisfies and discharges on a timely basis each of the covenants, obligations and liabilities of Purchaser and the Surviving Corporation under this Agreement, and Parent shall be jointly and severally liable with Purchaser and the Surviving Corporation for the due and timely performance and satisfaction of each of said covenants, obligations and liabilities.

8.11. Specific Performance. The parties hereto agree that irreparable damage would occur in the event any of the provisions of this Agreement were not to be performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof in addition to any other remedies at law or in equity. Each party agrees to waive any requirement for the posting of, or securing of, a bond in connection with any such remedy.

8.12. Cumulative Remedies. All rights and remedies of either party hereto are cumulative of each other and of every other right or remedy such party may otherwise have at law or in equity, and the exercise of one or more rights or remedies shall not prejudice or impair the concurrent or subsequent exercise of other rights or remedies.

8.13. Representation by Counsel. Each party hereto represents and agrees with each other that it has been represented by or had the opportunity to be represented by, independent counsel of its own choosing, and that it has had the full right and opportunity to consult with its respective attorney(s), that to the extent, if any, that it desired, it availed itself of this right and opportunity, that it or its authorized officers (as the case may be) have carefully read and fully understand this Agreement in its entirety and have had it fully explained to them by such party’s respective counsel, that each is fully aware of the contents thereof and its meaning, intent and legal effect, and that it or its authorized officer (as the case may be) is competent to execute this Agreement and has executed this Agreement free from coercion, duress or undue influence.

8.14. Construction.

(a) For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders.

(b) The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement.

(c) As used in this Agreement, the words “include” and “including,” and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.”

(d) Except as otherwise indicated, all references in this Agreement to “Sections,” “Exhibits,” “Annexes” and “Schedules” are intended to refer to Sections of this Agreement and Exhibits, Annexes and Schedules to this Agreement.

(e) All references to a document or instrument having been made available to Parent shall be deemed to include the making available of such document or instrument to Parent’s counsel, to Parent’s financial advisor or to any other representative of Parent.

(f) All references in this Agreement to “$” are intended to refer to U.S. dollars.

(g) Each reference in this Agreement to a “Contract,” “plan,” “offer” or “commitment” shall be deemed to refer only to a Contract, plan, offer or commitment that is legally binding.

(h) Unless otherwise specifically provided for herein, the term “or” shall not be deemed to be exclusive.

(i) The titles, captions or headings of the sections and subsections herein are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.

Parent, Purchaser and the Company have caused this Agreement to be executed as of the date first written above.


INVERNESS MEDICAL INNOVATIONS, INC.

By:		/s/ ▇▇▇ ▇▇▇▇▇▇▇▇▇
		Name: ▇▇▇ ▇▇▇▇▇▇▇▇▇ Title: CEO and President


INCA ACQUISITION, INC.

By:		/s/ ▇▇▇▇ ▇. ▇▇▇▇▇▇
		Name: ▇▇▇▇ ▇. ▇▇▇▇▇▇ Title: Secretary


BIOSITE INCORPORATED

By:		/s/ ▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇▇▇
		Name: ▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇▇▇ Title: Chief Executive Officer

[SIGNATURE PAGE TO AGREEMENT AND PLAN OF MERGER]

ANNEX I CONDITIONS OF THE OFFER

Purchaser shall not be obligated to accept for payment, and (subject to the rules and regulations of the SEC) shall not be obligated to pay for, any Company Shares tendered pursuant to the Offer (and not theretofore accepted for payment or paid for) unless, prior to the expiration of the Offer (as it may have been extended pursuant to Section 1.1(d) of the Agreement):

(1) there shall have been tendered and not validly withdrawn Company Shares that, considered together with all other Company Shares (if any) beneficially owned by Parent and its Affiliates, represent a majority of the total number of Company Shares outstanding at the time of the expiration of the Offer (determined on a fully diluted basis);

(2) any applicable waiting period under the HSR Act relating to the Offer shall have expired or been terminated, any antitrust or competition Legal Requirements of any other applicable jurisdiction shall have expired or been terminated and all other foreign antitrust and competition approvals required to consummate the Offer shall have been obtained (in the case of foreign Legal Requirements or approvals, only if such Legal Requirements or approvals: (a) would have suspensory effect, (b) if not obtained would reasonably be expected to result in material limitations on the ownership or operation by Parent of the assets of Parent, its Subsidiaries or the Surviving Corporation or (c) if not obtained, would subject Parent or Purchaser to the payment of a material fine or penalty).

The condition set forth in clause “(1)” above is referred to as the “Minimum Condition.”

Furthermore, Purchaser shall not be required to accept for payment, and (subject to the rules and regulations of the SEC) shall not be obligated to pay for, any Company Shares tendered pursuant to the Offer (and not theretofore accepted for payment or paid for) if, upon the expiration of the Offer (as it may have been extended pursuant to Section 1.1 of the Agreement) and before acceptance of such Company Shares for payment, any of the following conditions exists and is continuing, regardless of the circumstances giving rise to such condition:

(a) any one or more representations and warranties of the Company set forth in the Agreement shall be inaccurate in any respect and such inaccuracies, individually or in the aggregate, shall have had, and shall continue to have, a Company Material Adverse Effect; provided, however, that the existence of such inaccuracy shall be determined without giving effect to any “Company Material Adverse Effect” or other materiality qualifications contained in such representations and warranties;

(b) the covenants of the Company contained in the Agreement that are required to have been performed by the Company prior to the Acceptance Time shall not have been performed in all material respects; or

(c) since the date of this Agreement, there shall have occurred any adverse event or development which, individually or in the aggregate, has had, or is reasonably likely to have, a Company Material Adverse Effect.

EXHIBIT A

CERTAIN DEFINITIONS

For purposes of the Agreement (including Annex I and this Exhibit A):

Acquisition Inquiry. “Acquisition Inquiry” shall mean an inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by Parent or Purchaser) that would reasonably be expected to lead to an Acquisition Proposal.

Acquisition Proposal. “Acquisition Proposal” shall mean any offer or proposal (other than an offer or proposal made or submitted by Parent or Purchaser) relating to a possible Acquisition Transaction.

Acquisition Transaction. “Acquisition Transaction” shall mean any transaction or series of related transactions (other than the transactions contemplated by this Agreement) involving or resulting in: (i) any acquisition or purchase from the Company by any Person or “group” (as defined in or under Section 13(d) of the Exchange Act), directly or indirectly, of more than 15% of the total outstanding voting securities of the Company, or any tender offer or exchange offer that, if consummated, would result in the Person or “group” (as defined in or under Section 13(d) of the Exchange Act) making such offer beneficially owning 15% or more of the total outstanding voting securities of the Company; (ii) any merger, consolidation, share exchange, business combination, acquisition of securities, recapitalization, tender offer, exchange offer or other similar transaction involving the Company pursuant to which the stockholders of the Company immediately prior to the consummation of such transaction would hold less than 85% of the equity interests in the surviving or resulting entity of such transaction immediately after consummation thereof; (iii) any sale, lease, exchange, transfer, license, acquisition or disposition of more than 15% of the assets of the Company (including the interest of the Company in the Company Subsidiaries) (measured by either book or fair market value thereof) or the net revenues or net income of the Company; or (iv) any liquidation, dissolution, recapitalization or other significant corporate reorganization of the Company.

Affiliate. A Person shall be deemed to be an “Affiliate” of another Person if such Person directly or indirectly controls, is directly or indirectly controlled by or is directly or indirectly under common control with such other Person.

After Consultation. “After Consultation” by a Person shall mean after consultation with a financial advisor of nationally recognized reputation and such Person’s outside legal counsel.

Agreement. “Agreement” shall mean the Agreement and Plan of Merger to which this Exhibit A is attached, together with Annex I and this Exhibit A, as such Agreement and Plan of Merger (including Annex I and this Exhibit A) may be amended from time to time.

▇▇▇▇▇▇▇. “▇▇▇▇▇▇▇” shall mean ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Inc., a Delaware Corporation.

▇▇▇▇▇▇▇ Merger Agreement. “▇▇▇▇▇▇▇ Merger Agreement” shall mean that certain Agreement and Plan of Merger dated as of March 24, 2007, as amended on May 1, 2007, by and between the Company, ▇▇▇▇▇▇▇ and ▇▇▇▇▇▇▇ Subsidiary, as may have been amended from time to time thereafter.

▇▇▇▇▇▇▇ Subsidiary. “▇▇▇▇▇▇▇ Subsidiary” shall mean Louisiana Acquisition Sub, Inc., a Delaware corporation.

CLIA. “CLIA” shall mean the Clinical Laboratory Improvement Amendments of 1988 or any successor statutes.

Code. “Code” shall mean the Internal Revenue Code of 1986, as amended.

Company Board. “Company Board” shall mean the board of directors of the Company in office at any given time.

Company Compensation Arrangement. “Company Compensation Arrangement” shall mean (i) any employment agreement, severance agreement or change of control agreement between the Company or a Company Subsidiary and any holder of Company Shares and any amendments thereto entered into during the 12 months immediately prior to, on, or after, the date of this Agreement, (ii) any Company Options or other equity awards awarded, or any acceleration of vesting of any Company Options or other unvested equity awards during the 12 months immediately prior to the date of this Agreement; (iii) the treatment of Company Options under Section 5.9 hereof; (iv) the Non-competition, Non-disclosure and Intellectual Property Assignment Agreements, dated as of the date hereof, among Parent, Purchaser and certain employees of the Company; (v) the provision of employee benefits as specified in Section 5.10 hereof; (vi) the provision of the D&O Insurance Policy for the benefit of the Company’s directors and officers as specified in Section 5.11(b) hereof; and (vii) any other plan, program, agreement or arrangement between the Company and a holder of Company Shares that is an Employment Compensation Arrangement.

Company Material Adverse Effect. “Company Material Adverse Effect” shall mean any change, effect, development, circumstance, condition or worsening thereof (“Effect”) that, individually or when taken together with all other Effects that exist at the date of determination, (i) has had or would reasonably be likely to have a material adverse effect on the business, operations, results of operations or condition (financial or otherwise) of the Company and the Company Subsidiaries, taken as a whole; or (ii) would reasonably be expected to directly or indirectly materially impair the validity or enforceability of this Agreement, prevent or materially delay the consummation of the transactions contemplated by this Agreement or subject Parent or Purchaser to criminal or material civil liability in connection with the transactions contemplated by this Agreement; provided, however, that none of the following shall be deemed either alone or in combination to constitute, and none of the following shall be taken into account in determining whether there has been or would be, a Company Material Adverse Effect: (A) any Effect that results from general economic, business, financial or market conditions in the United States or global economy as a whole; (B) any Effect arising from or otherwise relating to any of the industries or industry sectors in which the Company or any of the Company Subsidiaries operates to the extent that it does not disproportionately affect the Company and the Company Subsidiaries (taken as a whole) relative to other participants in the medical device industry; (C) any Effect arising from or otherwise relating to any act of terrorism, war, national or international calamity or any other similar event; (D) any Effect (including any loss of employees, any cancellation of or delay in customer orders or any litigation) arising from or otherwise relating to the announcement or pendency of this Agreement, the Offer, the Merger or any prior or subsequent offer, proposal or possible transaction with, by or involving Parent, Purchaser, ▇▇▇▇▇▇▇ or any affiliate thereof; (E) the failure of the Company to meet internal or analysts’ expectations or projections, in and of itself (for the avoidance of doubt, this clause (E) shall not preclude the underlying cause of any such failure to meet internal or analysts’ expectations or projections being taken into account in determining whether there has been a Material Adverse Effect); (F) any Effect arising from or otherwise relating to any action required by this Agreement to be taken by the Company or any Company Subsidiary; or (G) a decline in the Company’s stock price, in and of itself (for the avoidance of doubt, this clause (G) shall not preclude Parent from asserting that the underlying cause of any such decline in the Company’s stock price being taken into account in determining whether there has been a Material Adverse Effect).

Company Option Plans. “Company Option Plans” shall mean the following stock option plans of the Company: (a) the Amended and Restated 1989 Stock Plan, (b) the Amended and Restated 1996 Stock Incentive Plan and (c) the 2002 Nonqualified Stock Incentive Plan.

Company Options. “Company Options” shall mean options to purchase Company Shares from the Company, whether granted by the Company pursuant to the Company Option Plans or otherwise.

Company Rights. “Company Rights” shall mean the rights issued pursuant to the Company Rights Agreement.

Company Rights Agreement. “Company Rights Agreement” shall mean the Rights Agreement dated as of October 22, 1997, between the Company and BankBoston, N.A., as Rights Agent, as amended by Amendment No. 1 dated as of December 9, 1999 between the Company and Fleet National Bank (f/k/a BankBoston, N.A.) by Amendment No. 2 dated as of July 18, 2001, among the Company, Fleet National Bank and American Stock Transfer & Trust Company, as successor Rights Agent, by Amendment No. 3 dated as of March 24, 2007 and Amendment No. 4 dated as of the date hereof, between the Company and American Stock Transfer & Trust Company, a New York banking corporation, as successor Rights Agent.

Company Shares. “Company Shares” shall mean shares of common stock, $0.01 par value per share, of the Company. Except where the context otherwise requires, all references in the Agreement to Company Shares shall include the associated Company Rights.

Confidential Agreement. “Confidential Agreement” shall mean the agreement specified in Part 5.6(c) of the Company Disclosure Schedule.

Continuing Director. “Continuing Director” shall mean any member of the Company Board, while such person is a member of the Company Board, who is not an Affiliate, representative or designee of Parent or Purchaser and was a member of the Company Board prior to the date of the Agreement, and any successor of a Continuing Director while such successor is a member of the Company Board, who is not an Affiliate, representative or designee of Parent or Purchaser and was recommended or elected to succeed such Continuing Director by a majority of Continuing Directors.

Contract. “Contract” shall mean any loan or credit agreement, bond, debenture, note, mortgage, indenture, guarantee, lease or other contract, commitment, agreement, instrument, arrangement, understanding, obligation, undertaking or license, whether oral or written (each, including all amendments thereto).

Controlled Substances Act. “Controlled Substances Act” refers to 21 U.S.C. §§ 801 et seq.

Encumbrance. “Encumbrance” shall mean, with respect to any property or asset, any mortgage, easement, lien, pledge (including any negative pledge), security interest or other encumbrance of any nature whatsoever in respect of such property or asset.

Entity. “Entity” shall mean any corporation (including any non-profit corporation), general partnership, limited partnership, limited liability partnership, joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity (including any Governmental Entity).

ERISA. “ERISA” shall mean the Employee Retirement Income Security Act of 1974, as amended.

ERISA Affiliate. “ERISA Affiliate” shall mean any Company Subsidiary or any entity (whether or not incorporated) other than the Company or any Company Subsidiary that, together with the Company, is required to be treated as a single employer under Section 414(b), (c), (m) or (o) of the Code.

Executive. “Executive” shall mean any employee of the Company that is eligible to participate in the Company’s Change in Control Severance Benefit Plan.

Exchange Act. “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

FDA. “FDA” shall mean the United States Food and Drug Administration.

FDCA. “FDCA” shall mean the Federal Food, Drug and Cosmetic Act of 1938, as amended.

FDA Laws. “FDA Laws” shall mean the FDCA, the Public Health Service Act, CLIA, Controlled Substances Act and, for each of the foregoing, all comparable state Legal Requirements and the rules and regulations promulgated thereunder by FDA and any other comparable Governmental Entities.

GAAP. “GAAP” shall mean United States generally accepted accounting principles.

Governmental Authorization. “Governmental Authorization” shall mean any permit, license, registration, qualification, certificate, clearance, variance, waiver, exemption, certificate of occupancy, exception, franchise, entitlement, consent, confirmation, order, approval or authorization granted by any Governmental Entity (including all authorizations under the FDCA and the Public Health Services Act, and the regulations of the FDA promulgated thereunder).

Governmental Entity. “Governmental Entity” shall mean any federal, state, local or foreign government or multi-national organization or body or any agency, authority, subdivision or instrumentality of any of the foregoing, including any court, tribunal, department, bureau, administrative agency, commission or board, or any quasi-governmental or private body duly exercising any regulatory, taxing, inspecting or other governmental authority.

HSR Act. “HSR Act” shall mean the ▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Antitrust Improvements Act of 1976, as amended.

Indebtedness. “Indebtedness” shall mean (i) indebtedness for borrowed money, including indebtedness evidenced by a note, bond, debenture or similar instrument, and any guarantees, endorsements or keep-well obligations or other contingent obligations in respect thereof, or (ii) obligations in respect of outstanding letters of credit, acceptances and similar obligations created for the account of such Person.

Intellectual Property Rights. “Intellectual Property Rights” shall mean all (a) United States and foreign patents and patent applications (and any patents that issue as a result of those patent applications), and any renewals, reissues, reexaminations, extensions, continuations, continuations-in-part, divisions and substitutions relating to any of the patents and patent applications, as well as all related foreign patents and patent applications that are counterparts to such patents and patent applications, (b) United States and foreign trademarks, service marks, trade dress, logos, trade names and corporate names, whether registered or unregistered, and the goodwill associated therewith, together withy any registrations and applications for registration thereof, (c) United States and foreign copyrights and rights under copyrights, whether registered or unregistered, including moral rights, and any registrations and applications for registration thereof, (d) United States, and foreign mask work rights and registrations and applications for registration thereof, (e) rights in databases and data collections (including knowledge databases, customer lists and customer databases) under the laws of the United States or any other jurisdiction, whether registered or unregistered, and any applications for registration therefor; (f) trade secrets and other rights in know-how and confidential or proprietary information (including any business plans, designs, technical data, customer data, financial information, pricing and cost information, bills of material,

or other similar information), (g) URL and domain name registrations, (h) inventions (whether or not patentable) and improvements thereto, and (i) all other proprietary or intellectual property rights now known or hereafter recognized in any jurisdiction.

Latest Balance Sheet. “Latest Balance Sheet” shall mean the audited consolidated balance sheet of the Company and the Company Subsidiaries as of December 31, 2006, which is included in the Company’s Report on Form 10-K filed with the SEC for the fiscal year ended December 31, 2006.

Leased Real Property. “Leased Real Property” shall mean real property that is leased by the Company or any Company Subsidiary.

Legal Proceeding. “Legal Proceeding” shall mean any claim, lawsuit, court action, suit, arbitration, investigation by a Governmental Entity or other judicial or administrative proceeding.

Legal Prohibition. “Legal Prohibition” shall mean any final, permanent Legal Requirement that is in effect and that prevents or prohibits consummation of the Offer, the Merger or any of the other material transactions contemplated in this Agreement or limits or would limit Parent’s activity in connection with its ownership, operation or control of the Surviving Corporation (including any hold separate order).

Legal Requirement. “Legal Requirement” shall mean any federal, state, local or non-U.S. law, statute, code, ordinance, regulation, code, order, judgment, writ, injunction, decision, ruling or decree promulgated by any Governmental Entity.

Option Conversion Ratio. “Option Conversion Ratio” shall mean the quotient, calculated to five decimal places, obtained by dividing (x) the Offer Price by (y) the Parent Share Price at the Effective Time.

Ordinary Course of Business. “Ordinary Course of Business” shall mean ordinary course of business, consistent with past practices, including with respect to frequency and amount.

Owned Real Property. “Owned Real Property” shall mean real property owned by the Company or a Company Subsidiary.

Parent Share Price. “Parent Share Price” shall mean the closing per-share price of a Parent Share as listed on the AMEX.

Parent Shares. “Parent Shares” shall mean shares of common stock, $0.01 par value per share, of Parent.

Permitted Encumbrances. “Permitted Encumbrances” shall mean: (a) Encumbrances for Taxes not yet due and payable; (b) liens, Encumbrances or imperfections of title that have arisen in the Ordinary Course of Business; (c) liens, Encumbrances or imperfections of title resulting from or otherwise relating to any of the contracts referred to in the Company Disclosure Schedule; (d) liens, Encumbrances or

imperfections of title relating to liabilities reflected in the financial statements (including any related notes) contained in the Company SEC Documents; (e) liens, pledges or Encumbrances arising from or otherwise relating to transfer restrictions under the Securities Act and the securities laws of the various states of the United States or foreign jurisdictions; and (f) liens, Encumbrances or imperfections of title which would not have a Company Material Adverse Effect.

Person. “Person” shall mean any individual or Entity.

Products Under Development. “Products Under Development” shall mean the products currently under development and subject to current clinical trials set forth on Schedule A attached hereto.

Proxy Statement. “Proxy Statement” shall mean a proxy statement relating to the Special Meeting (together with any amendments thereof or supplements thereto and any other required proxy materials in connection therewith).

SEC. “SEC” shall mean the United States Securities and Exchange Commission.

Securities Act. “Securities Act” shall mean the Securities Act of 1933, as amended.

Subsidiary. An Entity shall be deemed to be a “Subsidiary” of another Person if such Person directly or indirectly owns, beneficially or of record: (a) an amount of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members of such Entity’s board of directors or comparable governing body; or (b) at least 50% of the outstanding equity interests issued by such Entity.

Special Meeting. “Special Meeting” shall mean a special meeting of the Company’s stockholders held solely for the purpose of considering and taking action upon this Agreement and the Merger.

Superior Proposal. “Superior Proposal” shall mean any unsolicited, bona fide written offer made by a third party unaffiliated with the Company to purchase (by way of merger, tender or exchange offer or otherwise) greater than 85% of the Company’s assets or greater than 85% of the outstanding Company Shares (other than Company Shares already held by such third party) that the Company Board shall have determined in good faith (After Consultation, and after taking into account, among other things, the financial, legal and regulatory aspects of such offer (including any financing required and the availability thereof), as well as any revisions to the terms hereof proposed by Parent pursuant to Section 7.1(f) hereof) is: (a) more favorable to the Company’s stockholders (in their capacities as such) than the terms of the Offer and the Merger (taking into account any revisions to the terms hereof proposed by Parent pursuant to Section 7.1(f) hereof), and (b) reasonably certain of being consummated on the terms proposed.

Tax or Taxes. “Tax” or “Taxes” shall mean all taxes of whatever kind or nature, including those on or measured by or referred to as income, gross receipts, sales, use, ad valorem, franchise, profits, license, estimated, withholding, payroll, employment, excise, severance, stamp, occupation, premium, value added, property or windfall profits taxes, customs, duties or other similar fees, assessments or charges of any kind whatsoever (together with any interest and any penalties, additions to tax or additional amounts), whether disputed or not, imposed by any Governmental Entity or Tax authority (domestic or foreign).

Tax Returns. “Tax Return” shall mean any report, return (including information return), claim for refund, or statement relating to Taxes or required to be filed with any Tax authority (domestic or foreign), including any schedule or attachment thereto, and including any amendments thereof.

Technology. “Technology” shall mean tangible embodiments of Intellectual Property Rights, including in electronic, written or other media, technical documentation, specifications, designs, bills of material, build instructions, test reports, schematics, algorithms, application programming interfaces, user interfaces, routines, formulae, databases, materials, compounds, reagents, lab notebooks, processes, prototypes, samples, works in progress, inventories, studies, or other know-how and other works of authorship.

Uncured Inaccuracy. There shall be deemed to be an “Uncured Inaccuracy” in a representation or warranty of a party to the Agreement as of a particular date only if such representation or warranty shall be inaccurate as of such date as if such representation or warranty were made as of such date, and the inaccuracy in such representation or warranty shall not have been cured in all material respects since such date; provided, however, that if such representation or warranty by its terms speaks as of the date of the Agreement or as of another particular date, then there shall not be deemed to be an Uncured Inaccuracy in such representation or warranty unless such representation or warranty shall have been inaccurate as of the date of the Agreement or such other particular date, respectively, and the inaccuracy in such representation or warranty shall not have been cured in all material respects since such date.

Other Defined Terms

The following terms shall have the meanings defined for such terms in the Sections set forth below:


Term		Section
Acceptance Time		1.4(a)
Alternative Financing		5.16
Appraisal Shares		2.8(c)
Assumed Option		5.9(a)
▇▇▇▇▇▇▇ Termination Fee		5.18(a)
Certificate of Merger		2.3
Company		Preamble
Company Change in Recommendation		5.3(b)
Company Disclosure Schedule		3
Company ESPP		3.5(a)
Company Plan		3.21(a)
Company Recommendation		5.3(a)
Company SEC Documents		3.6(a)
Company Stock Certificate		2.6
Company Termination Fee		3.30
Compensation Committee		3.21(l)
Confidentiality Agreement		1.3(c)
Continuing Employee		5.10(a)
D&O Insurance Policy		5.11(b)
Debt Commitment Letter		4.5
Debt Financing		4.5
DGCL		Recitals
Effective Time		2.3
Employment Compensation Arrangement		3.21(l)
Environmental Laws		3.23
Environmental Permits		3.23
Foreign Plans		3.21(j)
Harmful Code		3.12(g)
Hazardous Substances		3.23
Indemnified Party		5.11(d)
Initial Expiration Date		1.1(d)
Matching Period		7.1(f)
Material Contract		3.13(a)
Merger		Recitals
Merger Consideration		Recitals
Minimum Condition		Annex I
Multiemployer Plan		3.21(e)
Non-Budgeted Capital Expenditure		5.1(u)
Notice of Recommendation Change		5.3(c)
Offer		Recitals
Offer Commencement Date		1.1(a)


Offer Conditions		1.1(b)
Offer Documents		1.2(a)
Offer Price		Recitals
Outside Date		7.1(b)
Parent		Preamble
Parent Plans		5.10(a)
Payment Agent		2.7(a)
Preferred Shares		3.5(a)
Purchaser		Preamble
Representatives		5.2(a)
Schedule 14D-9		1.3(b)
Significant Required Governmental Approval		Annex I
Surviving Corporation		2.1
Termination Fee		7.3(a)
Top-Up Closing		1.6(c)
Top-Up Exercise Notice		1.6(c)
Top-Up Option		1.6(a)
Top-Up Option Shares		1.6(a)

EXHIBIT B

AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION

BIOSITE INCORPORATED

FIRST: The name of the corporation (hereinafter the “Corporation”) is: BIOSITE INCORPORATED.

SECOND: The name and address, including street, number, city and county, of the registered agent of the Corporation in the State of Delaware are:

The Corporation Trust Company

▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇

▇▇▇▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇

THIRD: The nature of the business and the purposes to be conducted and promoted by the Corporation shall be to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.

FOURTH: The total number of shares of stock which the Corporation shall have authority to issue is One Thousand (1,000) shares. The par value of each such share is $0.001. All such shares are of one class and are shares of Common Stock.

FIFTH: The Corporation is to have perpetual existence.

SIXTH: The personal liability of the directors of the Corporation is hereby eliminated to the fullest extent permitted by paragraph (7) of subsection (b) of Section 102 of the General Corporation Law of the State of Delaware, as the same may be amended and supplemented.

SEVENTH: The Corporation shall, to the fullest extent permitted by Section 145 of the General Corporation Law of the State of Delaware, as the same may be amended and supplemented, indemnify any and all persons whom it shall have power to indemnify under said section from and against any and all of the expenses, liabilities or other matters referred to in or covered by said section, and the indemnification provided for herein shall not be deemed exclusive of any other rights to which those indemnified may be entitled under any Bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such person.

EIGHTH: From time to time any of the provisions of this certificate of incorporation may be amended, altered or repealed, and other provisions authorized by the laws of the State of Delaware at the time in force may be added or inserted in the manner and at the time prescribed by said laws, and all rights at any time conferred upon the stockholders of the Corporation by this certificate of incorporation are granted subject to the provisions of this Article EIGHTH. In addition to the other powers expressly granted by statute, the Board of Directors shall have the power to adopt, repeal, alter, amend and rescind the Bylaws of the Corporation.

AGREEMENT AND PLAN OF MERGER by and among: INVERNESS MEDICAL INNOVATIONS, INC., a Delaware corporation; INCA ACQUISITION, INC., a Delaware corporation; and BIOSITE INCORPORATED, a Delaware corporation Dated as of May 17, 2007

Document Metadata

Document Metadata

Table of Contents